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ABSTRACT 
 
Katherine Anne Moga: RAPIDLY DISSOLVABLE PRINT MICRONEEDLES FOR THE TRANSDERMAL 
DELIVERY OF THERAPEUTICS 
 (Under the direction of Joseph M. DeSimone) 
 
 In recent years, microneedle devices have become an attractive method to overcome the 
diffusion-limiting epidermis and effectively transport therapeutics to the body. Microneedles are 
arrays of micron-sized projections that pierce the skin to administer drugs, manually creating 
channels for the passage of a therapeutic. Biodegradable or water-soluble microneedles are of 
high interest due to their safety, low device complexity, and ability to deliver agents of nearly 
any size. The main limitation of biodegradable microneedles is their arduous manufacturing, 
requiring long vacuum and centrifugation steps to fill a mold. The fabrication of microneedles 
via the highly scalable and reproducible Particle Replication in Non-wetting Templates 
(PRINT®) platform has great promise to expand this growing field by eliminating these obstacles 
to clinical translation.  
Herein, the fabrication of 100% water-soluble PRINT microneedles on flexible substrates 
is demonstrated. The ability of these devices to load therapeutics of nearly any size, shape, and 
surface charge – while maintaining the function of the cargo throughout – has been shown 
through the encapsulation of small molecule dyes, proteins, and hydrogel nanoparticles. PRINT 
microneedle devices were seen to pierce skin and transport cargo in both ex vivo and in vivo 
studies. Utilizing optical coherence tomography, it was seen that flexible microneedle patches 
increase the depth and reproducibility of needle penetrations (as compared to rigid patches). The 
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permeation kinetics of the small molecule, protein, and particulate drug surrogates through full 
thickness murine skin were investigated; microneedles greatly increased the delivered dose of 
small molecules when compared to topical formulations. Both proteins and nanoparticles were 
seen to deposit in the skin after application with PRINT microneedles, but the permeation 
kinetics through this tissue slowed as cargo size increased. PRINT microneedle device 
application in vivo was optimized on nude murine models, and it was shown that these devices 
efficaciously deliver small molecule drug surrogates to living tissue. The ability of the PRINT 
microneedles pierce excised human skin was shown, highlighting the capability of the 
technology to transition into a clinically-relevant product. Finally, PRINT microneedle devices 
were adapted to two therapeutically-relevant systems: the delivery of butyrylcholinesterase as a 
countermeasure against nerve gas overexposure, and the treatment of skin-invading breast 
cancers by introducing chemotherapeutics via microneedles. Therefore, efficacious water-soluble 
microneedle devices have been made reproducibly and quickly via PRINT technology, 
advancing the field of transdermal drug delivery as a whole. 
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CHAPTER 1 MICRONEEDLE TECHNOLOGY FOR THE ADVANCEMENT OF TRANSDERMAL 
DRUG DELIVERY 
 
1.1 Challenges in Drug Delivery 
 Every year, research laboratories in corporations and universities aim to create new 
prescription drugs, over-the-counter medications, cancer treatments, and gene therapy agents, 
many of which are novel, unique molecules. Before a drug can be implemented in clinics across 
the country, it must be rigorously tested to assure its safety and effectiveness. Of the thousands 
of newly developed drugs each year, less than fifty, on average, are fit to apply for approval from 
the Food and Drug Administration (FDA).1 Each of these represents a unique innovation, the 
time and manpower of many, and often hundreds of millions of dollars. In recent history, from 
2006 to 2010, as few as eighteen (seen in 2007) and as many as twenty-six (seen in 2009, see 
Figure 1.1) have been approved.1  
 
Figure 1.1 FDA New Molecular Entities (NME) approved from 2006-2010.1 
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 However, the delivery route of every new drug, as well as the thousands of existing 
medications, greatly impacts its effectiveness, influencing dose, biodistribution, 
pharmacokinetics, and pharmacodynamics. Many promising new therapeutics are large 
biomolecules, such as peptides, proteins, antibodies, and nucleic acids.2 These molecules can be 
too large, fragile, or insoluble for delivery by traditional routes of introduction.3,4 They may be 
unable to overcome biological barriers, disassociate before they reach their target, or be difficult 
to formulate in necessary solvents.2-4 Therefore, large volumes of these drugs are usually 
required to be effective, significantly raising costs.3,4 Additionally, highly cytotoxic drugs, such 
as cancer therapies, can lead to harsh side effects.4 In these cases, lower drug dosages would be 
preferred for treatment; however, the amount required remains quite high in order to achieve a 
clinically-relevant therapeutic effect. In spite of the high levels of administered therapeutic, as 
little as 1% of the dosed therapy reaches solid tumors by standard systemic delivery alone.5 
 Standard delivery of drugs can be focused in four main categories: oral, inhaled, 
hypodermic injection, and transdermal application. Oral drugs, commonly pills or liquids, are 
very familiar to patients and are generally low cost. However, the harsh environment of the 
gastrointestinal tract and likelihood of first pass metabolism by the liver limit the selection of 
drugs delivered orally.6 Inhaled therapies allow the localized delivery of medication to the lungs 
with minimal side effects, but these generally are more costly than oral formulations. 
Additionally, the technique of administration affects the drug’s effectiveness, for some common 
inhaled medications are administered by the patient or non-trained personnel.7 Hypodermic 
injection (including intravascular, intramuscular, etc.) enables the delivery of sensitive 
therapeutics, but they induce pain, provide opportunities for accidental needle sticks that 
contribute to the spread of infectious disease, and produce sharp, biohazardous waste.3,8-10 
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Furthermore, intramuscular injections – common for vaccines – do not deliver doses to the 
optimum location to elicit an immune response; they penetrate into muscle, a region known to 
have a lower density of immunologically sensitive cells than skin.3,11-13  Therefore, a large 
volume of active agent is used, leading to higher cost. Transdermal patches are effective for 
select time-released drugs (like nicotine and motion sickness medications), but the epidermis 
(specifically the stratum corneum) limits the diffusion of most drugs through the skin.8-10 Clearly, 
the ability to transport therapeutics effectively into the body remains a significant challenge.  
1.2 Transdermal Drug Delivery  
 While there are limitations to traditional transdermal drug delivery, which typically relies 
on the passive diffusion of therapeutics through the skin, this route of administration remains 
very promising. First, the gastrointestinal tract and first pass metabolism would be avoided by 
introducing the therapy transdermally.8-10 Drug peak plasma levels are reduced, compared to 
intravascular delivery, leading to decreased side effects.9 Also, drugs with short biological half-
lives or narrow therapeutic windows could be introduced effectively within the skin.9 Finally, by 
introducing drugs to the skin, therapeutic exposure at the point of entry would allow for the 
treatment of local aliments. Due to the structure of the skin itself, systemic exposure through 
lymphatic drainage via Langerhans or dermal dendritic cells and diffusion into the blood system 
could be achieved.8 
The skin is the largest organ of the body, and is its first shield against microbial or viral 
invasion.2,14 Seen in Figure 1.2, it is composed primarily of three layers: the epidermis, dermis, 
and subcutaneous fat.2,15 The epidermis is the outer protective barrier of the skin, approximately 
150-200 µm thick.2 The top epidermal layer, the stratum corneum or nonviable epidermis (10-15 
µm), is comprised mainly of dead, keratin-rich skin cells, corneocytes; it is the skin’s main 
4 
 
barrier of diffusion. Due to the densely-packed, lipophilic cells layered 10-15 μm thick, 
molecules larger than 500 Daltons (Da) cannot passively breach this layer.6,8-10,14 Directly below 
the stratum corneum is the viable epidermis. While not vascularized, this layer is composed of 
live skin cells and Langerhans cells, the immune cells of the epidermis. The dermal layer is much 
more robust than the epidermis, functioning as the connective tissue between the epidermis and 
subcutaneous fat. The junction between the epidermal and dermal tissue is a complex 
glycoprotein structure, forming a 50 nm mechanical support that anchors the two layers.2,16 A 
therapeutic must pass through this structure to reach the rich network of capillaries 
approximately 200 µm below the skin surface; it has been shown that therapeutic dermal reach is 
indicative of systemic exposure and absorption.2 In addition, the dermal layer also houses 
lymphatics, hair follicles, sweat glands, and is rich in dendritic immunostimulatory cells. 
Encapsulated nerve endings do reach the upper dermal layer of the skin, but it has been shown 
that these receptors respond to gentle pressure, not pain.2 Pain receptors are located much deeper 
in the skin, at the junction of the dermal and subcutaneous layers.  
 
Figure 1.2 The anatomy of the skin.2 
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The transdermal route, therefore, has become a focus of innovative research in drug 
delivery after the approval of the first transdermal medication in 1981 (patches for the delivery 
of the motion sickness drug scopolamine).9 Since then, more than thirty-five transdermal 
products have been approved in the US.9 Research labs across the country have been focusing on 
how to overcome the passive diffusion limit of the skin and widen the scope of medications that 
can be delivered transdermally. 
While many approaches have been published and implemented, transdermal enhancement 
methods fall into three major categories: formulation-based, electrically-based, and structure-
based (Table 1.1). Formulation-based and electrically-based methods are generally described as 
non-invasive methods of enhancement.10 Adding a chemical permeability enhancer, such as a 
fatty acid or surfactant, to the drug formulation allows for lipophilic molecules to be carried 
through the skin by disrupting the bilayer structure of the epidermis.6,10 Even though this method 
is non-invasive, the excipients used can irreversibly damage the epidermis and cause high levels 
of skin irritation.  
Table 1.1 Methods of enhancing transdermal delivery 
Method Formulation-
Based 
Electrically-
Based 
Structure-
Based  
Chemical Enhancers X   
Ultrasound  X  
Iontophoresis  X  
Electroporation  X  
Skin Ablation   X 
Jet Injection   X 
Microneedles   X 
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 Electrically-based methods increase the permeability of the skin by exposing it to a 
focused current or energy, but they are generally associated with complex, expensive devices.6 
Iontophoresis drives charged or neutral drugs across the skin by applying a small, constant 
electric potential to a reservoir of drug in contact with the skin. Charged drugs penetrate the skin 
via electrophoretic mobility, while the electroosmotic flow of water molecules carries in weakly 
or uncharged drug molecules.6,9 This method can be used to transport molecules up to a few 
thousand Da through the stratum corneum.6,9 Skin irritation can still occur because iontophoresis 
is not localized to this upper epidermal layer. Ultrasound increases the permeability of the skin 
by applying a pressure wave at a frequency much higher than what is detectible by the human 
ear.6 This disrupts the lipid structure of the stratum corneum, allowing larger molecules to 
passively diffuse through the skin (up to a few thousand Da). Again, damage to the lower layers 
of the skin is possible due to the heat generated from these waves. Finally, electroporation 
utilizes high voltage pulses to form small, transient pores in the skin. After undergoing 
electroporation treatment, macromolecule therapies up to 40 kDa have been successfully 
delivered transdermally.6 While the high electrical resistance of the stratum corneum protects 
deeper tissue through one treatment, repetitions of the therapy can cause damage to the lower 
tissue. 
 Structure-based approaches, alternately, are considered minimally invasive. Skin ablation 
methods aim to physically change the structure of the skin by removing the stratum corneum, 
exposing the viable epidermis and applying a drug to this layer. This can be done in a variety of 
ways, from cosmetic microdermabrasion to sanding with emery paper.9 While these methods 
have shown enhanced delivery, they do leave the skin without a protective barrier against 
infection after application that could invite the invasion of pathogens. Jet injection physically 
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interrupts the stratum corneum by delivering a liquid or powdered drug with high pressured 
compressed gas.2,17 A supersonic flow of gas (with a velocity ranging from 100-200 m/s) 
penetrates deep into the dermis; when the therapeutic of interest is introduced to the stream, it is 
deposited into the skin. Such needleless injections have been successful in delivering vaccines 
and lidocaine, but require expensive equipment and show high variability in dosing accuracy.2 
Presently, microneedle devices are considered the most promising, novel structure-based 
enhancement, demonstrating the successful delivery of small to large therapeutics both locally 
and systemically; such devices are the focus of this research. 
1.3 Microneedles  
Microneedles are arrays of micron-sized projections for localized and systemic drug 
delivery. Considered minimally-invasive, these devices pierce the skin, like hypodermic needles, 
creating channels for the passage of a therapeutic (see Figure 1.3).8-12,18 However, the small size 
of the micro-projections (typically 25 – 2000 µm in length) allows them to enter the skin 
painlessly, for they only reach encapsulated nerve endings that serve as pressure receptors.2 In 
fact, a number of studies involving human subjects have confirmed the painless nature of 
microneedle devices when administered to the forearm.2,18-21 Depending on their physical 
geometry, microneedles can transport pharmaceutical agents of virtually any size, from small 
molecules to nano- and microparticles.22-27 Tuning the length, strength, and geometry of the 
microneedles allows them to selectively target regions of the skin; for example, the viable 
epidermis, rich in Langerhans cells, could be targeted by shorter microneedles, while longer 
microneedles may deliver therapeutics to the dermal vasculature and lymphatics to facilitate 
systemic exposure.28 A dose sparing effect for the therapeutic itself has been observed compared 
to traditional transdermal patches.11 Additionally, the low complexity of microneedle devices 
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may enable inexpensive fabrication and patient self-administration. Therefore, an optimized 
microneedle device could offer the efficacy of a hypodermic needle with the advantages of 
transdermal delivery.   
                                        
Figure 1.3 Transdermal drug delivery via microneedle devices.29 
1.3.1 Types of Microneedles  
 While hundreds of microneedles technologies have been proposed since their first 
successful use in 1998, these devices can be grouped into four main configurations: solid and 
uncoated, solid and coated, hollow, and biodegradable (Figure 1.4).10,30 In the first (Figure 1.4A), 
described as the “poke then patch” approach, arrays of bare solid microneedles are used to pierce 
skin to create micron-sized holes in the epidermis; a topical drug formulation is then applied over 
the treated area to passively diffuse through the skin. The second configuration (Figure 1.4B), 
termed “coat then poke,” employs these solid microneedles coated post-fabrication with a 
formulation containing active drug.2 The assembled device is then applied to the epidermis, left 
in the skin until the coating dissolves, and removed. Shown in Figure 1.4C, biodegradable 
microneedles encapsulate the drug of interest into the needle matrix, and the payload is released 
when the device dissolves in the skin.2,10   Finally, hollow microneedles have been developed for 
the introduction of a liquid drug matrix while the device remains in the skin. After application of 
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a hollow needle array, a pump drives drug from an external reservoir through the skin; the device 
would be removed after dosing, as shown in Figure 1.4D. 
 
Figure 1.4 Schematics of the application strategies for the four main configurations of microneedle devices. (A) 
solid and uncoated, (B) solid and coated, (C) biodegradable, (D) hollow.10 
To these aims, microneedles have been made from a wide variety of materials in 
numerous shapes, sizes, lengths, and configurations.3,10-13,22,31 Predominately, the fabrication of 
microneedle arrays employs manufacturing techniques common to the microelectronics industry, 
such as injection molding, isotropic etching, bulk machining, reactive ion etching, 
photolithography, and two-photon polymerization.2,3,10,32-35 The device material, desired 
geometry, and intended therapeutic payload influences which specific fabrication technology 
may be selected for device assembly. Figure 1.5 illustrates four microneedle devices made from 
common materials (metals, silicon, and biodegradable or water-soluble polymers) that represent 
recent advances in the field. Metal microneedles with an in-plane geography, in which the 
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microneedles are fabricated via laser etching in-plane with the backing then bent to be out-of-
plane for application, can be seen in Figure 1.5A. Solid silicon microneedles (Figure 1.5B) are 
commonly made via deep reactive ion etching through a chromium mask.2,11,18 In Figure 1.5C, a 
silicon wafer, first etched with an array of holes via deep reactive ion etching, was processed to 
create a microneedle around each hole via subsequent etching, resulting in an array of hollow 
silicon microneedles orders of magnitude smaller than a hypodermic needle.36 Polymeric 
microneedles (carboxymethyl cellulose), made via molding technologies after the fabrication of a 
master template with traditional photolithography, are shown in Figure 1.5D.   
 
Figure 1.5 Recent advances in microneedle technologies. (A) Metal microneedles made from etched aluminum.18 
(B) Solids silicon microneedles.18 (C) Hollow microneedles (500 µm tall) shown next to a hypodermic needle.36 (D) 
Polymeric microneedles via molding technologies.11 
Each microneedle technology is associated with its own advantages and disadvantages. 
The fabrication techniques for solid metal and silicon microneedles are highly established and 
reproducible, but they do result in sharp, biohazardous waste after administration and have the 
A B 
C D 
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potential to fragment in the body, posing immunogenic consequences.2,10 While hollow 
microneedle arrays allow the most control over dose and reduce payload variability, they also 
require removal, more sophisticated fabrication, and require pumps that raise the complexity – 
and cost – of the devices.8,32 Biodegradable and water-soluble microneedle arrays eliminate the 
sharp, biohazardous waste created with solid and hollow microneedles, eradicating potential 
immunogenicity concerns and extensive disposal.2,10-13 Due to the promise of biodegradable and 
water-soluble microneedles, this work focuses exclusively on the development of such devices.  
1.3.2 Biodegradable/Water-soluble Microneedles  
 Biodegradable or water-soluble microneedles have been of great interest to the 
microneedle community since the early 2000’s, when the limitations of metal and silicon 
microneedle products were reported by multiple groups.38-40 The non-biodegradable and non-
biocompatible nature of metal and silicon have been postulated to limit the regulatory 
acceptability of such devices by the FDA.2 There is much interest in creating microneedles made 
out of materials the FDA classifies as Generally Regarded As Safe (GRAS); the reduction in 
immunoinflammatory response provided by such needles, coupled with their low cost, may lead 
to an easier path to market.2 Therefore, the ideal microneedle product for market may be a 
biocompatible device. Such an apparatus is envisioned to be strong enough to penetrate the 
stratum corneum effectively, inexpensive, and compatible with a wide range of drug substances. 
The material should be dissolvable in aqueous environments to release its payload without 
posing immunogenic consequences. Healthy skin is only seen to be 60-70% hydrated, so the 
release kinetics of the encapsulated drug depends on the solubility of the material in such an 
environment.41 Finally, manufacturing reproducible devices on a relevant scale of production is 
paramount for the success of the ideal biocompatible microneedle device.  
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 In recent years, this generation of microneedle devices has utilized a number of materials 
to efficaciously deliver small molecules, biomolecules, and particulate cargo in pre-clinical ex 
vivo and in vivo studies. For example, the Prausnitz group has pioneered many technologies with 
polymeric microneedles, such as the polyvinylpyrrolidone (PVP) devices shown in Figure 1.6 for 
the delivery of red fluorescent bovine serum albumin (BSA).3,6 Another water-soluble polymer, 
poly(methylvinylether-co-maleic anhydride) (PVME/MA), has been used by Donnelly et al. to 
mold microneedles for the delivery of theophylline, a hydrophilic drug with a molecular weight 
of 180 Da.42 The use of other materials – including carboxymethyl cellulose (CMC), poly(lactic-
co-glycolic acid), and other constituents – are common for the delivery of small molecules, large 
proteins, and nanoparticles. Table 1.2 summarizes recent advances in biodegradable and water-
soluble microneedles, demonstrating the chemical and pharmaceutical diversity of this promising 
field. While such devices have shown great promise in animal models – including mice, rats, 
guinea pigs, and non-human primates – dissolving microneedles have only been translated to 
human testing with a limited number of technologies.21,39,40,42-44 Hirobe et al. have applied 
microneedles made from a sodium hyaluronate/dextran/Povidone blend (without therapeutic 
cargo) to the forearms of the patients to assess dissolution kinetics, skin irritability, pain, and 
epidermal water loss; findings concluded that the optimized devices did not cause significant 
adverse reactions in any of the test subjects, and the group aims to begin vaccination studies as 
Phase I clinical trials.21 MicroCor, a dissolving microneedle patch developed by Corium 
International, Inc., has progressed through Phase I safety clinical trials; they began testing these 
devices for the delivery of parathyroid hormone in 2014.43,45 
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Figure 1.6 Polymer microneedle array manufactured by the Prausnitz group.3,6 
Table 1.2 Recent advances in biodegradable and water-soluble microneedles  
Material Therapeutic  
(Cargo) 
Therapeutic Size  
(Small, Medium, Large)  
Reference 
PVP BSA Medium 3,6 
PVME/MA Theophylline Small 42,46 
Maltos Nicardiapine HCL Small 40 
 Human immunoglobulin G  Large 44,47 
CMC Litocaine HCL Small 48 
CMC/PVP Ovalbumin Medium 26 
Galactose BSA Medium 39 
PLGA BSA Medium 49 
 Calcein Small 38 
 CMC nanoparticles  Large 50 
Dextran  Insulin  Medium 51 
 Human growth hormone Medium 52 
 Interferon-alpha Medium 53 
 Desmopressin Large 54 
Amylopectin  Lysozyme Medium 11 
Poly(methylvinylether/ 
maleic acid) 
Ibuprofen Small 55 
Poly(acrylic acid) PLGA microparticles Large 56 
 The high ex vivo and in vitro success of biodegradable and water-soluble microneedles, 
such as those developed by Corium, has led other companies such as 3M, Merck, NanoPass, and 
TheraJet to set sights to commercialize this technology.2,43,44,57 However, due to the seemingly 
low dose delivered by the patch; long, arduous manufacturing; and lack of reproducibility across 
the patches, these devices are currently in the research stage only, and no commercial 
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biodegradable microneedles are currently sold on the market.2,43,44,57 Without the ability to 
produce a clinically-relevant number of patches that maintain a reproducible size, shape, dose, 
and configuration, these elegant devices may remain in the lab. By utilizing an inexpensive, fast, 
reproducible manufacturing technology, biodegradable microneedle devices could be applied to 
a number of disease models, opening the door for painless vaccines, routine injections, and novel 
cancer treatments.  
1.4 Particle Replication In Non-wetting Templates (PRINT®) Technology  
 One way to overcome the limitations of current biodegradable microneedle fabrication 
technologies (discussed in detail in Chapter 2) may be afforded via Particle Replication In Non-
wetting Templates (PRINT) technology. The DeSimone Group developed the PRINT technique 
in the mid-2000’s, leading to the founding of Liquidia Technologies to commercialize the 
technology.58 PRINT combines lithographic techniques common in the semiconductor industry 
with flexible, fluorinated molds, allowing for  nanomaterials with precisely controlled size, 
shape, chemical composition, and surface characteristics to be manufactured.4,58-63 The PRINT 
process employs a nonwetting, nonswelling mold, made from perfluoropolyether (PFPE); this 
photocurable polymer has a highly fluorinated surface, which provides a nonwetting interface 
that allows for organic materials to be removed cleanly. Individual particles on the micro- and 
nanoscale can be fabricated and isolated using PRINT, adapted easily to a wide variety of 
matrices.4,58-63 The mild conditions required allow biologic cargo to maintain its function 
throughout the process.4,58-63 Furthermore, PRINT is a highly scalable, current good 
manufacturing practices (cGMP) compliant manufacturing technology.  
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Figure 1.7 Scheme depicting the PRINT process; (1) delivery sheet casting; (2) particle fabrication; (3) particle 
collection; (4) particle harvesting.4 
A brief description of the PRINT process for nanofabrication follows. PRINT begins 
after the fabrication of a master template, a silicon wafer patterned with the feature size and 
shape of interest using traditional photolithography techniques. PFPE (mixed with photoinitiator) 
is then applied to the silicon master template and chemically cross-linked under ultraviolet (UV) 
light to create an elastomeric mold with cavities of the desired shape and size. The low surface 
energy of the PFPE allows for it to wet the entire surface of etched silicon wafer, resulting in 
faithful reproduction of the master template.  
With the desired mold in hand, the process begins, as shown in Figure 1.7. A pre-particle 
solution (red) is mixed, containing a host of materials including polymers, monomers, drugs, 
nucleic acids, or any additional agent of interest. The pre-particle solution is then dispersed onto 
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polyethylene terephthalate (PET), forming a thin film. Residual solvent is removed by heating 
the thin film, leaving a solid-state film that serves as the delivery sheet for the mold. The 
uniformity of the thin film allows for particles with controlled size, shape, and chemical 
composition. 
Next, particle fabrication takes place, adhering the delivery sheet (red) to the PFPE mold 
(green). The PFPE mold is mated to the delivery sheet and passed through a laminator; for 
matrices that require increased thermal conditions to fill, the laminator is heated. As the sheet 
(red) leaves the laminator, the mold is then split from the sheet. The cavities in the mold have 
been filled via capillary action with the particle matrix. The highly fluorinated surface of the 
PFPE leads to high chemical resistance, preventing the deformation of the PRINT mold when 
exposed to any residual organic solutions used in pre-particle films and assuring the fidelity of 
the produced particles to the original master template; no interconnecting or flash layer is 
observed.58 For thermally cross-linked particles made using the heated laminator, the solution 
solidifies as the mold cools to room temperature.58 
To remove the particles for use, the mold (green) is then laid on a harvesting film 
(yellow) and once again passed through the laminator. The harvesting film is made from a 
sacrificial adhesive, such as cyanoacrylate or low molecular weight polymers, which adhere the 
particles to the harvesting surface.61 As the particles are removed from the mold, they maintain 
their shape and singularity. The particles on the harvesting film are then treated to remove the 
adhesive layer, creating a suspension of individual particles. 
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1.5 Summary and Hypothesis 
 Employing the PRINT technique, novel microneedle devices could be made to overcome 
the manufacturing, cost, and reproducibility limitations of biodegradable and water-soluble 
microneedles discussed above. After the creation of a master template with the ideal features of a 
microneedle patch, PRINT can be optimized for a wide variety of matrices, amenable to many 
cargos due to the mild conditions required. Microneedle devices made from an adapted PRINT 
platform could be applied to vaccine delivery, preventative medicine, cancers, etc.12,13,64 Herein, 
we outline the fabrication of PRINT microneedles loaded with small molecules, proteins, and 
nanoparticle drug surrogates and therapeutics. An investigation of the efficacy of these 
microneedles to pierce skin (both murine and human) and transport cargo is described through ex 
vivo and in vivo studies. The determination of the kinetic parameters for drug surrogate delivery 
from PRINT microneedles is investigated by varying their size, charge, and loading. Finally, two 
therapeutically-relevant cargos are studied to outline the promise of PRINT microneedle devices: 
the delivery of butyrylcholinesterase as a countermeasure against nerve gas overexposure and the 
treatment of skin-invading breast cancers by introducing chemotherapeutics (namely docetaxel) 
via microneedles.   
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CHAPTER 2 FABRICATION AND CHARACTERIZATION OF PRINT MICRONEEDLE PATCHES 
 
2.1 Introduction 
 In assessing the limitations of water-soluble or biodegradable microneedles across the 
field, it is apparent that many devices are manufactured in a way that fundamentally restricts the 
advancement of the field as a whole. Traditionally, biodegradable microneedles are made by 
filling a mold with a matrix containing the drug of interest; generally, multiple vacuum and 
centrifugation steps are required to completely fill the molds, arduous steps that lead to lengthy 
fabrication times and pose issues to scale-up manufacturing.1-5 A thick substrate, or backing 
layer, is attached to the array of microneedles to form a patch. After preparing microneedle 
patches, they generally are administered as shown in Figure 2.1A. Conventionally, the 
microneedle patch is applied topically to pierce the skin and penetrate into the viable epidermis 
or dermis, depending on the physical dimensions of the needles. Due to skin’s elastic qualities, 
the entirety of the needle does not enter the skin.6 The needles are left in the skin for the duration 
of the treatment period, from minutes (min) to hours (h), and the substrate is then removed, 
extracting all parts of the needle that have not yet dissolved (usually 5-20% of each 
microneedle).1,3-5 Consequently, a portion of the drug contained in the patch is removed, leading 
to a lower delivered dose than what was intended for the device. 
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Figure 2.1 Schematics of the applications of traditional biodegradable microneedles made using PRINT. (A) The 
needles and substrate (red) are inserted into the skin (top layer = epidermis, middle layer = dermis, bottom layer = 
subcutaneous fat). The backing is then removed. (B) The needles (red) and substrate (yellow) are inserted into the 
skin. The backing is then dissolved with tap water. 
  To overcome the barriers in fabrication of microneedles seen previously, we have created 
microneedle arrays using Particle Replication In Non-wetting Templates (PRINT®) technology, 
as described in Chapter 1.7 In summary, this technique combines a “top-down” method of soft 
lithography with traditional polymerization to create reproducible features on the nano- and 
micro-scale with precise control of size, shape, and chemical composition.7-14 A wide range of 
materials, including biodegradable and water-soluble polymers, sugars, and pure drug could be 
used, and the mild conditions required allow biologic cargo to maintain its function throughout 
the process. While the process was first utilized for the fabrication of nano- and microparticles 
less than 8 µm, the process is amenable to the creation of much larger microstructures (300-400 
µm in height) after the fabrication of masters in this size range via traditional photlithography.7-14 
PRINT allows for arrays to be made very quickly; after the desired mold is created, it can be 
used to make a microneedle patch in less than 5 min for batch processes. It can be adapted on 
 
B 
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any scale of production; this particular advantage will allow for patches of virtually any size to 
be made affordably and quickly.15 
A schematic of a microneedle device made using PRINT can be seen in Figure 2.1B. 
Through this process, an array of discrete microneedles would be manufactured and collected on 
a flexible, water-soluble substrate. Traditional microneedle arrays are often subject to the “bed of 
nails” effect, in which the force on each needle is distributed across the array, resulting in the 
inability of all needles to overcome the elasticity of the epidermis and pierce the skin.6 The 
flexibility of the substrate allows the array of highly-dense microprojections to avoid this effect 
and break the stratum corneum more efficiently.6 After application, the needle patch remains in 
the skin long enough to allow the polymer to dissolve or degrade, releasing its drug cargo. The 
substrate would then be dissolved, leaving the entire microneedle array in the skin. In this 
configuration, the entire payload of drug in the patch would be delivered. While this has been 
suggested, to our knowledge, no such patches have been created to date. Herein, we demonstrate 
the fabrication of 100% water-soluble microneedles on flexible substrates and their ability to 
load drug surrogates of nearly any size, shape, and surface charge while maintaining the function 
of the cargo after manufacturing.   
2.2 Results and Discussion  
To adapt the PRINT process to the high-throughput manufacturing of microneedle 
patches, a new mold shape must be created. Initially, a master template with the features of 
interest must be made. However, due to the unique shape of the intended microprojections – i.e. 
high aspect-ratio square pyramids that come to a sharp tip – traditional photolithographic 
procedures could not be utilized to create the structures, for they are not equipped to make high 
aspect-ratio or tapered structures using light field masks.16,17 By employing a tilted, rotated 
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approach, the intended structures can be made accurately. Unlike the master templates employed 
to make PRINT nano- and microparticles, though, the microneedle master templates are negative 
features; a positive replicate must be made as an intermediate before ideal molds can be created. 
These polydimethylsiloxane (PDMS) replicas, showing identical dimensions to the master 
templates, can be used to make perfluoropolyether (PFPE) molds, for the low surface energy of 
the polymer allows it to spread across and wet the replica as it would a silicon wafer.12-14 The 
mold is then used to create PRINT microneedles. Figure 2.2 shows Environmental Scanning 
Electron Microscopy (ESEM) images of each component of the development of the PRINT 
microneedle patches – masters, replicas, molds, and needles.  
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Figure 2.2 ESEM images of SU-8 Master template (A & B), PDMS template (C & D) and PFPE mold (E & F) and 
PVP microneedles (G & H) made from R2 SU-8 master (200 µm squares, 200 µm spacing). Needles show 
comparable lengths and tip radii. Scale bars on A, C, E, and G are 500 µm. Scale bars for B, D, F, and H are 200 
µm. 
2.2.1 Master Template Fabrication  
 Master templates were first prepared using a tilted-rotated photolithography approach 
adapted from Han et al.16,18,19 Briefly, a polished silicon wafer was coated with an anti-reflective 
layer; it was seen that this layer significantly reduced backside reflections and greatly increased 
the resolution of the resulting master templates (Figure 2.3). A thick layer of negative photoresist 
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(SU-8) was applied to the wafer via spin coating. Next, a mask with 200 µm x 200 µm squares 
and 200 µm spacing (base to base) was placed over the SU-8, and the complex was exposed to 
ultra-violet (UV) light at incidence angles of 18-25° (Figure 2.4). Both the mask dimensions and 
the incident angle of UV light determine the depth of the mold, and ultimately, the length of the 
microneedles.16,17 The wafer was then rotated 90° about the surface normal and exposed again; a 
total of four exposures led to female master templates with square-pyramidal cavities. These 
templates were imaged via ESEM to determine the length and tip radii of curvature that would be 
achieved through replication. Seen in Figure 2.2A-B, the template used for this study was 360 
µm in length and had tip radii of curvature under 10 µm. This length was selected based on the 
desire to reach the viable epidermis after piercing the stratum corneum. 
 
 
Figure 2.3 Effect of the anti-reflection chrome layer on a silicon wafer after UV exposure. (A) ESEM image 
confirming the occurrence of backside reflections without the presence of an anti-reflection coating. (B) ESEM 
image showing the absence of these reflections by adding the anti-reflection coating. 
 
Figure 2.4 Inclined, rotated photolithography schematic for making microneedle master templates. An SU-8 coated 
wafer is placed on a tilted stage (18-25°) and exposed. The substrate was then rotated 90° about the surface normal 
and exposed once more. After a total of four exposures, the wafer is post-exposure baked (PEB) and developed, 
leaving a negative master template. 
A B 
28 
 
2.2.2 PDMS Replica Fabrication  
A positive replica of the master template was made as an intermediate. The replicas were 
fabricated using commercially available PDMS due to its low surface energy, ease of use, high 
flexibility, and low cost.2 The replicas showed notable reproducibility of the master templates, 
having comparable needle lengths and tip radii of curvature via ESEM (Figure 2.2C-D).  
2.2.3 PFPE Mold Fabrication  
The positive replica was then used to make PRINT-compatible molds from a 
photocurable PFPE elastomer. PFPE is non-wetting and non-swelling, resulting in molds with a 
highly fluorinated surface that allow for microneedles of diverse chemical compositions to be 
made.7-11 The PFPE dimethacrylate utilized for PRINT molds of this dimension (i.e. considerably 
thicker than those utilized to manufacture nanoparticles) was made in house. In summary, PFPE 
dimethacrylate (Mw = 4 kDa) was synthesized as outlined in Scheme 2.1 from ZDOL 4000 and 
diazabicycloundecene (DBU) precursors.  
 
Scheme 2.1 Synthesis of PFPE dimethacrylate 
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The elastomer was cast over the replica and cured under UV light to create molds for 
microneedle manufacturing. The PRINT molds are consistent with the dimensions of the 
replicas, reproducibly mimicking the SU-8 master templates (seen via ESEM, Figure 2.2E-F). It 
should be noted that, based on laboratory findings, each master template can be used to make 
hundreds of PDMS replicas, and each replica can be used to make at least fifty PFPE molds. 
Each PFPE mold can be used to create at least ten microneedle arrays via PRINT processing.15  
2.2.4 Microneedle Fabrication 
2.2.4.1 Substrate Development 
The substrate for the microneedle backing was designed to be flexible and water-soluble. 
This is desirable for two reasons: 1) to facilitate improved penetration of the stratum corneum by 
avoiding the “bed of nails” effect, and 2) to create a microneedle patch that is 100% dissolvable 
to eliminate sharp, hazardous biowaste.6,20 A matrix of Luvitec VA64, a 
polyvinylpyrrolidone/polyvinylacetate blend, was selected due to its high water solubility and 
biocompatibility for topical use.21 Thick films of this polymer cast in methanol were not 
sufficiently flexible; therefore, multiple plasticizers were studied to lower the glass transition 
temperature (Tg) of the film to impart flexibility. In particular, triethyl citrate and trimethyl 
citrate in 1-3 weight percent (wt%) loadings showed promise for use as substrates; these films 
were analyzed by thermal gravimetric analysis (TGA) and differential scanning calorimetry 
(DSC). TGA studies were done to determine the 95% degradation temperature of the materials to 
avoid decomposition in the DSC. The DSC scans can be found as Figure 2.5.  
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Figure 2.5 DSC traces for harvesting layers investigated for the flexible, water-soluble harvesting layers. (A) VA64, 
(B) VA64+2% triethyl citrate, (C) VA64+2% triethyl citrate+0.5% fluorescein dye.  
A glass transition temperature around 25 °C was seen for the triethyl citrate films with 
loadings of 1-3%; this Tg allowed for optimal flexibility and thermal stability at room 
temperature (RT). Therefore, the blend of Luvitec VA64 in methanol and 2 wt% loading of 
triethyl citrate was selected for the fabrication of optimal substrates.  
2.2.4.2 PRINT Microneedle Fabrication  
While PRINT can be applied to fabricate microneedles out of a wide variety of chemical 
compositions, polyvinylpyrrolidone (PVP) was selected as the first matrix for study. This 
polymer was chosen because it is highly water soluble, has a high tensile strength, and is a 
biocompatible, FDA approved pharmaceutical excipient.1 Specifically, PVP with a molecular 
weight (Mw) of 10 kDa was used because it has been shown that masses less than 20 kDa are 
cleared efficiently from the kidney after subcutaneous injection and, therefore, are safe for 
human use.1 PVP microneedles were fabricated using the PRINT process as optimized for the 
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fabrication of structures over 100 µm (i.e. microneedles), previously unexplored through this 
platform (Figure 2.6). A solution of PVP in water (15-20 wt% total solids) was used for film 
casting; the solution was cast onto plastic sheets and left to dry for 24-48 h. The film was then 
mated to the PRINT PFPE microneedle mold and passed through a heated nip. Due to the non-
wetting characteristic of the PFPE molds, excess PVP was wicked away after passage through 
the nip, leaving arrays of discrete microneedles that were harvested onto the flexible substrates. 
Fabricated patches contained approximately 500-700 needles; however, the PRINT process is 
highly scalable for cost-effective manufacturing, enabling patches of virtually any size to be 
created affordably and quickly.15   
 
Figure 2.6 Schematic of the PRINT process for making microneedles, including the fabrication of individual 
microneedles and harvesting onto the flexible, water-soluble substrate. (A) A film of PVP (red) is mated to a 
perfluoropolyether mold (green) and passed through a heated nip at 98-105 °C. The filled mold is then separated 
from the film. (B) The filled mold is mated to a flexible, water-soluble substrate (yellow) for harvesting and passed 
through a heated nip at 65 °C. After separation, a microneedle array on the substrate remains. 
The microneedles were then characterized by ESEM (Figure 2.2G-H). Microneedles 
demonstrated remarkable reproducibility, with bases measuring 195.1 ± 4.4 µm, lengths of 361.4 
A 
B 
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± 5.7 µm, and tip radii of curvature of 9.93 ± 1.7 µm (n = 15). These dimensions also closely 
mimic the master template, indicating that the microneedles retained their original shape and 
sharpness throughout processing. The flexibility of the array can be seen in Figure 2.7. The rigid 
microneedles remained intact after the gentle bending of the array by hand. Both the 
microneedles and the substrate were seen to dissolve rapidly in the presence of a few drops of 
water; after 5 min, the device was completely dissolved. Therefore, novel 100% water-soluble 
microneedle patches on flexible substrates can be made quickly and reproducibly via PRINT 
processing. 
  
Figure 2.7 Array of PRINTed PVP microneedles harvested on engineered flexible substrate.   
2.2.5 Drug Surrogate Loading into Microneedles  
 To explore the versatility of the PRINT microneedle platform – as well as the 
fundamental ex vivo kinetic release profiles and in vivo biodistribution of possible therapeutics – 
a number of “drug surrogates” were loaded into PVP microneedle patches, from small molecule 
dyes to proteins to nanoparticles also made via PRINT. As outlined, the size of the cargo 
delivered via microneedles is determined by the size of the channels created by the needles 
themselves.22 Since PRINT microneedles serve as both a means to physically create channels 
through the skin as well as the method of payload delivery, any cargo that can be incorporated 
into the PRINT microneedles can, in concept, be delivered via the devices. We have established 
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that the integration of a wide variety of drug surrogates into PRINT microneedles can be done by 
simply including the cargo into the solid-state PVP film used for microneedle manufacturing. 
The amphiphilic nature of PVP, due to its highly polar amide groups in conjunction with apolar 
methylene and methane moieties on the backbone, lends to the formation of homogenous films 
of cargos of any surface charge.23 Drug surrogate loading was optimized for each dye, protein, or 
particle of interest to establish the maximum loading (wt%) of the cargo that resulted in 
microneedles of adequate tensile strength to overcome the elastic skin barrier effectively.  
2.2.5.1 Fluorescent Dyes  
 Two fluorescent dyes were investigated as small molecule drug surrogates to demonstrate 
the ability of PRINT microneedles to encapsulate cargo – rhodamine B and DyLight 680 (Figure 
2.8). Rhodamine B was utilized for all ex vivo studies due to its low cost and availability, but 
could not be employed in live animal studies quantitatively; DyLight 680 was selected to 
overcome this limitation but was not used exclusively due to its high cost. Additionally, the 
differences in surface charge – rhodamine B positive at neutral pH (7.4) and DyLight 680 
negative under the same conditions – demonstrated the ability of PRINT microneedles to load 
small molecules of either charge.  
 
Figure 2.8 Fluorescent drug surrogates incorporated into PRINT microneedles. (A) Rhodamine B base, shown with 
a chloride counter ion. (B) DyLight 680, shown with a maleimide functional handle.24,25  
A B 
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To make the microneedles with dye, rhodamine B or DyLight 680 (at a loading of 0.1-1 
wt% of total solids) was included in the matrix by mixing it into the PVP/water solution before 
film casting. Films including each drug surrogate were imaged via confocal microscopy to 
confirm cargo homogeneity (Figure 2.9). DSC analysis of each film (after storage at 30% relative 
humidity) was performed to determine the thermal properties of each material, an indication of 
its strength.26 The Tg’s can be found in Table 2.1. It was found that the Tg’s of the materials were 
not significantly altered by the addition of small molecule drug surrogates, resulting in no 
significant changes in the materials. However, the Tg of the microneedle matrix is not the sole 
predictor of the ability of device to penetrate skin under force of thumb; it has been reported that 
the microneedles tip radius, aspect ratio, and needle density across an array all play a significant 
role in the force required to penetrate the epidermis.27 Therefore, the thermal data served as a 
guide to demonstrate potential to serve as an effective device.  
Table 2.1 Glass transition temperatures of films containing drug surrogate cargos 
Material Tg, °C 
PVP (100 wt%) 50.1 
PVP (99.9 wt%) 
Rhodamine B (1 wt%) 
45.4 
PVP (99.5 wt%) 
DyLight 680 (0.1 wt%) 
55.9 
 
Films encapsulating each cargo were PRINTed in accordance with the procedure 
described above for PVP microneedle fabrication; there were no additional changes needed to 
produce microneedles with the desired cargo. Figure 2.10 shows macroscopic images of 
microneedles loaded with the rhodamine B drug surrogate, B-C highlighting the flexibility of the 
arrays. Figure 2.9 shows confocal microscopy images of the microneedles, emphasizing the 
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distribution of the drug surrogate throughout the needle matrix. It can be seen that the dyes 
permeate the entirety of the needle, but a slight increase in fluorophore density can be seen at the 
tip of the microneedle. In conclusion, the PVP microneedle matrix can encapsulate both positive 
and negative fluorescent drug surrogates, resulting in microneedle devices optimized for ex vivo 
and in vivo analysis.  
 
 
Figure 2.9 Confocal microscopic images of films and microneedles incorporating the selected fluorescent drug 
surrogates, rhodamine B and DyLight 680. (A) Rhodamine B film, (B) Rhodamine B microneedle, (C) DyLight 680 
film, (D) DyLight 680 microneedle. 
 
A B 
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Figure 2.10 Brightfield macroscopic images of a microneedle patch. (A) The microneedle array morphology, 
showing reproducible needles. Scale bar is 200 µm. (B) A curled microneedle array, showing the flexibility of the 
array. Scale bar is 1 cm. (C) A side view of a curled microneedle array, showing the size of the array in comparison 
to human fingers. Scale bar is 1 cm. 
2.2.5.2 Proteins  
 One of the most promising applications of microneedle technology is the delivery of 
protein or peptide therapeutics transdermally, due to the many disadvantages of introducing these 
macromolecular therapeutics via oral ingestion or hypodermic injection.1,5,8,27 Microneedles offer 
the advantage of delivering the therapeutic to the body without exposure to the gastrointestinal 
tract while eliminating the pain and safety concerns associated with needles.1,5,8,27 The delivery 
of proteins via microneedles has been successful with a variety of approaches: application of a 
topical solution containing the protein therapeutic before or after microneedle insertion via the 
“poke then patch” approach, coating the surface of microneedles with a lyophilized therapeutic 
A 
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formulation for dissolution upon application, infusion via pumping a solution containing the 
therapeutic though an array of hollow microneedles, and passive diffusion out of a biodegradable 
microneedle after encapsulation into the matrix itself.27-29 However, many biodegradable 
microneedle fabrication schemes employ processing conditions too harsh or solvents too 
incompatible with these therapeutics to maintain protein structure/activity post-fabrication; also, 
many biocompatible polymers lack the structural stability necessary to successfully penetrate 
skin.29 PRINT fabrication allows for the successful incorporation of active biologic cargo due to 
the mild conditions required, and the high strength of the PVP polymer provides a robust matrix 
for protein incorporation; therefore, PRINT microneedles may provide an attractive method to 
deliver protein therapeutics.8-10  
Two model proteins – ovalbumin (OVA) and aldolase – were selected as protein drug 
surrogates for incorporation into PRINT microneedles (Figure 2.11). OVA, a model protein 
antigen derived from avian egg, is approximately 45 kDa and has an isoelectric point (pI) of 
4.6.29 Aldolase, an enzyme involved in gluconeogenesis derived from rabbit muscle, is much 
larger in size, 161 kDa, and has a pI of 8.5.30,31 These two proteins vary drastically in size, and 
their differences in pI give them opposite surface charges at philological pH, for at a pH below 
their pI, proteins carry a net positive charge (aldolase at pH 7.4); above their pI, they carry a net 
negative charge (OVA at pH 7.4). This allows for the investigation of how protein size and 
charge influence loading and release from PRINT microneedles. Prior to use, both proteins were 
tagged with a fluorescent tag (fluorescein or AlexaFluor 488) via a N-hydroxysuccinimide 
(NHS) ester, chemically conjugating to a primary amine on the backbone of the protein.  
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Figure 2.11 Crystallography structures of the drug surrogate proteins selected for microneedle incorporation. (A) 
OVA, (B) Aldolase.30,31  
 The drug surrogate proteins were incorporated into the aqueous pre-microneedle solution 
(15-20 wt% total solids) and cast as solid-state films as described previously. It was determined 
that a protein loading of 20 wt% (80 wt% PVP comprising the solids composition) was the 
maximum loading that yielded a homogenous film. Additionally, DSC analysis revealed that pre-
microneedle films loaded with up to 20 wt% showed Tg’s above 40 °C, making them candidates 
to be strong enough for skin penetration. Microneedle patches were then fabricated via PRINT, 
merely modifying the nip temperature to protect the thermally-liable proteins. While all previous 
microneedles had been made with a nip temperature of 105 °C, the Tg of the PVP films is much 
lower (Table 2.1), allowing it to flow into the molds at reduced temperatures under optimized 
filling conditions. Therefore, the nip temperature was lowered to 77-82 °C. The resulting 
microneedle patches were imaged via ESEM and confocal microscopy, as seen in Figure 2.12; 
pre-microneedle films were also analyzed via confocal microscopy, and, as shown, both cargos 
distribute homogeneously throughout the matrix.  
A B 
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Figure 2.12 Confocal microscopy and ESEM images of pre-microneedle films (top) and microneedles (bottom) 
containing protein drug surrogates. (Left) Fluorescein-tagged OVA at a loading of 20 wt%, (Right) Fluorescein-
tagged aldolase at a loading of 20 wt%. Scale bars on ESEM images are 400 µm. 
To determine if the protein cargos maintained function throughout microneedle 
fabrication, biological assays were performed on the pre-microneedle solution, films, and 
patches. In order to assess OVA intactness, a NativePAGE gel was performed. Films and patches 
loaded with OVA were dissolved in aqueous solution to facilitate the analysis for comparison to 
standard and pre-microneedle solutions. Figure 2.13A shows the NativePAGE results as 
compared to a ladder. The bands at 45 kDa, corresponding to the OVA protein, can be seen in 
20 wt% OVA 20 wt% Aldolase 
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lanes 2-5, representing the pre-microneedle solution, film, patch, and unconsumed film (due to 
the space between features in the mold, fundamental to the PRINT process) respectively. 
Therefore, we can conclude that the tertiary structure of the OVA is retained throughout 
microneedle fabrication, indicating the protein can still perform all primary functions in vivo. 
Due to the enzymatic nature of aldolase, an activity assay was done to observe any net changes 
in conversion. In these studies, films containing aldolase were either analyzed after drying (pre-
processing) or after lamination at the fabrication conditions optimized for protein microneedles 
(post-processing).  Figure 2.13B shows that the aldolase retains 98% of its activity after 
processing (n = 3). Clearly, the function of the aldolase is not harmed through the PRINT 
process. In sum, microneedles loaded with proteins can retain both structure and function after 
exposure to the mild conditions required for PRINT processing.  
 
 
Figure 2.13 Assessment of protein intactness after fabrication via PRINT. (A) NativePAGE gel of OVA 
microneedles. Lane: 1) ladder, 2) pre-microneedle solution, 3) film, 4) microneedle patch, 5) unconsumed film. (B) 
Aldolase activity of solid-state microneedle films pre- and post-processing via PRINT, expressed as a percentage of 
the activity found for the pre-microneedle solution. 
2.2.5.2 PRINT Particles  
 The delivery of nanoparticles via microneedles has been of interest for some time due to 
the numerous advantages of nanocarriers for controlled subcutaneous release, including 
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increased efficacy, dose sparing, and improved safety.27 Additionally, the high density of antigen 
presenting cells (APC’s), Langerhans cells, in the epidermal layer (20-25% of the surface area) 
make the skin an ideal route of administration for vaccines; both innate and adaptive immune 
responses are generated in the skin upon the uptake of antigens by these APC’s.33,34  Microneedle 
vaccines have been fairly limited due to the fragility of the cargos, but nanocarriers offer many 
advantages, including: mimicking the size and shape of the pathogen, inherently protecting 
vaccine antigens and adjuvants, showing an improved immunogenicity from the delivery of 
soluble subunits, and providing a dose sparing effect that results in a lower required dose for 
human vaccination.27, 35-38 Many strategies have been employed to incorporate nanoparticles into 
a microneedle-based drug delivery system; adsorbing particles to the surface of solid 
microneedles and administering a topical formulation (including the particles) after applying 
microneedles via the “poke then patch” approach have been successful in recent years.27,39 While 
nanomaterials have been incorporated into biodegradable microneedles for the purpose of 
increasing the strength of the matrix for some time, delivering a nanovaccine via release from 
biodegradable or water-soluble microneedle device has only been investigated by a small group 
of researchers, showing great promise.29,41,42 Zaric et. al. has targeted skin dendritic cells by 
delivering an nanoencapsulated antigen via poly-D,L-lactide-co-glycolide (PLGA), resulting in a 
complete protection in vivo against melanoma models and murine para-influenza.41,42 Due to the 
many advantages of particulate delivery via microneedles, we have fabricated PRINT 
microneedle devices that encapsulate PRINT hydrogel nanoparticles with a range of surface 
chemistries to determine the ability of the microneedles to deliver “large” drug surrogates.  
 An 80 x 320 nm hydrogel PRINT nanoparticle was selected as the particulate drug 
surrogate of interest. The hydrogel matrix, comprised mainly of hydroxy tetraethylene glycol 
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monoacrylate (HP4A), results in particles that are inherently non-immunogenic, and this 
advantage – as well as their versatility of chemical modification – made them ideal for the 
investigation of how particle surface charge plays a role in microneedle encapsulation and 
subsequent release. Particles were made via a continuous roll-to-roll PRINT process, as 
optimized by Perry et. al.12 Briefly, a 3.5 wt% solution of the particle composition (found in 
Table 2.2) was prepared, and solid-state films were cast on a highly charged poly(ethylene 
terephthalate) (PET) sheet. The film was then mated with a thin PFPE mold and sent through a 
pressure nip before curing under a UV-LED lamp. The cured particles were transferred to a 
harvesting layer composed of polyvinyl alcohol (PVOH); this layer was selectively dissolved in 
water, leaving the intact hydrogel particles in solution. The bare (non-modified) particles were 
visually characterized via scanning electron microscopy (SEM), and dynamic light scattering 
(DLS) was employed to determine the size, polydispersity index (PDI), and surface charge (δ-
potential) (Table 2.3 and Figure 2.14).  
Table 2.2 Hydrogel particle composition for 80 x 320 nm PRINT particles  
Hydrogel Component Wt% 
Hydroxy tetraethylene glycol monoacrylate 
(HP4A) 
67-68 
Polyethylene glycol (PEG) diacrylate, Mw = 
700 g/mol  
10 
2-aminoethyl methacrylate HCL (AEM) 20 
2,4,6 trimethylbenzoyl diphenylphosphine 
oxide (TPO) 
1 
Fluorescent dye 
(Fluorescein o-acrylate (F-o-A), DyLight 488 
maleimide, or AlexaFluor 488 maleimide) 
1-2 
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Table 2.3 Particle characterization for 80 x 320 nm PRINT particles  
 Particle  Size (nm) Polydispersity 
Index 
Zeta Potential 
(mV) 
Bare (+) 272.8 ± 7.2 0.083 ± 0.017 33.6 ± 2.18 
PEGylated (neu) 551.5 ± 6.6 0.314 ± 0.014 24.3 ± 0.55 
Acetylated (-)  489.3 ± 4.4 0.307 ± 0.003 -16.4 ± 0.451 
 
 
Figure 2.14 SEM images of 80 x 320 nm hydrogel PRINT particles.  
 Due to the AEM incorporated into the hydrogel matrix, a functional handle on the 
particles’ surface allows for chemical modification, controlling the surface characteristics, and 
therefore, charge of the nanocarrier. Bare hydrogel particles carry a positive surface charge, 
+33.6 mV (Table 2.3), due to the highly positive AEM. To make a more neutral particle, 
polyethylene glycol (PEG) was conjugated to the particles (PEGylation). This strategy is 
frequently used to increase circulation half-life of a therapeutic by minimizing the binding of 
serum proteins, reducing the frequency of detection and clearance by the mononuclear phagocyte 
system.12,43 For these studies, particles were PEGylated by incubation overnight with a 
maleimide-PEG (Mw = 5 kDa) before removing the residual PEG via centrifugation.
12 The 
resulting PEGylated particles showed a surface charge of +24.3 mV, a more neutral δ-potential 
(characterization data shown in Table 2.3).  
 Following PEGylation, particles were acetylated with acetic anhydride to quench any 
unreacted amines, yielding particles with a negative surface charge. Briefly, the PEGylated 
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particles in dimethylformamide (DMF) were mixed with an excess of pyridine and acetic 
anhydride, subsequently quenched with borate buffer (pH 9.5), then resuspended in water to 
form an aqueous particle suspension. The resulting acetylated particles showed a surface charge 
of -16.4 mV, a negitave δ-potential ideal for our studies (characterization data shown in Table 
2.3). 
 After particle fabrication and characterization, all three particle types (bare, PEGylated, 
and acetylated) were encapsulated into microneedles via PRINT. As anticipated, all three 
hydrogel particles swell considerably in water; the use of aqueous casting solvents, as optimized 
for all other microneedle matrices, may not result in ideal microneedles.12 A variety of organic 
solvents were investigated to determine the ideal casting solution for microneedles incorporating 
hydrogel components, initially utilizing the bare 80 x 320 nm particles. Due to PVP’s high 
solubility in a number of solvents owing to its amphilicity, acetonitrile (ACN), isopropanol 
(IPA), ethanol (EtOH), and methanol (MeOH) were all examined and compared to a water (H2O) 
control. Pre-microneedle films were made by mixing a 15-40 wt% total solids solution (90 wt% 
PVP, 10% bare 80 x 320 nm particles, the maximum particle concentration that resulted in 
homogenous films) in each solvent, drop-casting each onto plastic sheets, and allowing the films 
to dry for 24-48 h; a majority of the casting solvent (95-99%) evaporates after this time, making 
the casting solvent itself a minor constituent of the resultant films. Films were then mated to 
microneedle molds and PRINTed using the optimized conditions for manufacturing with small 
molecule drug surrogates. Films and microneedles were visualized via confocal microscopy, as 
seen in Figure 2.15. While all films showed similar particle distribution, and appeared 
homogenous, the microneedles showed high variability based solely upon the casting solvent. 
After the use of H2O, ACN, and IPA as casting solvents, particles were highly concentrated near 
45 
 
the tip of the microneedles, while the casting with EtOH or MeOH yielded particles that were 
evenly distributed throughout the microneedle.  
 
Figure 2.15 Films and microneedles with bare (+) 80 x 320 nm particles incorporated via a variety of solvents at a 
loading of 10 wt%. (A) H2O, (B) ACN, (C) EtOH, (D) IPA, (E) MeOH.  
Films cast in ACN and MeOH both demonstrated adequate strength to penetrate skin, and 
due to their stark differences in distribution, these two solvents were chosen for further 
investigation and downselection. Bare particles (2.5 wt% total solids) were loaded into films and 
microneedles, and the resulting materials were imaged via confocal microscopy and ESEM 
(Figure 2.16). While the microneedles appeared identical on the ESEM, it was seen that the 
distribution of particles contrasted between the two solvents, consistent with the results at a 
loading of 10 wt%. Particles were generally more localized to the tip of the microneedles 
resulting from ACN casting, while the MeOH microneedles showed a homogenous distribution 
of particles throughout the needle; it should be noted, however, that the difference in distribution 
was much more stark at a loading of 10 wt%. Therefore, to determine the ideal casting solvent 
for these microneedles, the final loading, or particle wt% of the fabricated patch, was determined 
and compared to the particle wt% charged (2.5 wt%). To do so, microneedle patches made with 
both ACN and MeOH were massed, dissolved in sterile water, and centrifuged to create a pellet 
of particles; residual PVP was removed via three centrifugal water washes. The resulting particle 
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suspensions were analyzed via TGA, and the final encapsulation efficiency was calculated by 
dividing the mass of particles recovered by the mass of the patch before dissolution. The results 
can be seen in Table 2.4. It was seen that the particles loaded into the microneedles with a MeOH 
casting solvent resulted in a 15% higher encapsulation efficiency than ACN; therefore, MeOH 
was selected as the casting solvent for all microneedles incorporating hydrogel particles.  
 
 
 
 
 
Figure 2.16 ESEM (left) and confocal microscopy (right) images of PVP microneedles and films loaded with 80 x 
320 nm bare hydrogel particles.  
Table 2.4 Loading efficiency of 80 x 320 nm bare hydrogel particles into PVP microneedles, as compared to the 
particle wt% charged, 2.5% 
Casting Solvent  Particle wt% loading Encapsulation Efficiency, 
%  
ACN 0.71 28 
MeOH 1.08 43 
 
 Utilizing MeOH as the casting solvent, microneedle patches were fabricated using the 
optimized PRINT process for 80 x 320 nm hydrogel particles, incorporating separately the bare, 
PEGylated, and acetylated particles. A particle loading of 5 wt% total solids was optimized for 
further ex vivo experiments with the purpose of ensuring both high loading and distribution 
2.5 wt % bare 80 x 320 nm particles, cast in ACN 
2.5 wt % bare 80 x 320 nm particles, cast in MeOH 
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homogeneity. ESEM and confocal images of the resulting microneedle patches can be seen as 
Figure 2.17. The particles of all three surface charges distribute throughout the microneedles, 
showing the ability of PVP PRINT microneedles to encapsulate “large” drug surrogates of 
various charges.   
 
Figure 2.17 Films (above) and microneedles (below) loaded with 5 wt% 80 x 320 nm hydrogel particles. All 
particles have been tagged (during PRINTing) with 488 maleimide for ex vivo compatibility. (A) Bare (+) particles, 
(B) PEGylated (neu) particles, (C) Acetylated (-) particles. 
2.3 Conclusions  
 Herein, we have described the fabrication of PRINT microneedles, a new size and shape 
that has been added to the library of structures made via this powerful manufacturing technology. 
With a main limitation of biodegradable microneedles being their arduous manufacturing and 
lack of reproducibility, the PRINT platform has great promise to expand this growing field.15 To 
provide proof of concept that these devices could encapsulate a therapeutic cargo, drug 
surrogates of various sizes, shapes, and surface charge (small molecule dyes, proteins, and 
hydrogel nanoparticles) have been incorporated into the microneedles at concentrations projected 
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to be therapeutically relevant. Further studies (Chapter 3) include the investigation of these 
materials ex vivo and in vivo to provide pre-clinical efficacy data, exploring the differences in 
drug surrogate release profiles and kinetics observed as we vary cargo size and charge.  
2.4 Experimental 
2.4.1 Master Template Fabrication 
Rigid SU-8 2150 (MicroChem) microneedle templates were fabricated using a tilted-
rotated UV lithography approach.15,16,18,19 In summary, a single crystalline silicon (Si[100]) 
wafer was coated with an antireflective coating consisting of a CrOx/Cr multilayer. The thickness 
of the CrOx layer was chosen to minimize reflections of 365 nm UV light from the substrate. The 
substrate was then spin-coated with 600 µm thick SU-8 and soft baked at 100 °C for 8 h.  The 
coated silicon wafer was cleaved into squares pieces, which were then attached to a light-field 
mask of 200 µm × 200 µm chromium squares. The substrate was then exposed to filtered UV 
light incident at angles between 18-25°. The exposure was performed in four 450 mJ/cm2 
increments in which the substrate was rotated 90° about its surface normal between each 
exposure. The PEB was performed at 65 °C for 30 min. At the end of the PEB, the temperature 
was slowly ramped down to room temperature and the substrate was allowed to relax for 60 min. 
The unusually low-temperature PEB and the subsequent gentle cooling steps were critical to 
reduce stress in the SU-8, which can cause the template to break. The substrate was then 
developed with propylene glycol monomethyl ether acetate (PGMEA) in an ultra-sonic bath for 
10 min and rinsed with IPA. This development sequence was repeated three times to ensure the 
molds were fully developed. Select templates were sputter-coated with a 100 nm-thick layer of 
gold to facilitate PDMS release. Templates were characterized by ESEM (FEI Quanta 200). 
Optimal masters had 200 µm base widths, 385 µm heights, and 10 µm tip radii. 
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2.4.2 PDMS Replica Fabrication  
Replicas of the SU-8 templates were made by casting a thick layer of silicone (Sylgard 
184, Dow Corning) over the master. The PDMS was degassed in a vacuum desiccator for 2 h 
before centrifugation for 20 min at 3000 g and 4 °C; this process was then repeated once. The 
replica was left to cure under vacuum overnight at RT and was finished with a 2 h bake in a 65 
°C oven. Templates were characterized by ESEM (FEI Quanta 200). 
2.4.3 PFPE Synthesis and Mold Fabrication  
PFPE dimethacrylate, the monomer utilized to make PRINT-compatible molds, was 
synthesized in house with the molecular weight of 4 kDa. To a flame dried 200 mL round bottom 
flask that was cooled under argon, ZDOL 4000 (50 g, 13.2 mmol), 1,1,1-3,3-pentafluorobutane 
(45 mL), and 2-isocyanatoethylmetha-crylate (4.4 g, 28.2 mmol) were added under ambient 
conditions. Following this, DBU (50 µL) was added as a catalyst, and the solution was heated to 
42 °C under a nitrogen/argon purge. After reflux was observed, the mixture was allowed to stir 1 
h before the flask was removed from heat; the flask was cooled to ambient temperatures (~1 h). 
Then, silica gel (20 g) was added to the flask and stirred for 15 min before filtration through 
coarse filter paper. The mixture was separated via rotovap, and the clear oil that resulted was 
subjected to 1H NMR (Figure 2.18). The ZDOL (Solvay), 1,1,1-3,3-pentafluorobutane (Solvay), 
2-isocyanatoethylmetha-crylate (Aldrich), and DBU (Aldrich) were all used as received.  
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Figure 2.18 1H NMR traces for the starting product and final product show a complete disappearance of the alcohol 
at 3.8 ppm (A) and the appearance of methylene at 4.45 ppm and vinyl proteins around 5-5.6 ppm (B).  (A) Z-DOL 
4000, (B) 4K PFPE-dMA. 
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 Optimized PDMS templates were used to create PRINT molds using the PFPE 
dimethacrylate. A 0.2 wt% solution of 2,2-diethoxyacetophenone (98%, Acros) in PFPE 
dimethacrylate was drop-cast onto the replica, and a flexible plastic sheet was applied to serve as 
a supportive backing. The mold was cured in nitrogen-purged UV oven (λ = 365 nm), and the 
finished mold was separated from the replica for use. Molds were characterized by ESEM. 
2.4.4 Substrate Development 
Flexible, water-soluble substrates served as the backing to the microneedle patches. 
Blends of a polyvinylpyrrolidone/polyvinylacetate copolymer (Luvitec VA64, BASF) and a 
variety of plasticizers were mixed in methanol at 30 wt% loadings, cast upon plastic sheets, and 
allowed to dry for 24 h at RT. Plasticizers studied included glycerol, castor oil, Tween80, PEG 
(400 g/mol), triethyl citrate (TEC), tributyl citrate, and trimethyl citrate (TMC) at loadings of 1-
10 wt%. Substrates plasticized with TEC and TMC at loadings of 1-5% showed adequate 
flexibility and were subjected to TGA (PerkinElmer Pyris 1) and DSC (Q200, TA Instruments) 
analysis to determine the optimal blend. TGA decomposition experiments were done by heating 
5-10 mg of substrate from 0-550 °C at 10 °C/min, and the 95% decomposition temperature was 
determined; the upper temperature limit for the DSC experiments was to be no more than 50 °C 
lower than the 95% decomposition temperature for each material. DSC was used to determine 
the Tg’s of the substrates. Samples (5-10 mg) were crimped into aluminum pans and heated from 
-20 °C to 100-120 °C at a rate of 5 °C/min, cooled at a rate of 10 °C/min to -20 °C, and heated 
again in a second cycle. Tg’s were determined from the second heating cycle. Results of these 
studies can be found in Table 2.5. After analysis, triethyl citrate in 2% loading was selected as 
the optimal plasticizer for the flexible substrates in VA64. Select substrates were loaded with 0.5 
wt% fluorescein (pure, Acros) for imaging by mixing the dye into the solution prior to casting.  
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Table 2.5 Glass transition temperatures (Tg) observed via DSC of VA64 substrates loaded with plasticizers and 
fluorescein dye. 
 
 
 
 
 
Tg, 
°C 
Material 
VA64 VA64 + Plasticizer VA64 + Plasticizer + Dye 
Film VA64 
+ 1% 
TEC 
VA64 
+ 2% 
TEC 
VA64 
+ 3% 
TEC 
VA64 
+ 5% 
TEC 
VA64 
+ 3% 
TMC 
VA64 + 
3% TEC 
+ 1% 
Dye 
VA64 + 2% 
TEC + 
0.5% Dye 
VA64 + 
3% TMC 
+ 0.5% 
Dye 
50.08 24.05 27.59 13.24 17.76 25.66 21.01 26.72 24.83 
 
2.4.5 PRINT Particle Fabrication and Characterization 
2.4.5.1 Materials  
PEG diacrylate (Mw = 700 g/mol), AEM, TPO, and F-o-A were obtained from Sigma-
Aldrich. DyLight 488, acetic anhydride, triethylamine, borate buffer (pH 9.5), pyridine, DMF, 
and IPA were purchased through Fisher Scientific, and AlexaFluor 488 via Life Technologies. 
Polyvinyl alcohol (Mw = 2 kDa) (PVOH) was bought from Acros Organics. Methoxy-PEG(5k)-
succinimidyl carboxy methyl ester was purchased from Creative PEGworks. All commercial 
materials were used as received. 
PET sheets and PRINT molds (80 x 80 x 320 nm) were obtained from Liquidia 
Technologies. HP4A was synthesized in-house as previously described.
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2.4.5.2 Particle Fabrication 
Hydrogel 80 x 320 nm PRINT particles were fabricated via PRINT in a continuous roll-
to-roll manner (Liquidia Technologies), optimized previously by Perry et al.12-14 Pre-particle 
solutions, using the composition described in Table 2.2, were prepared in IPA (3.5 wt% solids). 
A thin film of the pre-particle solution was drawn onto corona-treated PET using a #3 Mayer rod 
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(R.D. Specialties) at a speed of 12 ft/min. Simultaneously, solvent evaporation was achieved by 
exposing the film to a hot air dam derived from heat guns. The dried film (delivery sheet) was 
laminated at 80 PSI to 80 x 320 nm PRINT mold, followed by delamination at the nip. The 
hydrogel particles were cured by passing the filled mold through a UV-LED (Phoseon, λ = 395 
nm). A harvesting sheet, a thin film of PVOH, mated to the filled mold and passed through a 
heated nip (140 °C, 80 PSI). Particles were harvested manually by splitting the harvesting sheet 
from the mold and dissolving the PVOH in a bead of water (1 mL of water per 5 ft of harvesting 
sheet). Any large particulates were removed by passing the particle suspension through a 2 µm 
filter (Agilent). Centrifugation (Eppendorf Centrifuge 5417R) at 21,000 g for 15 min was 
employed to remove the excess PVOH. The supernatant was removed and the particles were re-
suspended in sterile water; a total of four washes produced a pure solution of 80 x 320 bare 
hydrogel particles.  
To PEGylate a portion of the particles, a solution of approximately 5 mg of bare particles 
was resuspended in DMF in accordance with the centrifugation protocol outlined above; the final 
concentration of the particles was 5 mg/mL. The particle solution (1 mL) was shaken at 1400 
RPM (Eppendorf) with 100 µL of triethylamine for 10 min at RT. Next, 140 µL of a 100 mg/mL 
solution of methoxy-PEG(5k)-succinimidyl carboxy methyl ester, also in DMF, was added to the 
reaction mixture; the total volume of the mixture was brought to 1.4 mL with DMF. The 
PEGylation reaction was allowed to shake overnight before a series of centrifugal washings 
(three times in DMF, an additional four times in water), resulting in an aqueous suspension of 
particles.  
A subset of the PEGylated particles was then acetylated to create a particle with a 
negative surface charge for microneedle encapsulation. A solution of 5 mg/mL of PEGylated 
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particles (in DMF) was mixed with an excess of pyridine (50 µL) and acetic anhydride (70 µL). 
The solution was left to shake for 30 min at RT at 1400 RPM (Eppendorf). The particles were 
washed via centrifugation, once with DMF and once with a borate buffer (pH 9.5) to quench the 
reaction and remove any acetic acid that may have resulted via a side reaction. The particles 
were returned to an aqueous suspension via four centrifugal washes as outlined above.  
2.4.5.3 Particle Characterization  
Particles were characterized post-fabrication (bare), after PEGylation, and at the 
conclusion of acetylation. Particle concentrations in situ were determined via TGA (Q5000IR, 
TA Instruments). Electron microscopy images were taken via Scanning Electron Microscopy 
(SEM); particles were dispersed on a silicon wafer and coated with ~1.5 nm of gold-palladium 
alloy (Hitachi S-4700, FEI Helios Nanolab 600) before imaging. A Zetasizer Nano ZS Particle 
Analyzer (Malvern Instruments Inc.) was employed to determine ζ-potential measurements; 
analysis of all particle types was conducted on aqueous dispersions at a concentration of ~20 
µg/mL. 
2.4.6 Microneedle Fabrication  
2.4.6.1 Blank PVP Microneedles  
 Microneedles were fabricated using an adapted PRINT process (Figure 2.6).1,7,15 PVP 
(Mw = 10 kDa, Sigma Aldrich) films (15-20 wt%) were drop-cast onto PET in water and left to 
dry for 24-48 h at RT. Films were stored at 30% relative humidity before use. Next, a film 
(~250-380 µm thick) was mated to the PFPE mold, covered with a plastic sheet, and passed 
through a heated nip at 105 °C (50 PSI), filling the mold. After cooling to RT, the plastic sheet 
was removed and, with it, any unconsumed film. The filled mold was mated to the 
aforementioned flexible, water-soluble substrate, covered with a plastic sheet, and passed 
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through a heated nip at 105 °C. The mold and plastic sheet were then removed, leaving a 100% 
water soluble microneedle patch.  
2.4.6.2 Drug Surrogate Loaded Microneedles  
Microneedles incorporating small molecule dye drug surrogates were prepared identically 
to the blank microneedles (2.4.6.1), with one small modification: the chosen dye [rhodamine B 
(99%, Acros) or DyLight 680 (Fisher Scientific)] was mixed into the pre-microneedle solution 
(15-20 wt% total solids) at a loading of 0.1-1 wt% of total solids. All other fabrication 
parameters remained consistent.  
Proteins were tagged with fluorescein or AlexaFluor 488 prior to microneedle 
encapsulation. OVA with AlexaFluor 488 conjugate (Life Technologies) was purchased pre-
tagged; aldolase from rabbit muscle (Sigma) was tagged with an AlexaFluor 488 NHS Ester 
(Life Technologies). When performing initial investigations, both proteins were tagged with an 
NHS fluorescein (Thermo Scientific) due to its low cost. To do so, protein in phosphate buffered 
saline (PBS) was mixed with the probe (in DMF) at a molar excess of dye (3:1) and allowed to 
mix for 1 h at RT. The tagged protein was separated from the unreacted dye via centrifugal 
filtration with a 3 kDa filter (Millipore) at 14,000 RPM at 4 °C for 25 min. The protein 
concentration was determined via absorption at 280 nm (Nanodrop 2000) through the extinction 
coefficient (E1%
 = 8.52). The tagged protein was dialyzed overnight using a 20 kDa molecular 
weight cut-off dialysis device (Thermo Scientific) at RT before use.    
The tagged OVA and aldolase were mixed into the pre-microneedle solution at a 15-20 
wt% loading of total solids, the remaining solids comprised solely of PVP. The solutions were 
made in sterile water at a 15-20 wt%. Microneedles incorporating proteins were made using the 
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protocol for small molecule dye microneedles, with the additional change of lowering the 
temperature of the nip to 77-82 °C in order to maintain protein functionality post processing.  
Bare hydrogel particles (80 x 320 nm) made via PRINT as described in 2.4.5.2, and 
incorporated into microneedles via a variety of casting solvents. In addition to the water-based 
pre-microneedle solutions used previously, IPA, EtOH, MeOH, and ACN were also investigated 
as casting solvents. All solvents were purchased from Fisher Scientific and used as received. The 
microneedle formulation comprised of 10 wt% nanoparticles and 90 wt% PVP. Pre-microneedle 
solutions were made at 40 wt%, excluding those cast in water (15 wt%). Films of each solution 
were drop-cast onto plastic sheets and allowed to dry at RT for 24-48 hours before use. 
Microneedles were then PRINTed identically to the optimized conditions for fabrication of blank 
microneedles (2.4.6.1). After selecting ACN and MeOH as solvents of interest, the microneedle 
composition was altered slightly, with loadings of 2.5-5 wt% particles. Needles made with 
PEGylated and acetylated particles were also made with loadings of 2.5-5 wt% particles, under 
the optimized conditions for fabricating blank microneedles (2.4.6.1).  
2.4.7 Microneedle Characterization  
Microneedle patches and films were characterized with ESEM (FEI Quanta 200), 
confocal microscopy (Zeiss LSM 700), and brightfield macroscopy (Leica-Wild M420 
Macroscope). Thermal properties of the microneedle films were determined via TGA 
(PerkinElmer Pyris 1) and DSC (Q200, TA Instruments) after storage at 30% relative humidity. 
Both the TGA decomposition experiments and the DSC thermal scans were performed 
identically to those run on the flexible harvesting layers (2.4.4).  
57 
 
OVA protein structure was assessed via a NativePAGE gel (Life Technologies), 
purchased as a kit and used according to manufacturer recommendations. Briefly, samples 
containing OVA (pre-microneedle solution, film, microneedle patches, and unconsumed film) 
were dissolved in buffer (sample buffer, Life Technologies) and diluted to concentrations of 
~0.04-0.02 µg/µL. The gel was loaded with 25 µL of sample per well; a protein and OVA 
standard were also added at the appropriate concentration. Cathode and anode running buffer, 
containing a Coomassie G-250 stain, were prepared and loaded into the running cell along with 
the prepared gel. After securing the electrodes, the gel was allowed to run at 150 V at room 
temperature for 100-120 min. The gel was removed, and visible bands were assessed by eye. 
Aldolase activity was assessed via a BioVision activity assay and used in accordance 
with the manufacturer’s instructions. In summary, the relative activity was determined by 
comparing samples containing aldolase (pre-microneedle solution as well as pre- and post-
processed films) to aldolase standards. Processed films were treated by passing them through a 
laminator at 77-82 °C, mimicking microneedle manufacturing conditions. All films were 
dissolved in PBS, and 50 µL was added to wells of a black 96 well plate. A 50 µL reaction mix 
(prepared using assay buffer, enzyme mix, developer, and substrate) was added to each well and 
the plate was mixed. The place was read a 450 nm after a 60 min incubation period at 37 °C. 
Relative activity was determined via comparison to a nicotinamide adenine dinucleotide 
(NADH) standard curve (one aldolase unit generates 1.0 µmol of NADH per minute at pH 7.2 
and 37 °C).  
Microneedle particle loading concentrations in ACN and MeOH (at 2.5 wt% solids) were 
determined by mass assessed via TGA (Q5000IR, TA Instruments). Patches (n = 9 per group) 
were massed before dissolution in sterile water, and the solutions were centrifuged to create a 
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pellet of particles (Eppendorf). The supernatant was removed, and three additional centrifugal 
washes were done in sterile water to remove any residual PVP. The TGA was loaded with ~ 20 
µL of each solution, and a total particle mass (for all n = 9) was determined. The particle loading 
(wt%) was determined by dividing the total particle mass by the total mass of the patches. 
Encapsulation efficiency was found by dividing each particle loading (wt%) by the charged wt% 
(2.5%) of the original particle films.  
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CHAPTER 3 EX VIVO AND IN VIVO DELIVERY OF DRUG SURROGATE CARGOS VIA PRINT 
MICRONEEDLES 
 
3.1 Introduction  
As outlined in Chapter 2, PRINT microneedles fabricated from polyvinylpyrrolidone 
(PVP) have been seen to show consistent geometry, high reproducibility, and can load cargos of 
virtually any desirable size and charge. Thermal analysis, differential scanning calorimetry 
(DSC), performed on the materials suggests that the PVP microneedles are strong, with glass 
transition temperatures (Tg’s) well above room temperature.1 The flexibility of the microneedle 
arrays may lead to an increased depth of penetration compared to conventional microneedles, for 
they can roll gently into the tissue and avoid the “bed of nails” effect.2 Finally, the water-soluble 
backing layer eliminates the need to remove the array, which may increase the payload of the 
devices to the skin.3 However, PRINT microneedles need to be tested on skin models to 
determine the efficacy of these devices to penetrate the stratum corneum and deliver their cargo. 
Typically, transdermal formulations are tested first for efficacy ex vivo on excised tissue 
or model skin. Model skin is typically one of two materials: a polymeric network that simulates 
the nature of this barrier (a pore size of ~0.45 μm) or human skin equivalents, tissue engineered 
scaffolds made by culturing human skin cells in a 3D gel.4-6 While it was first thought that skin 
was an homogenous barrier, it is now know each layer serves a specific defensive purpose, 
displaying unique physical properties at each level.4,5,7-9 In fact, the highly lipophilic stratum 
corneum results in hydrophobic drugs passing easily through this layer; the viable epidermis is 
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much more hydrophilic, resulting in the inability of these therapeutics to transverse past the 
epidermis.10 Therefore, diffusion through a homogenous synthetic membrane, even if it 
accurately reproduces the pore size density and elasticity of skin, may not equate to skin 
permeability. In contrast, excised tissue from animal or human models is widely accepted as a 
model for screening therapeutics and their transdermal formulations.4 In these studies, excised 
tissue was used exclusively to most accurately determine the behavior of PRINT microneedles ex 
vivo.  
The specific choice of the skin model is mainly dependent on the purpose of the 
transdermal study. The exact permeation profiles of a therapeutically-relevant device would be 
best investigated on human skin, for all animal models differ in structure, permeability 
resistance, and enzymatic activity from humans.11 However, studies that aim to observe the 
release characteristics of a therapeutic highly value the reproducibility of the skin model, as well 
as the ability to easily transition to pre-clinical in vivo studies with continuity.11 Animal models 
offer the advantages of: reduced risk of disease transfer, rapid availability, and high 
reproducibility. Skin from multiple animal models has been used for permeation studies since the 
1980’s; snakes, mice, rats, guinea pigs, minipigs, and domestic pigs have all been reported.4,11-15 
It has been shown that the structure and drug permeability of porcine skin, specifically that of the 
Gottengen minipig, most accurately models human, and the genetic inbreeding of these animals 
increases the consistency of in vivo investigations on transdermal formulations.11 While this 
model is ideal for mimicking human skin, performing statistically-significant in vivo 
biodistribution and pharmacokinetic studies on these pigs would be best done with microneedles 
optimized for the delivery of a therapeutic, due to the high cost of the animals themselves.  
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As we aimed to determine the ability of PRINT microneedles to deliver drug surrogate 
cargo of various sizes and charges, performing ex vivo permeation studies that can easily 
translate into in vivo models was of high priority. Nude murine models (nu/nu), the class of 
rodents bred to be largely hairless, have been used in pre-clinical studies since their introduction 
in 1850.13 These animals are readily available, inexpensive, and validated as an in vivo model. 
Studies are somewhat contradictory on the ability of murine tissue to model human transdermal 
permeation kinetics; while some compounds diffuse in a similar manner, others have been 
reported to permeate at a rate of 2-10 times faster.4,13 Murine and human skin have also been 
shown to respond identically to the application of permeation enhancers.4 Undeniably, many of 
these discrepancies arise from the difference in thickness of murine and human skin; while skin 
from the mouse is typically 300-500 μm in thickness across 70% of its surface area, human skin 
varies widely in thickness, ranging from 600-3,000 μm depending on location.4-5,16 Due to the 
consistency afforded by murine tissue, nude mice were utilized as the animal model in all 
preliminary studies for their ability to correlate ex vivo results to in vivo studies; the potential of 
PRINT microneedle devices for translation to the clinic was investigated through trials with 
excised human tissue.  
In this work, we show the ability of PRINT microneedle devices to pierce the stratum 
corneum of ex vivo murine and human skin. The importance of the flexible backing was assessed 
by comparing the penetration depth of microneedles with a rigid plastic backing to the 
microneedles on engineered substrates. The ability of the microneedles to release small molecule 
drug surrogates rapidly determined through initial penetration studies. Subsequently, the release 
parameters of a number of drug surrogates – small molecule dyes, proteins, and nanoparticles – 
were determined via permeation testing with a Franz cell apparatus. In vivo, we optimized the 
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application of the devices to the back of nude mice and confirmed the delivery of a small 
molecule dye to the skin after microneedle penetration and dissolution.  
3.2 Results and Discussion  
3.2.1 Administration of PRINT Microneedles to Ex Vivo Murine Skin – Penetration 
Studies with Optical Coherence Tomography 
PRINT microneedle devices were applied to excised murine skin to determine if the 
materials were strong enough to pierce the stratum corneum via studies with Optical Coherence 
Tomography (OCT). This technique allows for the visualization of microneedle penetration into 
tissue in a non-destructive manner, allowing for measurements of the exact depth of penetration 
in real time.7,17-20 The procedure has been utilized extensively in the microneedle literature to 
survey the ability of biodegradable microneedles to overcome the epidermis, calculate depth of 
penetration of the materials, and even determine the kinetics of microneedle channel closure in 
vivo.19-21 Because the tissue only interacts with light during data collection, it is not physically 
altered in any way and true in situ conditions are maintained. Additionally, all materials used do 
not need to be fluorescent, allowing for the imaging of the PVP microneedles without a tag.  
The ability of OCT to image ex vivo and in vivo tissue perpendicularly in a non-destructive 
manner stems from the nature of light itself. Light waves can be described by their degree of 
temporal coherence, or how well each individual wave aligns with itself at a later time. If the 
wave has low coherence, optical depth ranging can be performed; OCT is one method that 
employs this technique, analogous to conventional ultrasound merely employing light waves 
instead of sound.20,21 The penetration depth of most OCT systems is approximately 2.0-3.0 mm, 
allowing for imaging well into the dermal layer.17,21 Both 2D and 3D images can be constructed 
with the system at high resolution in both time and space.21 Biodegradable microneedles are 
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particularly amenable to OCT  because their coherence matches closely to that of tissue, 
minimizing backscatter and imaging artifacts.  A custom, ultrahigh resolution OCT system was 
utilized for these studies; the instrument was built in the lab of Dr. Amy Oldenberg (UNC 
Department of Physics), and the data was taken and analyzed in collaboration with her group.    
The major factors that contribute to microneedle performance ex vivo include the material, 
needle height, tip radius, base diameter, needle density, and application technique.3,7 For these 
studies, we aimed to determine the effect of application technique (i.e. “rolling” the patches into 
the skin with a flexible backing layer vs. traditional flat application with a rigid patch) while 
maintaining the same needle properties with PVP PRINT microneedles. Flexible arrays were 
constructed in accordance to methods described in Chapter 2. To make rigid microneedle 
devices, one small change was introduced to the PRINT manufacturing: the harvesting layer was 
composed of a very thin layer of Luvitec VA64 (the major component of the flexible layers) on a 
poly(ethylene terephthalate) (PET) sheet. These rigid layers were equally effective at harvesting 
the microneedles from the arrays, and served as the substrate for these experiments.  
Microneedle patches were tested on ex vivo nude murine skin in accordance with animal 
protocols approved by the UNC Institutional Animal Care and Use Committee. All skin samples 
used were excised from the back of nude mice and found to be 300-500 µm in thickness (via 
digital micrometer). Skin was flash-frozen upon harvesting and stored at -20 °C until use. 
Thawed skin samples were pinned over corkboard and blotted dry to simulate in situ conditions 
before microneedle testing. Microneedle patches of each design (flexible or rigid) were applied 
into the skin and pressure (simply with the force of thumb) was held for 10 seconds (s) (n = 3). 
Skin was then rapidly transferred to the custom-built OCT system for imaging, for we aimed to 
assess the initial penetration depth of the highly water-soluble microneedles before significant 
67 
 
dissolution. Based on experimental findings, it was seen that the microneedles were visibly 
dissolving after 4-5 minutes (min), and penetration depth was only collected from images taken 
within 3 min of microneedle application. Depth profiles were taken rapidly (every 35-50 µs) as 
the system scanned across the tissue in the y-direction at 5 µm intervals. Images (2D) of the 
tissue were constructed using algorithms written in-house.  
 Representative images of microneedles of the flexible and rigid backings can be seen as 
Figure 3.1. Images depict microneedle patches (upper part of the frame) inserted into the tissue 
(lower part of the frame); for clarification, brackets indicate the microneedles and skin. First, it is 
important to note that the PRINT microneedles were seen to overcome the stratum corneum and 
pierce the epidermis in both configurations, demonstrating clearly the efficacy of the PVP 
microneedles. As expected, the microneedles with a flexible backing pierced the skin in a more 
reproducible pattern than those with the rigid backing. The microneedle piercing showed 
consistent spacing across the tissue. Rigid microneedles did pierce the epidermis in select cases, 
but the reproducibility of piercing events was low. Microneedles were also seen to enter the skin 
at inconsistent angles; these findings qualitatively show the advantages of the flexible substrate 
when all other microneedle parameters (material, length, spacing, etc.) are held constant.   
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Figure 3.1 OCT images taken after the application of flexible (left) and rigid (right) PVP PRINT microneedle 
patches. Brackets indicate the different features imaged. (A) Air above the patch, (B) Backing layer (C) Murine skin. 
Protrusions into the skin are due to microneedle penetration. Scale bar is 350 µm.  
To quantitatively determine the depth of microneedle penetration for each selected 
application, measurements (in the z-plane) were taken for microneedles at their maximum point 
of entry in comparison to the epidermal layer of the skin. Collected 2D images were assessed in 
Image J; every frame was examined to determine the maximum depth of penetration for each 
analyzed needle (n = 12). It was seen that the flexible backing not only increased the average 
depth of penetration, but significantly decreased the standard deviation, indicating highly 
improved reproducibility. We can conclude from these studies that the flexible backing 
significantly improves the efficacy of the PRINT microneedle devices.  
Table 3.1 Microneedle depth of penetration as determined by OCT.  
Microneedle Backing Depth of Penetration, µm 
(mean ± stdev) 
Flexible 245 ± 30 
Rigid 155 ± 61 
 
3.2.2 Delivery of Drug Surrogate Cargo to Ex Vivo Murine Skin  
The study of pharmaceutical transport across the skin, a formidable barrier, has been 
examined in detail for topical transdermal formulations.7 Many factors contribute to the ability of 
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those therapeutics small enough to passively transport through skin (<500 Da): drug partition 
coefficient, permeation pathway, melting points, and charge.4,7,22,23 The partition coefficient of 
the drug is particularly important, for the highly lipophilic stratum corneum is the main obstacle 
for initial skin diffusion. This effect is generally described by Fick’s laws of diffusion, assumed 
to be the mass transfer of individual solutes driven by random molecular movement. The rate of 
transport, according to these laws, is expressed in Equation 1, where C is the initial concentration 
of drug, C0 the donor concentration, K the partition coefficient, D the diffusion coefficient, and h 
the thickness of the barrier (stratum corneum).4,7 It has been seen that a partition coefficient 
(octanol/water) of above 2.4 greatly increased the uptake of salicylates and anti-inflammatory 
drugs when a liquid formulation was applied to the skin.7,22 The charge of the drug has a 
different effect on transport depending on permeation pathway; for example, if diffusing through 
the skin intracellularly, neutral drugs have been shown to permeate more effectively, but those 
transported transcellularly (through cell internalization) may be more effective with charged 
therapeutics due to their ability to interact with the charged cell.7,24,25 
𝒅𝑪
𝒅𝒕
=  
𝑲𝑫𝑪𝟎
𝒉
                                                   Equation 1 
 While these parameters are well known for liquid formulations, patches, and creams, the 
factors contributing to the release and permeation from a biodegradable microneedle device are 
postulated to be much different.2,7,26 The effects of the microneedle material and dimensions, the 
time of application, and properties of the therapeutic all play a role in this complicated process.26 
PRINT microneedles made from PVP have been shown to load cargos with a wide range of 
physical properties, allowing for the systematic study of how the properties of the therapeutic 
effect release and distribution in the skin. Herein, we explore the effect of the cargo’s size and 
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charge on skin permeation while maintaining microneedle material, height, and time of 
application.  
3.2.2.1 Small Molecule Drug Surrogates  
3.2.2.1.1 Initial Skin Penetration and Rhodamine Release at Short Times 
 Optimized PRINT microneedle arrays loaded with rhodamine B were fabricated as 
described in Chapter 2.3 Patches were administered to ex vivo murine skin samples to assess the 
ability of these microneedle arrays to penetrate skin and release cargo. Murine skin excised from 
the back of nu/nu mice was used as described for the studies with blank microneedles. Flexible 
patches were “rolled” on and pressed into the skin with the gentle force of a thumb. Three 
different experimental conditions were compared: control (no microneedles applied), patches left 
in the skin for 10 s and then removed, and patches left in the skin for 10 min followed by the 
dissolution of the substrate with water.  
 Initial testing assessed the ability of the microneedles to successfully penetrate the 
stratum corneum of the murine skin samples with the incorporated dye. For this evaluation, 
patches left were in the skin for 10 s, removed, and a green tissue marking dye was immediately 
applied to the skin and subsequently wiped off so that locations of skin penetration could be 
identified macroscopically. Figure 3.2 shows a greyscale image of a murine skin specimen after 
the application of microneedles for 10 s. The locations of epidermal breach can be seen on the 
skin; this was verified by histology.  Additionally, the microneedles showed evidence of 
dissolution within the skin after 10 s. The drug surrogate could be visually perceived within sites 
of microneedle insertion and could not be wiped from the surface. Further brightfield 
macroscopic images of the patches after removal also showed at least half of the microneedle 
length had dissolved within this 10 s time period, seen in Figure 3.3.  
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Figure 3.2 Brightfield macroscopic image after testing with microneedle patch for 10 s. The pattern of the 
microneedles can be seen on the skin. In the insert, a single piercing is highlighted. Scale bar is 400 µm. 
 
Figure 3.3 Brightfield macroscopic images of a microneedle array before and after insertion into ex vivo mouse skin 
for 10 s.  (A) Microneedle array before testing and, (B) Array after testing and removal. Scale bars are 400 µm. 
 After verifying that the microneedles efficaciously pierced the stratum corneum, further 
studies were conducted to evaluate the complete dissolution of the microneedle patches and 
release of the drug surrogate. For this work, all patches were left in the skin for 10 min followed 
by the application of a few drops of water to the back of the microneedle patch.  Within 5 min, 
the entire substrate (loaded with fluorescein) was dissolved (Figure 3.4) and the skin was wiped 
clean. No further dyes were applied. Rhodamine B was easily visible within the skin; the dye 
was not localized to the site of microneedle insertion but, rather, was present throughout the skin 
(Figure 3.5), suggesting that the drug surrogate was able to diffuse within the skin after 10 min.  
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Figure 3.4 Image of murine skin after the application of a rhodamine-loaded microneedle patch for 10 min and less 
than 200 µL of water to dissolve away that patch backing. Image was taken immediately after dispensing water onto 
the patch. The backing used was loaded with 0.1% fluorescein dye for imaging purposes. Scale bar is 1 cm. 
 
Figure 3.5 Brightfield macroscopic images of murine skin after fixation. (A) Control murine skin, not exposed to 
microneedles. (B) Murine skin after the insertion of rhodamine-loaded microneedles for 10 min. After insertion, the 
flexible backing was dissolved, and the skin was wiped clean before fixing. The dye can be seen throughout the skin 
after this processing, indicating that the drug surrogate diffused within the skin. Scale bar on all images is 1 cm. 
 The skin samples from all aforementioned experiments (10 s, 10 min, and control) were 
successively fixed and cryosectioned for histology to confirm that the microneedles breached the 
murine stratum corneum and to evaluate the distribution of the drug surrogate. Half of the skin 
sections underwent staining with haematoxylin and eosin (H&E). Haematoxylin stains the nuclei 
of cells via a dye-metal complex; the oxidation product of haematoxylin, hematein, forms a 
complex with aluminum ions, termed “hemalum”.27 The hemalum colors cell nuclei by binding 
to DNA, resulting in dark purple/blue color. Eosin Y traditionally colors eosinophilic structures, 
such as intracellular or extracellular proteins, including most of the cell cytoplasm.27 This acidic 
dye adheres to the basic backbone of the proteins, staining the structures shades of pink. 
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However, eosin Y is shown to have a broad fluorescence spectrum, emitting from 530-600 nm 
with a maximum of 545 nm, while rhodamine B is observed to have a maximum emission at 580 
nm.27-29 Therefore, half of the sections were left unstained to observe the rhodamine B 
fluorescence without the interference of eosin.  
 After H&E staining and brightfield imaging, the control samples did not show any 
epidermal breach as expected; the skin was consistently smooth (Figure 3.6A). Evidence of 
epidermal breach was seen in skin sections from both the 10 s and 10 min experiments, shown in 
Figure 3.6B-C by the breaking of the stratum corneum (the outer epidermal layer seen as dark 
purple). The penetration depths of the microneedles observed were consistently shorter than the 
lengths of the microneedles, but the insertion depth was longer for the 10 min tests, where 
pressure was held longer. This is believed to be due to the elasticity of the skin and geometry of 
the needles themselves.2,30 However, it is promising that the depth of the needle penetration seen 
increased when the patches were applied for 10 min, which more accurately reflects the ultimate 
intended clinical application of the 100% dissolvable patch. 
 
Figure 3.6 Brightfield microscopic images of skin sections after sectioning and histology (A) Control skin. (B) Skin 
after 10 second microneedle application. (C) Skin after 10 minute microneedle application. Epidermis = top. Scale 
bar on all images is 35 µm. 
C B A 
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 Images of the unstained sections via fluorescent microscopy showed the efficiency of the 
drug surrogate delivery via microneedles to the skin. Seen in Figure 3.7, a large qualitative 
difference in fluorescence intensity was observed among the three samples. While the control 
showed no fluorescence (Figure 3.7A), an observable fluorescence was seen in select areas of the 
skin after 10 s (Figure 3.7B). Comparatively, considerably higher fluorescence intensity within 
the skin was seen for the 10 min time period throughout the whole skin section (Figure 3.7C). 
This confirms that the drug surrogate was released from the needles and deposited beneath the 
stratum corneum throughout the duration of the patch application.  
 
Figure 3.7 Fluorescent microscopy images of skin after sectioning. (A) Control skin, (B) Skin after 10 second 
microneedle application, (C) Skin after 10 minute microneedle application. Epidermis = top. Scale bar is 35 µm. 
3.2.2.1.2 Rhodamine Release from Microneedles Over 24 Hours  
 The kinetics of drug release from the microneedles was investigated using a Franz 
diffusion cell apparatus, the gold standard of ex vivo testing for transdermal formulations.5,6 The 
apparatus is used to model the behavior of the formulation when applied to skin; in these studies, 
the tissue is thought of as a membrane, for in vivo behavior does not identically replicate the 
profiles obtained from a Franz diffusion cell due to the rich network of biological processes 
happening in skin.5 However, due to the complexity of skin as a layered membrane, the studies 
A B C 
75 
 
are ultimately considered a good way of assessing therapeutic ability to cross the stratum 
corneum in vivo.  
The Franz diffusion cell, shown in Figure 3.8, consists of a donor compartment, a 
membrane, and a receptor compartment with a sampling port; the receptor compartment is 
insulated with a water jacket.6 Receptor fluid, usually phosphate buffered saline (PBS), is filled 
into the compartment at a known volume. Typically, the membrane is anchored in place with a 
clamp, then the drug formulation is applied through the donor compartment onto the membrane; 
the entire device is submerged in 37 °C water to fill the jacket at body temperature. Samples are 
taken from the port at selected time points to determine the concentration of drug in the receptor 
fluid. In the static Franz cells used, after sampling, an equivalent volume of receptor fluid is 
introduced to replace the aliquot analyzed. The concentration of drug in the receptor fluid can be 
analyzed by a number of analytical methods, including chromatography, fluorescence, or 
biological assays.5,6,16 For all studies with PRINT microneedles, the selected membrane was skin 
from the back of a nude mouse, samples of receptor solution were taken over the course of 24 
hours (h) at regular intervals, and rhodamine concentration was determined via fluorescence with 
a standard plate reader. 
 
Figure 3.8 Static Franz diffusion cell apparatus.6 
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 Since it is well established that small molecules less than 500 Da can passively permeate 
skin, we first aimed to determine if PRINT microneedles increased the percent of applied dose 
that reaches the receptor compartment (percent delivered dose, %), or if use of the devices 
influenced the permeation kinetics of rhodamine (Mw = 442 Da) through full thickness tissue.
7,16 
Thus, murine skin was treated with drug surrogate in two ways: applying pre-microneedle 
solution (1 wt% solids rhodamine, 99 wt% solids PVP, in water) and administering microneedles 
of the same loading. Solution was applied to the skin via the traditional use of a Franz cell 
device; after affixing the skin as a membrane, a small aliquot (0.022 mg) was delivered to the 
tissue through the donor compartment. The microneedles, however, required application before 
the skin was affixed to the cell. After determining the dose of each device via quantitative 
fluorescence imaging (~0.022 mg), devices were applied to the skin with the gentle force of 
thumb, holding pressure for 10 s. The backing of the device was wiped away after 8 min, and the 
skin was transferred to the Franz cell. Any rhodamine removed from the surface of the tissue 
with the wipes was extracted with PBS and quantified by equating solution fluorescence (taken 
at 590 nm on a plate reader) to mass via a standard curve; the applied dose was subsequently 
determined by subtracting this amount from the patch dose. Aliquots of the receptor solution 
were taken at various time points over 24 h, and the delivered dose of the rhodamine was also 
determined by correlating fluorescence at 590 nm to mass through a standard curve.  
 Figure 3.9 shows the percent delivered dose of rhodamine for both the solution and 
microneedles. It was seen that the microneedles greatly increased the amount of rhodamine that 
permeated the skin at every time point. After 24 h, 17% of the dose applied to the skin had been 
released from the microneedles, while only 6% of the dose of the solution reached the receptor 
compartment. This stark difference shows that PRINT microneedles are an effective permeation 
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enhancer for even small molecule therapeutics. Additionally, it was seen that the kinetics of 
transport are quite different. Rhodamine delivered via solution showed a percent delivered dose 
that increased linearly through the duration of the experiment. The microneedles, however, show 
non-linear release, slowing considerably after 12 h. These kinetic profiles outline the differences 
in passive diffusion and enhancing permeation with microneedle devices.  
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Figure 3.9 Release profiles of rhodamine through ex vivo murine tissue over 24 h. It was seen that the microneedles 
delivered a significantly higher dose than the solution at all given times.  
 While diffusion through the skin is of great interest in the dermatological community, 
specifically as a way to screen for clinical relevance, there is still great value to depositing a 
therapeutic in the skin itself.4,6,7,16 If treating a cutaneous disease, the drug may not need to 
transport through full thickness skin to reach its site of action, and – due to the rich network of 
blood vessels in the dermal layer – systemic circulation may be achieved by just reaching this 
layer.7 Therefore, mapping the remaining drug surrogate in the skin after 24 h may assist in 
predicating the in vivo behavior of drug surrogates at this time. To visualize drug surrogate 
distribution, the murine tissue was fixed and cryosectioned at the conclusion of the Franz 
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diffusion cell experiments for tandem fluorescence/brightfield microscopy imaging; control skin 
was also prepared.  
Representative images of the skin sections treated with rhodamine pre-microneedle 
solution and microneedles, as well as the control skin, can be seen as Figure 3.10. No 
fluorescence signal was seen in the control tissue, but both samples treated with rhodamine 
showed observable fluorescent drug surrogate. The skin exposed to solution was saturated 
throughout with free rhodamine. Alternatively, the skin treated with microneedles showed 
rhodamine fluorescence localized to the epidermis and associated with dermal dendritic cells. 
These findings align with the release profiles observed for each method of application, for only 
free rhodamine is likely to permeate to the receptor compartment. The skin treated with solution 
showed linear release that did not peak over 24 h, which is supported by the presence of free 
rhodamine throughout the skin. If left longer, it is likely that drug surrogate would continue to 
passively diffuse. In contrast, a stark difference can be seen between the microneedle-treated 
tissue after 10 min (3.2.2.1.1) and 24 h; while the free rhodamine was abundant in the 10 min 
images, it is no longer present at 24 h, supporting the peak in release seen at 12 h. Clearly, 
PRINT microneedle devices affect the delivery parameters of a small molecule drug surrogate 
though murine skin.  
 
Figure 3.10 Fluorescent microscopy images, shown as overlays with the brightfield channel, of skin after the 
application of a rhodamine drug surrogate for 24 hours on a Franz cell apparatus. (A) Control (no rhodamine 
applied), (B) rhodamine delivered via pre-microneedle solution, and (C) rhodamine delivered via microneedles. 
Epidermis = top. Scale bar is 40 µm.    
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3.2.2.2 Protein Drug Surrogates  
Next, the kinetics of release of the selected protein drug surrogates, aldolase and 
ovalbumin (OVA), were investigated on a Franz diffusion cell apparatus. Again, these proteins 
were selected for their differences in size (aldolase = 161 kDa, OVA = 45 kDa) and isoelectric 
point (aldolase pI = 8.5, OVA pI = 4.6). Because it has been clearly shown in literature that 
therapeutics of this size cannot passively diffuse through the skin, delivery via microneedles was 
not compared to delivery with a topical formulation on the Franz diffusion cells.2,7,30,31 Still, it 
was confirmed that the protein would not pass the stratum corneum by applying a solid-state pre-
microneedle film to the skin for 8 min, subsequently dissolving the film in tap water, wiping the 
skin clean, and imaging sections after fixing and cryosectioning the tissue. Figure 3.11 shows 
brightfield and fluorescent overlays, taken simultaneously on an upright microscope, of skin after 
the application of an aldolase (A) and OVA (B) film; no visible fluorescence from either protein 
could be detected below the stratum corneum, supporting the hypothesis that it cannot diffuse.  
 
Figure 3.11 Fluorescent microscopy images, shown as overlays with the brightfield channel, of skin after the 
application of pre-microneedle films containing protein drug surrogates[(A) aldolase, (B) OVA]. The fluorescence 
of the protein, tagged with AlexaFluor 488, cannot be seen in the skin. Epidermis = top. Scale bar is 40 µm.    
Diffusion studies with protein-loaded microneedles were performed as described for the 
small molecule drug surrogates (3.2.2.1.2). Briefly, microneedles were fabricated with 20 wt% 
protein (as outlined in Chapter 2), and patches were imaged via IVIS to determine the dose of 
protein per patch (~0.06 mg of each protein). Devices were applied to full thickness murine skin 
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for 8 min before patch dissolution. After application, the skin was transferred to the Franz cell; 
receptor solution was sampled at various time points over 24 hours. The delivered dose of each 
protein was also determined by equating fluorescence to mass via a standard curve collected on 
standard plate reader; emission was read at 550 nm due to the AlexaFluor 488 tag on both 
proteins. Upon cell termination, the skin was fixed, cryosectioned, and imaged on the upright 
fluorescence/brightfield microscope to map the drug surrogate in the skin.  
Figure 3.12 shows the delivery profiles of each protein to the receptor compartment over 
24 hours. With the aid of the PRINT microneedles, both proteins were able to permeate the skin, 
a feat shown to be impossible without this physical enhancement. Additionally, the OVA was 
shown to diffuse through the full thickness tissue at a much quicker rate than the aldolase. While 
it is postulated that the size of the protein mainly influences this behavior, the charge of the 
protein upon release from the PVP microneedle may play a role. To simultaneously elucidate 
these differences and prepare microneedle devices with a true agent of interest, the enzymatic 
protein butyrylcholinesterase (340 kDa, pI = 4.2-4.9) has been investigated; these studies are 
described in detail in Chapter 4.  
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Figure 3.12 Release profiles of protein drug surrogates, aldolase and OVA, through ex vivo murine tissue over 24 h. 
It was seen that the smaller protein was able to permeate the skin at a much higher efficiency, up to 18% of the 
loaded dose. 
Fluorescent overlays of the tissue sections can be seen as Figure 3.13. While the large 
aldolase is seen in the skin under the epidermis, only small amounts have permeated beyond the 
lower dermis. OVA, on the contrary, is seen throughout the tissue, showing the ability of this 
smaller protein to transverse the skin after 24 h. Unlike the small molecule drug surrogates, 
however, some protein is still localized near the sites of penetration; this may be due to the 
increased affinity of the protein for the tissue. It is postulated that a delivered dose similar to the 
small molecule (17-18%) is seen because the free OVA can permeate the ~0.2-0.4 µm pores in 
native murine skin due to its size.4-6,32 Again, both surrogates reach the dermal layer of the skin, 
indicating that systemic circulation of proteins delivered via microneedles may be possible; in 
vivo studies are necessary to determine these profiles.  In summary, the images show that the 
proteins distribute quite differently in the skin after administration with identical PRINT 
microneedles, solely dependent on the properties of the cargo itself.  
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Figure 3.13 Fluorescent microscopy images, shown as overlays with the brightfield channel, of skin after the 
application of microneedles loaded with aldolase (A) and OVA (B) for 24 hours on a Franz cell apparatus. While 
aldolase is localized below the skin in select regions of the upper dermis, OVA has penetrated the full thickness of 
the tissue. Epidermis = top. Scale bar is 40 µm.    
3.2.2.3 Particulate Drug Surrogates  
Finally, the release of hydrogel PRINT nanoparticles from microneedle devices was 
investigated through diffusion experiments on the Franz cell apparatus. Hydrogel 80 x 320 nm 
particles of three surface modifications bearing different charges – bare (+), PEGylated (neutral), 
and acetylated (-) – were selected as particulate drug surrogate cargos; particles and patches were 
fabricated as described in Chapter 2. As with the proteins, the particles were confirmed to be too 
large to passively diffuse through skin without microneedles (see Experimental 3.4.5). Diffusion 
studies with particle-loaded microneedles were performed as described for all other cargos (~0.2 
mg dose), and the presence of particles in the receptor fluid was detected at 550 nm due to the 
AlexaFluor 488 tag conjugated into all particles studied.  
 The microneedles did not deliver high amounts of the particles to the Franz cell receptor 
compartments after 24 h, which is not unexpected due to their size. Seen in Figure 3.14, all 
particulate formulations delivered less than 4% of the patch dose through the skin, showing 
release curves with high variability. No significant changes were seen in the release efficiency of 
particles with various surface charges; while there is some evidence that bare (+) particles have 
slower kinetics, longer studies need to be performed to determine the validity of these 
differences. However, these studies would need to be completed either in vivo, for the ex vivo 
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membranes are generally no longer considered intact after 24 h.5 Alternately, as nanoparticles are 
of high interest for vaccine delivery to the skin, the dose recovered may not be of highest 
importance; the mechanism of action for these particulates would be to interact with Langerhans 
and dermal dendritic cells, meaning delivery to the dermis would be adequate for therapeutic 
effect.2,33,34 With viable tissue in vivo, these interactions could be studied, elucidating the effect 
of surface charge on particulate delivery to the skin.        
0 5 1 0 1 5 2 0 2 5
0
1
2
3
4
5
6
7
P a r tic le  R e le a s e
T im e , h o u rs
P
e
r
c
e
n
t 
D
e
li
v
e
r
e
d
 D
o
s
e
, 
%
B a re
P E G y la te d
A c e ty la te d
 
Figure 3.14 Release profiles of bare (+), PEGylated (neu), and acetylated (-) 80 x 320 nm PRINT hydrogel particles 
through ex vivo murine tissue over 24 h. It was seen that the microneedles showed no significant differences in 
release profile due to surface charge over this time period.  
 The results of tandem brightfield/fluorescent microscopy imaging of skin removed from 
the Franz diffusion cells at 24 h (treated as previously described) are shown in Figure 3.15. It can 
be clearly seen that PRINT microneedles did deliver particulate cargo to the skin with each type 
of surface modification, identified near the sites of microneedle penetration under the stratum 
corneum. Particles (of all surface charges) remained localized to the lower epidermis/upper 
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dermal layers of the tissue, explaining the low percent delivered dose observed in the Franz cell 
receptor fluid. Again, the differences in particle behavior based upon surface modification could 
not be determined; all images qualitatively showed the equivalent delivery of the particles to the 
skin. Longer studies with PRINT microneedles must be done to clarify the role of surface charge 
on particle behavior in the skin. Excitingly, the particles were shown to be deposited to regions 
known to be rich in immunostimulatory cells, opening the door for PRINT microneedles for 
vaccination with nanocarriers.2,33,34 By moving to in vivo studies, the interactions of these cells 
with the particulate drug surrogates could be studied, further optimizing the devices for this 
application.      
 
Figure 3.15 Fluorescent microscopy images, shown as overlays with the brightfield channel, of skin after the 
application of microneedles loaded with 80 x 320 nm PRINT particles for 24 hours on a Franz cell apparatus. (A) 
control, (B) bare particles, (C) PEGylated particles, and (D) acetylated particles. Particles are show to be localized to 
the site of penetration with all surface charges. Epidermis = top. Scale bar is 40 µm.    
3.2.3 Delivery of Drug Surrogate Cargo to In Vivo Murine Models  
After showing that PRINT microneedle devices can pierce murine skin and deliver cargos 
of virtually any size to the epidermal and dermal layers of excised tissue, the application of these 
devices on live animals was optimized. A number of methods of microneedle application 
methods have been reported for biodegradable microneedles, many including the use of a highly 
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sophisticated applicator to provide enough force for the arrays to penetrate the stratum 
corneum.7,35 The flexible backing that serves as the substrate of PRINT microneedles allows 
them to “roll” into the skin, minimizing the “bed of nails” effect and eliminating the need for 
high force on the array as a whole.3 Therefore, the application of the devices was optimized 
without any additional equipment, considerably lowering the complexity of the device as a 
product. 
Few modifications of the application technique of the microneedles to ex vivo tissue were 
needed to transition to in vivo studies on nude mice; preliminary studies were performed with 
small molecule drug surrogates to visualize successful penetration. In short, nude mice (aged 4-6 
weeks) were obtained from the UNC Animal Core. Mice were anesthetized with isoflurane and 
placed on a heated stage at 37 °C for the duration of the experiments. Microneedle patches were 
applied to the back of the mouse by rolling the device onto the skin; light pressure was held on 
the patch for one minute. As seen on ex vivo tissue, the pattern of microneedle piercings was 
visible through the back of the substrate. After allowing the microneedles to dissolve, water was 
applied to the water-soluble back of the patch and subsequently wiped clean with medical wipes. 
Figure 3.16 shows the application of a PRINT microneedle patch to the back of the animal, 
penetrating the tissue.  
 
Figure 3.16 Nude mouse with a PRINT microneedle patch applied to the back. Patch is loaded with 0.1 wt% 
DyLight 680 cargo.  
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To determine the ideal properties of application to murine models, we first aimed to 
define the ideal amount of time to allow the microneedles to dissolve in the skin before substrate 
dissolution, ensuring the maximum delivered dose to the animal. While all considerations were 
made to ensure the ex vivo tissue was consistent with in situ conditions on the animal, living 
tissue is much more dynamic, potentially altering the optimized conditions used previously. 
Therefore, in a small pilot study, five different patch application times – 8, 20, 30, 45, and 60 
min – were investigated to determine if the patch delivered dose increased as the microneedles 
were given more time to release cargo in the skin before backing dissolution.  
A summary of the experimental parameters can be seen in Table 3.2. Microneedles were 
made as described in Chapter 2 with the small molecule drug surrogate DyLight 680, optimal for 
quantitative in vivo analysis with a live-animal fluorescence imaging (IVIS).  After anesthetizing 
each mouse with isoflurane, microneedle patches were applied as described above in the 
chamber of the IVIS fluorescent imaging system. At the end of each designated application time, 
small aliquots of water were applied and the skin was wiped clean with medical wipes 3-4 times; 
“clean” skin was verified after the last medical wipe showed no quantifiable fluorescent signal. 
Each mouse was monitored for 72 minutes under the IVIS; images were collected after 
application and at the conclusion of wiping. After sacrificing the animals, skin and other organs 
were harvested and imaged on the IVIS system; blood was collected via cardiac puncture, 
aliquoted into black 96 well plates, and fluorescence (emission) was read at 720 nm on the IVIS. 
Therefore, each mouse was treated identically except for the application time.  
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Table 3.2 Study parameters for the in vivo release and biodistribution of small molecule drug surrogates  
Mice  Male Nu/Nu, 6 weeks old  
Microneedles 0.1 wt% DyLight 680 dye in PVP 
Life Animal Imaging IVIS Lumina 
Blood draws Terminal (after 72 min, cardiac puncture)  
Wipe Time 8 min, 20 min, 30 min, 45 min, 60 min 
Terminal Organ Collection 
(subsequent IVIS imaging) 
Skin, underlying tissue, kidney, liver, spleen 
 
IVIS fluorescence images of the mice during this study can be seen in Figure 3.17. With 
all the patches on the mice, a high fluorescence can be seen locally at the site of microneedle 
application. Comparatively, after wiping and verifying the final wipe was dye-free, some 
fluorescence still remains in the skin. After all the mice had been wiped, it was clear dye was 
delivered to the skin of the mouse after 72 min.  
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Figure 3.17 Mice at three points during the time course small molecule dye study: (Top) All patches on, (Middle) 
two patches wiped, and (bottom) all patches wiped. The clean wipe after final water application is highlighted in the 
middle image.  
Quantitative measurements were taken on all harvested organs after terminal bleeds were 
concluded. The plate reading of the organs from one mouse (30 min) can be seen as Figure 3.18; 
it is seen that most organs did not show any observable signal. Additionally, whole blood taken 
from each mouse also read below the limit of detection of the instrument, indicating the dye did 
not reach systemic circulation. Only the treated skin displayed a quantifiable delivered dose of 
dye after 72 min. The percent delivered dose was determined by comparing the radiance 
observed in the skin due to DyLight 680 to the total loaded dose of dye in the microneedle patch, 
assessed before patch application. It was seen that the time before wiping away each patch 
backing did not statistically affect the percent delivered dose; the mouse wiped after 8 min 
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delivered 75% of the dose to the skin after 72 min, while the mouse wiped after 60 min delivered 
74%. Therefore, we can apply the devices for 8 minutes, consistent with our ex vivo studies, for 
further animal studies. The high localization of drug surrogate in the treated skin supports that 
the kinetics of small molecule release in vivo from the microneedles are similar to the kinetics of 
rhodamine release investigated ex vivo on the Franz cells. Future studies, consequently, can use 
these ex vivo profiles as guides for selecting appropriate time points for biodistribtion, 
pharmacokinetic, and pharmacodynamic studies on nude mice.  
 
Figure 3.18 Organ harvest of a mouse after the conclusion (72 min) of the small molecule dye study. Fluorescence 
from the delivered dye can only be seen in the treated skin.  
3.2.4 Delivery of Drug Surrogate Cargo to Ex Vivo Human Skin  
 In addition to optimization and validation in murine models, initial studies to determine 
the ability of the PRINT microneedles to pierce human skin were also conducted to investigate 
the ability of the devices to translate to clinical studies. Human tissue excised from the breast 
was obtained from the Cooperative Human Tissue Network (CHTN). Initial penetration testing 
with rhodamine-loaded microneedles was performed identically to the studies on ex vivo murine 
tissue (as described in 3.2.2.1). Briefly, flexible patches were “rolled” on and pressed into the 
skin with the gentle force of a thumb. A control (no microneedles applied) was compared to two 
    Treated Skin           Liver    Fat 
 
         Kidney            Spleen        Non-treated Skin 
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microneedle conditions: patches left in the skin for 10 s and then removed and patches left in the 
skin for 10 min followed by the dissolution of the substrate with water.   
 Preliminary results indicate that epidermal breach and subsequent drug surrogate release 
are also seen when PRINT microneedles are administered to human skin specimens. Figure 3.19 
shows a site of microneedle penetration and corresponding rhodamine fluorescence in human 
skin. As compared to the results obtained with the murine model, these results suggest that the 
drug surrogate release kinetics are slower in human skin than in murine skin, which was 
anticipated due to the increased thickness of human skin. While further optimization of the 
procedure and conditions will need to be done prior to clinical translation, these findings support 
the proof of concept that PRINT microneedles may be used to penetrate human skin and deliver 
loaded cargo.  
 
Figure 3.19 Microscopy images of skin penetration studies performed on ex vivo human skin from a patient. (A) 
Brightfield image of a skin after microneedle insertion for 10 s. (B) Fluorescence image after microneedle insertion 
for 10 min. Epidermis = top. Scale bar is 70 µm. 
3.3 Conclusions 
In these studies, we have demonstrated the ability of the PRINT microneedles to 
successfully penetrate murine skin and release cargo. First, the flexible PVP microneedles were 
shown to increase the depth of penetration of the microneedle arrays – as compared to rigid 
patches – via optical coherence tomography. Initial penetration studies with murine tissue and 
A B 
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small molecule drug surrogates showed the efficacy of the microneedles to release cargo at short 
times. Through release studies performed on a Franz diffusion cell apparatus, the permeation 
kinetics of the small molecule, protein, and particulate drug surrogates were investigated. It was 
seen that microneedles greatly increased the delivered dose of even small molecules. Both 
proteins and 80 x 320 nm hydrogel particles were seen locally in the skin after application with 
PRINT microneedles, but cargo size played a large role in the permeation kinetics through full 
thickness murine tissue. The application of PRINT microneedle devices was optimized in vivo on 
nude murine models, and it was shown that these devices efficaciously deliver small molecule 
drug surrogates to living tissue. Finally, the ability of PRINT microneedles to transition into a 
clinically-relevant product was shown through penetration studies with excised human tissue; 
however, microneedle dimensions would need to be altered (longer, sharper, etc.) to be highly 
efficacious.  
To further clarify the fundamental design rules of the ideal PRINT microneedle devices 
with drug surrogate cargos, in vivo biodistribution studies need to be performed to determine the 
differences in release when varying cargo size, charge, and loading. Additionally, transitioning to 
relevant therapeutic models is of great interest; Chapters 4 and 5 outline two applications of 
PRINT microneedles for therapeutic applications: the delivery of butyrylcholinesterase to 
combat organophosphate poisoning and the treatment of skin-invading cancers with 
chemotherapeutic microneedles, respectively.  
3.4 Experimental 
3.4.1 Microneedle Fabrication 
Microneedles for all studies were fabricated as outlined in detail in Chapter 2. All patches 
were stored at 20-30% relative humidity before use.  
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3.4.2 Optical Coherence Tomography  
PVP (Mw = 10 kDa, Sigma Aldrich) microneedles were fabricated on flexible substrates as 
described previously; additionally, microneedles were prepared on PET sheets coated with a thin 
layer of Luvitec VA64 (BASF) employing identical fabrication conditions. Microneedle patches 
were tested on ex vivo nude murine skin (UNC Animal Core Facility) with the permission of the 
UNC Institutional Animal Care and Use Committee (IACUC). Skin from nude mice (nu/nu) was 
excised from the back of the animals and flash-frozen. All skin samples were received and stored 
at -20 °C until testing occurred. The skin samples (in Eppendorf tubes) were thawed briefly in 37 
°C tap water, pinned over corkboard, and blotted dry to simulate in situ conditions before 
microneedle testing. Skin thickness was assessed with a micrometer (Mitutoyo). Microneedle 
patches were rolled or pressed into the skin, force of thumb was held for 10 s, and skin was 
transferred to the optical coherence tomography system for imaging.   
In collaboration with Dr. Amy Oldenburg (UNC Department of Physics), all images were 
acquired using a custom built, ultra-high resolution, spectral-domain optical coherence 
tomography system.  The OCT light source was a Titanium:Sapphire laser (Griffin, KMLabs, 
Inc.) with an 800 nm central wavelength and ~110 nm bandwidth.  The resolution of the system, 
in air, was 3µm x 12 µm [axial (z) vs. transverse (x)].  Sample power was kept below ~10 mW to 
reduce imaging artifacts due to high backscattering. Images were acquired using a line-scan 
camera (Piranha, Dalsa Inc.) at a rate of 5 kHz with 35-50 µs exposure time. 1000 A-lines were 
collected for each B-mode image (1000 1D lines stacked to obtain a 2D image).  Each image was 
3 mm wide, in x, with Δx = 3µm.  Bmode image stacks were obtained with a spacing (Δy) equal 
to 5 µm for a total stack size y = 3mm.  Each image was contrasted by method of normalization 
using custom code. Movies were made in MatLab (Mathworks), stitching images together in an 
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.avi file for presentation purposes. Images were taken from the time the skin was affixed to the 
system until the microneedle patch had been in the skin for a total of 3 min (approximately 2.5 
min). Measurements (in Image J) were taken on frames that demonstrated the longest depth of 
penetration observed for each microneedle.  
3.4.3 Skin penetration studies with rhodamine-loaded microneedles (Murine and Human) 
Microneedle patches were tested on ex vivo nude murine skin (UNC Animal Core Facility) 
and human skin from a patient with breast cancer (CHTN) with the permission of the UNC 
Institutional Animal Care and Use Committee (IACUC). Skin from nude mice (nu/nu) was 
excised from the back of the animals and flash-frozen. All skin samples were received and stored 
at -80°C until testing occurred. Prior to experimental studies, the skin samples (in Eppendorf 
tubes) were thawed briefly in 37 °C tap water. The thawed samples were then pinned over 
corkboard and blotted dry to simulate in situ conditions. Flexible PRINT microneedle patches 
were then applied to skin for either 10 s or 10 min with gentle thumb pressure and then rolled 
with a hand roller. For the 10 s tests, pressure was applied for the duration of the test then the 
patch backing was removed. The site of microneedle insertion was then exposed to green tissue-
marking dye for 5 min. Commercially available green tissue-marking dye (Cancer Diagnostics) 
was prepared by diluting the solution in a 1:1 mixture with isopropanol. The dye was swabbed 
off with tap water. For the 10 min tests, the patch was rolled for 1 min and then left for 9 min at 
ambient conditions. The patch backing was then dissolved with a small aliquot (<200 µL) of tap 
water. All skin samples were then fixed for 2 h in 2% Paraformaldehyde (PFA) and left 
overnight in 15% sucrose in 1X PBS (Boston Bioproducts) at 4 °C.  PFA was prepared by 
diluting a commercially available solution of 4% PFA (USB) in PBS with additional 1X PBS 
(Sigma) in a 1:1 mixture.  Control samples of murine and human skin were also prepared; these 
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samples were not exposed to microneedles but were fixed identically to the tested samples. 
Finally, the skin was imaged to identify microneedle insertion locations with brightfield 
macroscopy. 
Tested murine and human skin samples were then embedded in Tissue-Tec® Optimum 
Cutting Temperature medium (Sakura Finetek) and cryosectioned (Leica Cryostat). Sections (12 
µm) were taken at -25 °C based on manufacturer suggestions. Half of the sections were set aside 
for imaging using fluorescent microscopy (Olympus BX61 Upright Fluorescence Microscope). 
These sections were fixed briefly for 10 s in FROZEN-FIX (Cancer Diagnostics) prior to 
coverslipping. The remaining sections were H&E stained (CRYO-KIT, Cancer Diagnostics) for 
brightfield microscopy imaging (Olympus BX61 Upright Brightfield Microscope). Staining was 
done using the procedure outlined by Cancer Diagnostics for the CRYO-KIT prior to 
coverslipping. 
3.4.4 Franz Diffusion Cell Studies with Rhodamine Pre-Microneedle Solution 
Pre-microneedle solution (1 wt% solids rhodamine from Acros, 99 wt% solids 10 kDa 
PVP from Sigma) was tested on ex vivo nude murine skin (UNC Animal Core Facility) with the 
permission of the UNC IACUC (n = 3). Skin from nude mice (nu/nu) was excised from the back 
of the animals and flash-frozen. All skin samples were received and stored at -20 °C until testing. 
Prior to experimental studies, the skin samples (in Eppendorf tubes) were thawed briefly in 37 
°C tap water. Skin thickness was assessed with a micrometer (Mitutoyo) and the fatty layer was 
removed gently. 
Franz diffusion cells with a 5 mL receptor compartment and a 15 mm opening were 
obtained from PermeGear, Inc. and used as received. After filling the receptor compartment with 
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PBS (Sigma), the prepared tissue was placed upon the cell as the membrane, the donor 
compartment was clamped on, and a 12.5 mL aliquot of pre-microneedle solution (equating to a 
0.022 mg dose of rhodamine drug surrogate) was applied to the tissue. The apparatus was placed 
in a water bath at 37 ⁰C, and a stir bar in each cell mixed the receptor fluid for the duration of the 
experiment. Samples of the receptor fluid (400 μL aliquots) were taken at selected time points 
(0.5, 1, 3, 6, 9, 12, 20, and 24 h), immediately replacing the receptor fluid with an equivalent 
volume of 37 ⁰C PBS. Three 100 μL aliquots of the sampled receptor fluid from each time point 
were loaded into black 96 well plates, and the florescence of the rhodamine B was detected with 
a microplate reader (SpectraMax M5, Molecular Devices) at 590 nm. Rhodamine mass was 
determined from the raw fluorescence via a standard curve of serial dilutions in PBS, verified to 
linear to an R2 value of 0.99, and percent delivered dose was calculated by dividing the total 
mass of rhodamine in the receptor compartment at each given time to the original dose of 
rhodamine applied to the skin.  
Upon cell termination at 24 h, the skin was removed and immediately placed into fixative 
(2% PFA), and the samples were fixed and cryosectioned identically to those for the initial 
penetration studies (see 3.4.3). The 12 μm skin sections were fixed in FROZEN-FIX (Cancer 
Diagnostics), coverslipped, and imaged via both the fluorescent and brightfield channels of an 
upright microscope (Olympus BX61 Upright Microscope). Overlays of the fluorescence and 
brightfield images were obtained and constructed in Velocity (Improvision).  
3.4.5 Application of Protein and Particle-Loaded Films (Controls) to Ex Vivo Murine 
Tissue 
Solid-state pre-microneedle films loaded with pertinent cargos (proteins and 80 x 320 nm 
particles) were applied to ex vivo murine tissue to verify that the stratum corneum would not 
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allow the cargo to passively diffuse through the skin without microneedle features. Mimicking 
the microneedle application protocol, films were applied to ex vivo murine tissue by holding 
pressure on the film for 10 s; after 8 min, water was applied to the back of the film. The surface 
of the skin was wiped clean with medical wipes (Walgreens), and the tissue was subsequently 
fixed and cryosectioned as described previously. Images were taken on both the fluorescent and 
brightfield channels of an upright microscope (Olympus BX61 Upright Microscope). Overlays of 
the fluorescence and brightfield images were obtained and constructed in Velocity (Improvision). 
Particle controls are shown in section 3.2.2.2; Figure 3.20 shows a representative image of skin 
exposed to pre-microneedle film loaded with 80 x 320 nm particles (bare).  
 
Figure 3.20 Fluorescent microscopy image, shown as an overlay with the brightfield channel, of skin after the 
application of pre-microneedle films containing particulate drug surrogate (bare 80 x 320 nm particles). The 
fluorescence of the protein, tagged with AlexaFluor 488, cannot be seen in the skin. Epidermis = top. Scale bar is 40 
µm.    
3.4.6 Franz Diffusion Cell Studies with Microneedle Patches (All Cargos) 
To determine the dose of each drug surrogate cargo in the patches used for Franz 
diffusion studies, the fluorescent load was quantified via fluorescence imaging with an IVIS 
Kinetic imager (Caliper Life Sciences). Patches with rhodamine B cargo were imaged with the 
excitation and emission filters set to 535 nm and 580 nm respectively; since all protein and 
particulate cargos were tagged with AlexaFluor 488, an excitation of 465 nm and emission of 
520 nm was used for all patches. Radient efficiency was recorded for all patches. Patch dose was 
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determined by comparison to a standard curve of solid-state pre-microneedle films taken on the 
system; this was confirmed subsequently by dissolving sample patches in PBS and determining 
dose on the microplate reader. Standard curves were prepared in accordance to those utilized for 
the rhodamine pre-microneedle solution.   
Franz diffusion cells for all microneedle studies were set up as described above for the 
pre-microneedle solution experiments. However, the microneedles had to be applied to the skin 
before affixing the tissue as the membrane. After measuring the thickness of each skin section 
with a micrometer (Mitutoyo), the tissue was affixed to a corkboard. Microneedle patches were 
applied to the skin with the gentle force of thumb, applying pressure for 10 s. The microneedles 
were allowed to sit in the skin for 8 min before the application of 100 μL of water to the back of 
the patch. After the substrate dissolved, non-stick medical wipes (Walgreens) were used to wipe 
the surface of the skin clean. This process was repeated three times to assure the surface of the 
skin was clean. The skin was then affixed to the Franz cell as the membrane. All conditions were 
identical to the diffusion experiments with rhodamine pre-microneedle solutions, barring the 
wavelength of detection of the fluorophore on the plate reader (SpectraMax M5, Molecular 
Devices, 550 or 590 nm).  
To best assess the delivered dose of the rhodamine microneedle patches specifically, the 
cargo removed from the surface of the skin was quantified and subtracted from the original dose 
of the patch (determined via IVIS Kinetic imaging). Wipes used to clean the skin for each 
experiment were left to dry overnight, leaving only solids; the wipes were then placed in 2.0 mL 
Eppendorf tubes with 1.5 mL of PBS. After shaking for 1 h at 750 RPM at room temperature, the 
supernatant solution was removed and aliquoted (100 μm) into a black 96 well plate. Again, 
florescence of the rhodamine B was detected with a microplate reader at 590 nm. Wipes dosed 
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with known masses of rhodamine (as a solution in PBS) were treated identically and used to 
form a standard curve, accounting for the extraction efficiency of the rhodamine cargo.  
3.4.7 In Vivo Application of Microneedles to Nude Mice 
Microneedle patches were tested on nude murine skin in accordance with the animal use 
protocols approved by the UNC Institutional Animal Care and Use Committee (IACUC). Nude 
mice (4-6 weeks old) were bred by the UNC animal core facility. Microneedle patches loaded 
with DyLight 680 were utilized for all experiments to optimize animal application. Mice were 
anesthetized with isoflurane (Baxter) via continuous flow through nose cones of an IVIS Kinetic 
or IVIS Lumina system (Caliper Life Sciences); the stage of the instrument was set to 37 °C. 
Microneedle patches were rolled onto the skin on the back of the animals, and pressure was 
applied for 10 s to 1 min during optimization. Extreme care was taken to avoid excessive 
pressure administered to the animal. Once it was determined that light pressure for 1 min was the 
optimal application technique, these conditions were used throughout all further studies.   
Patch back dissolution experiments were performed with five male mice, obtained from 
the core for this pilot study. Microneedles containing DyLight 680 were imaged on the IVIS 
Lumina system, with an excitation and emission of 675 nm and 720 nm respectively. The radiant 
intensity of each patch was recorded. Microneedles were then applied to the mice as previously 
described, and IVIS images were collected under the above settings. After the allotted time (8-60 
min), small aliquots of water (100 µL) were applied to the patch backing and the skin’s surface 
was wiped clean with medical wipes (Walgreens). Wiping continued until the terminal wipe 
showed no observable fluorescent signal in an IVIS image. All mice were sacrificed 72 min after 
patch application. With the assistance of the Animal Studies Core at UNC, cardiac punctures 
were performed and blood was collected into ethylenediaminetetraacetic acid (EDTA)-coated 
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tubes (Milian, USA). Blood was subsequently aliquoted into black 96 well plates and imaged on 
the IVIS Lumina system. Tissues (treated skin, non-treated skin, underlying tissue, kidney, liver, 
spleen) were harvested, loaded into 6 well plates, and imaged on the IVIS Lumina. The radiant 
intensity of the non-treated skin was subtracted from the signal collected for the treated skin; the 
delivered dose of DyLight 680 was determined by subtracting the signal observed in treated skin 
from the signal of the original patch.   
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CHAPTER 4 PRINT MICRONEEDLES FOR THE DELIVERY OF BUTYRYLCHOLINESTERASE TO 
COMBAT ORGANOPHOSPHATE OVEREXPOSURE 
 
4.1 Introduction  
Organophosphates are among the most toxics compounds known to man, resulting in 
severe symptoms with just a fraction of the median lethal dose (LD50).
1-5 Due to their small size, 
rapid overexposure can occur through inhalation, ingestion, and dermal contact with these 
agents. Organophosphates such as malathion, parathion, diazinon, sorin, and sarin are commonly 
found in pesticides, insecticides, and chemical warfare agents (nerve gasses).1,2-5 These small 
molecules irreversibly inhibit acetylcholinesterase, the enzyme responsible for the breakdown of 
the neurotransmitter acetylcholine.1,2-5 The build-up of acetylcholine prompts the overstimulation 
of cholinergic receptors at the nerve synapses; this can lead to muscle weakness, respiratory  
distress, seizures, coma, and, rapidly, death.1 Over 1 million cases of organophosphate poisoning 
have been reported annually, resulting in hundreds of thousands of deaths.3-5  
The treatment of organophosphate overexposure has recently been approached by using 
scavenging enzymes to neutralize these compounds while still in the blood stream, before they 
reach acetylcholinesterase in the nervous system.1,2,6,7 One particularly promising enzyme is 
butyrylcholinesterase (BuChE), a stoichiometric scavenger of organophosphates (Figure 4.1).1,2 
BuChE is naturally found in the circulation and also functions as a co-regulator for cholinergic 
neurotransmission.2 Upon exposure to organophosphates, 1 mol of the toxin can be neutralized 
by 1 mol of BuChE; however, an overexposure event would introduce a significant excess of 
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these small molecules, resulting in the inability of BuChE to protect the system at native serum 
concentrations.6,7 Additionally, BuChE cannot passively cross the blood brain barrier, limiting 
the effective protection of the central nervous system in the event of high exposure.6    
 
Figure 4.1 Structure of monomeric human BuChE.8 
 Studies with BuChE have shown that increasing the concentration of this enzyme in 
systemic circulation is effective at counteracting organophosphate overexposure, particularly in 
the cases of the rapid onset nerve gas poisoning.1,2,6,7 In fact, a dose of 200 mg of human serum 
derived BuChE introduced intravenously has been shown to successfully protect humans when 
exposed to two times the LD50
  of sorin.9 The tetrameric form (Mw ~340 kDa) has been studied 
most frequently for use in scavenging applications, as it has the longest circulation half-life 
(tetrameric BuChE t1/2 = 16 hours), representing 95% of the soluble activity of BuChE.
10,11 
Nonetheless, the monomeric form is also effective, but its half-life (t1/2 = minutes) limits its 
ability to provide long term protection.7 Novel formulations, include nanoscale complexes of the 
enzyme, have been effective at crossing the blood brain barrier, affording increased central 
nervous system protection.6 While it has been seen that the serum derived human BuChE is 
highly difficult to isolate or synthesize, commercially available equine BuChE is an effective 
equivalent that has been readily accepted in pre-clinical studies.10-12 
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The transdermal route of administration of BuChE offers intriguing opportunities for 
patients, including improved compliance, rapid onset, access to local protection in the skin (a 
route of exposure), and systemic delivery.13-15 Prophylactic (to provide full body protection 
before an exposure event) or therapeutic (post-exposure) treatments are possible depending on 
the release kinetics of the enzyme from its vehicle. Despite their promise, advances of 
prophylactic and therapeutic treatments via transdermal administration, employing traditional 
permeation enhancers to allow for large molecule transport across the stratum corneum, are 
currently limited by low delivered dose consistency, slow systemic exposure of macromolecules, 
and difficulties with controlled release.7,13,14 Microneedles, uniquely, offer a convenient, pain-
free, and portable approach that may enhance the bioavailability of protein therapeutics on 
relevant time scales of organophosphate overexposure. Particle Replication in Non-wetting 
Templates (PRINT) allows for the design of microneedle counteragents that have long 
circulation profiles, access to relevant biological spaces, and the programmed release of 
therapeutic payloads.  
Specifically for the delivery of proteins, PRINT has proven to be an opportune technique 
to directly mold biomolecules into nano- and microparticles.16-18 Nanoscale vehicles are of high 
interest due to their tunable protein release profiles to optimize prophylactic applications. 
Particles have been fabricated in multiple sizes (5 µm to 200 nm) out of bovine serum albumin 
and insulin mixtures, resulting in monodisperse particle distributions.16 It has been shown that 
over 90% of the final particle is composed of functional protein.17 Additionally, novel surface 
crosslinkers have been used to control particle dissolution rate, rendering the molded protein 
transiently insoluble.17 In these studies, a reductively labile disulfide-based crosslinker was 
employed, leading to preferential release in a reducing environment, and the cleavage of the 
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cross-linker was shown to leave no chemical residue on the reactive amino group.17,18 Delivery 
of a self-replicating RNA was achieved with these transiently insoluble PRINT protein particles, 
and it is likely that this approach could be adapted for the delivery of BuChE.18 In addition, other 
novel methods for controlled protein release could be investigated, including protein binding via 
poly(vinyl alcohol), release from hydrogel materials, polyanhydride crosslinking, and utilizing 
other thioesters.19-22 
In this vein, we aim to optimize BuChE delivery to augment native levels of this enzyme 
and enhance organophosphate bioscavenging capabilities. Utilizing both particulate and free 
BuChE delivered via the microneedle route of administration may lead to either prophylactic or 
therapeutic treatment, respectively. PRINT technology enables the development of nano- and 
microparticles loaded with very large amounts of BuChE. These formulations can be further 
optimized for controlled, tunable, and potentially exposure-triggered BuChE release.  Particulate 
delivery via microneedles may result in high levels of enzyme in systemic circulation while 
offering additional local protection in other tissues of interest. In this work, progress towards the 
ideal microneedle device to these aims is reported, including the fabrication of devices 
encapsulating free and particulate BuChE and the examination of the release kinetics of free 
enzyme from microneedles both ex vivo and in vivo.  
4.2 Results and Discussion  
4.2.1 Fabrication and Characterization of PRINT Microneedles Incorporating BuChE  
4.2.1.1 Loading of Free BuChE  
First, PRINT microneedle devices were manufactured by loading low activity BuChE 
[~20 units (U)/mg] into our polyvinylpyrrolidone (PVP) matrix. Pre-microneedle solutions of 
PVP and BuChE in water were made at a variety of loadings [0.0002-30% weight percent (wt%) 
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BuChE of total solids]. Films were then drop-cast for microneedle manufacturing; they were 
dried at room temperature (RT) for 24-48 hours (h) before use. It was observed that considerable 
visual phase separation in the films occurred at loadings above 25 wt% BuChE; conclusively, 
higher loadings resulted in non-homogenous needles. To confirm films loaded with up to 20 wt% 
BuChE would maintain the strength needed for microneedle skin penetration, a film of this 
loading was analyzed by differential scanning calorimetry (DSC) to determine the glass 
transition temperature (Tg). A Tg of 54 °C was observed for this material, indicating that 
resulting microneedles would have similar efficacy to ovalbumin (OVA) and aldolase 
microneedles (Chapter 2).    
Microneedles were then fabricated from these solid-state films with BuChE loadings up 
to 25 wt%, using identical contiditions to the protein microneedles fabricated previously 
(Chapter 2).15 Briefly, microneedles were fabricated at a nip temperature of 77-82 °C and a 
pressure of 50 PSI. Each microneedle patch was under the laminator for approximately 1.5 
minutes, providing enough heat to melt and fill each mold without compromising BuChE 
activity. Patches were harvested on flexible layers, and stored at 20-30% relative humidity before 
use.  
Environmental Scanning Electron Microscopy (ESEM) images of patches with a variety 
of loadings can be seen in Figure 4.2. Microneedles are approximately 200 x 200 µm at the base, 
385 µm tall, and have a tip radius of approximately 10 µm. All loadings, reproducibly, resulted 
in microneedles of identical size and shape. 
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Figure 4.2 PVP microneedles with encapsulated BuChE made from films cast in water. (A) 5 wt% BuChE, (B) 10 
wt% BuChE, (C) 15 wt% BuChE, (D) 20 wt% BuChE, (E) 25 wt% BuChE. Scale bars are 200 µm on all.  
After microneedle fabrication, we confirmed that the BuChE maintained activity after 
processing. Representative films (pre- and post-processing) containing 20 wt% BuChE were 
subjected to a cholinesterase assay performed by the UNC Hematology Core.23 Briefly, patches 
were dissolved in water, and the solutions were deposited onto a slide treated with 
butyrylthiocholine and potassium ferricyanide. In the presence of water, cholinesterase reacts 
with the butyrylthiocholine to produce thiocholine. Activity (U/mL) was determined through 
reflectance spectrophotometry, detecting the loss of signal due to potassium ferricyanide as the 
thiocholine reduces it to potassium ferrocyanide. The percent activity retained in was determined 
in comparison to levels detected in pre-microneedle solution at each loading; the assessed 
solution, in each case, contained an equivalent mass of protein to the original solid-state film (n = 
3). Figure 4.3 shows the results of the analysis. Both the pre- and post-processed films were seen 
retain over 95% of BuChE activity, validating that all of the enzyme loaded into the devices is 
active.  
 
 
 
 
A B C 
D E 
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Figure 4.3 Recovered BuChE activity after PRINT processing determined via a spectrophotometric cholinesterase 
assay (UNC Hematology Core). Pre- and post-processed solid-state films contacting 20 wt% BuChE recovered over 
95% of the BuChE activity charged. 
After confirming the activity and stability of PVP microneedles made with up to 25 wt% 
BuChE, we wanted to determine the distribution of the protein throughout the devices 
themselves. To do so, the low activity BuChE was tagged with NHS-fluorescein via an amine 
linkage; this procedure was utilized to tag the aldolase drug surrogate (Chapter 2). The tagged 
BuChE was loaded into films and microneedle devices at loadings between 0.0002-25 wt% to 
observe differences in distributions. Figure 4.4 shows confocal micrographs of needles and films 
with a variety of loadings. Interestingly, the most homogenous distribution of BuChE was seen at 
the higher loadings of enzyme; aggregates formed when the protein was encapsulated at low 
wt%. The interaction between the BuChE and PVP, the casting solvent, the drying process, and 
the interaction between film and the perfluoropolyether (PFPE) mold all play a role in cargo 
distribution. Differences in dispersion as a function of loading are observed across all the PRINT 
systems, for all factors have to be optimized for ideal films. Because a high dose of BuChE is 
required to combat organophosphate poisoning, a high loading is ideal, making the most 
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homogenous film also our ideal film moving forward. In an effort to keep a high dose while 
minimizing protein consumption, a loading of 20 wt% was selected for further ex vivo studies, 
and the enzyme was tagged with AlexaFluor 488 for optimal performance. The homogeneity of 
these microneedles was confirmed via confocal microscopy, shown in Figure 4.5. 
 
Figure 4.4 Confocal images of PVP microneedles and films loaded with fluorescein-tagged BuChE. Representative 
images of 0.1 wt% (top), 5 wt% (middle), and 25 wt% (bottom) BuChE are shown. With increased BuChE loading, 
the distribution of protein became increasingly more homogenous.  
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Figure 4.5 Confocal microscopy images of microneedles loaded with 20 wt% BuChE tagged with an AlexaFluor 
488 probe.  
 While free BuChE is ideally suited for dissolution in water-based solution, PRINT 
BuChE particles are also water-soluble in their unmodified (non-crosslinked) form. It is of 
interest to explore any differences in the release of the molded and free protein from 
microneedles to distinguish any changes in kinetics merely due to the particulates.6,7 To 
encapsulate these protein particles into PRINT microneedle devices, a new casting solvent would 
be required; the ideal solvent would be compatible with both PVP and protein particles, create 
features strong enough for skin penetration, and maintain BuChE activity post-processing. 
Therefore, a preliminary study of other casting solvents was performed using free BuChE as a 
model. Organics known to readily solubilize the amphiphilic PVP were selected for study; these 
included acetonitrile (ACN), ethanol (EtOH), and isopropyl alcohol (IPA). Pre-microneedle 
solution was prepared with 5 or 10 wt% BuChE and solid-state films of each were cast.  
Films were subjected to DSC analysis; the thermal properties of each matrix can be found 
in Table 4.1. It was seen that the films cast in ACN and EtOH had thermal properties that may 
result in adequate microneedle devices; the IPA films were considerably weaker. In addition, 
they would not separate from their casting sheets, making it impossible to fabricate microneedles 
via PRINT. ESEM and confocal images of microneedles made from 5 wt% films (under 
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optimized fabrication conditions) can be seen in Figure 4.6. Microneedles showed ideal 
dimensions in both casting solvents, but distributed slightly differently in the fabricated needles. 
The tips of the needles cast in acetonitrile were saturated with BuChE, while the needles made 
from ethanol films showed some protein throughout the matrix. These differences were noted, 
but ultimately not used to eliminate a solvent; the particles will likely distribute differently than 
free protein due to the increased size of the cargo. 
Table 4.1 Glass transition temperatures of BuChE films cast in acetonitrile, isopropanol, and ethanol  
 
                        Casting Solvent 
  
ACN, Tg (°C) IPA, Tg (°C) EtOH, Tg (°C) 
5 wt%  10 wt% 5 wt%  10 wt% 5 wt%  10 wt% 
32 36 5 11 30 23 
    
 
Figure 4.6 Confocal (top) and ESEM (bottom) images of microneedles made with 5 wt% BuChE cast in either ACN 
(left) or EtOH (right).  
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After showing efficacy in producing microneedles of ideal dimensions and strength, the 
activity of the BuChE was assessed via the established cholinesterase assay. BuChE films of 5 
and 10 wt% loading were cast and subsequently dissolved in water. Because all films were the 
same size and had the same loading of BuChE, absolute activity was used to determine the effect 
of each solvent. Results of this study can be seen in Table 4.2. While the IPA films were shown 
to exhibit the highest activity, it was not a candidate for microneedles due to the poor mechanical 
properties of the films; the study did identify IPA as the ideal harvesting solvent for the water-
soluble BuChE PRINT particles after manufacturing. The results of both the thermal analysis and 
activity assays confirmed that ACN was best the casting solvent for microneedles made with 
water-soluble PRINT particles. 
Table 4.2 Absolute activity of BuChE recovered from films cast in EtOH, IPA, and EtOH 
   BuChE Activity, U/mL 
 ACN IPA EtOH 
5% Film 4.01 3.77 0.35 
10% Film 6.37 10.90 1.18 
 
4.2.1.2 Loading of Particulate BuChE  
In order to develop a prophylactic administration of BuChE that would be effective 
against organophosphate poisoning, long circulation times and controlled release of BuChE 
would be necessary.1,2,6,7 The quick burst release of the free enzyme would not provide the 
sustained release via microneedle administration, but BuChE incorporated into PRINT particles 
has great promise to do so through “depot” microneedles. Particulate formulations offer the 
potential for use as a prophylactic; this is achieved by delivering long circulating particles with 
stimulus triggered enzyme release upon gas overexposure. The rapid dissolution of the PVP 
microneedles would quickly introduce these particles to the body, allowing for the controlled 
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release of the BuChE cargo over time. The fabrication of protein particles has been previously 
optimized with the model protein bovine serum albumin; using these guidelines, the DeSimone 
Lab was successful in manufacturing 1 µm PRINT particles composed of 90% active tetrameric 
BuChE.17 A representative scanning electron micrograph of these particles can be seen in Figure 
4.7. To increase particle water stability – and therefore open the door to tunable BuChE release – 
the particles need to be stabilized via a tunable crosslinker. Initial studies to optimize the 
crosslinking procedure employ a disuccinimidyl suberate (DSS) linker, rendering them water-
insoluble; half of the particles for these studies were crosslinked in this way while the rest 
remained unmodified.  
 
Figure 4.7 SEM of 1 µm PRINT particles composed of 90% BuChE.  
 Particles including BuChE tagged with AlexaFluor 488 probe were incorporated into the 
ACN pre-microneedle solution at a loading of 5 wt%; crosslinked and non-crosslinked particles 
were encapsulated into separate devices. Film homogeneity was confirmed via confocal 
microscopy (Figure 4.8). Therefore, microneedles were fabricated at the standard conditions for 
protein cargos (77-83 °C nip temperature) with both particle compositions. ESEM and confocal 
images of the resulting microneedle devices can be seen as Figure 4.9. Consistent with the film 
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results, both types of particles showed homogenous distribution in the microneedles, showing the 
efficacy of PRINT microneedles to load even micron-sized cargo.  
 
Figure 4.8 Confocal images of PVP films containing BuChE 1 µm particles. (A) Non-crosslinked particles, and (B) 
Crosslinked BuChE 1 µm particles. 
 
Figure 4.9 ESEM and confocal images of PRINT PVP microneedles incorporating 1 µm BuChE PRINT particles. 
(top) Non-crosslinked, and (bottom) Crosslinked particles.  
A B 
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 To assess the activity of the BuChE release from the particles after microneedle 
fabrication, patches with non-crosslinked particulate cargo were dissolved in water post-
processing; a solid-state pre-microneedle film of the same composition was also prepared as a 
control. The aqueous environment both releases the particles from the highly water-soluble PVP 
matrix and dissolves the non-crosslinked BuChE particles themselves. These solutions were run 
on the afformentioned cholinesterase assay, and it was seen that BuChE released from the 
patches retained 50-60% of the activity loaded into the original film. Future studies included the 
assessment of the unconsumed film to determine the true percent recovered activity of the 
BuChE after processing; the material loss likely accounts for the activity loss observed. Still, 
these results indicate PRINT microneedles may be used to deliver active BuChE in particulate 
form transdermally.  
 It was also of interest to discern if the crosslinked particles retained their size and shape 
after release from PRINT microneedles. The DSS crosslinker is employed to provide long term 
stability of the particles in water, resulting in incredibly slow release kinetics; therefore, any 
morphological changes to the particles would be due to the microneedle manufacturing itself. 
After processing, microneedles loaded with these particles were dissolved in water, and PVP was 
removed via centrifugation; a solid-state film of the same composition was also processed to 
serve as a control. Particles were resuspended in IPA for SEM imaging (Figure 4.10). Pristine 
particles were recovered from both the film and microneedles, indicating that our processing 
does not inherently harm particle morphology. Moving forward with these studies, cleavable 
crosslinkers will be employed to tune the enzyme release kinetics from the particles, and the 
delivery of the particles to ex vivo tissue via PRINT microneedles will be investigated.  
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Figure 4.10 SEM images of crosslinked 1 µm BuChE particles after release from (A) PVP films and (B) PVP 
microneedles.  
4.2.2 Ex Vivo Permeation Studies with Microneedles Incorporating Free BuChE  
Next, microneedles loaded with 20 wt% free BuChE were applied to ex vivo murine 
tissue to assess the ability of the devices to adequately penetrate skin and release their cargo. 
With the aid of the Franz diffusion cell apparatus (Chapter 3), studies of this large protein were 
performed identically to those with the model proteins, OVA and aldolase, to directly compare 
their efficacy and release kinetics. The tetrameric equine BuChE used (Mw = 340 kDa, pI = 4.2-
4.9) has an isoelectric point very similar to OVA (pI = 4.6) but a mass much larger than even the 
aldolase (Mw = 161 kDa). Therefore, the major influence on protein skin permeation (size v. 
isoelectric point) can be examined through studies with this therapeutic enzyme, and significant 
progress towards the ideal microneedle device for nerve agent scavenging will be made.  
To perform these studies, microneedles loaded with 20 wt% of the AlexaFluor 488-
tagged enzyme were fabricated, and their dose was determined via quantitative fluorescence 
imaging on an IVIS Kinetic system. Franz cell permeation studies were then performed utilizing 
the procedure optimized on drug surrogate proteins. To summarize, microneedle patches were 
applied to murine skin excised from the back of a nude mouse, holding pressure for 10 seconds 
(s). After 8 minutes (min), the patch backing was dissolved with water and the skin surface was 
wiped clean. Skin was then affixed to the Franz cell apparatus to serve as the membrane. 
A B 
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Samples of the receptor fluid, phosphate buffered saline (PBS), were taken at regular intervals 
over 24 h. At the conclusion of the studies, a standard fluorescence plate reader was used to 
determine the mass of BuChE that transversed the skin at each time point detecting (emission = 
550 nm).  
The results of these studies can be found as Figure 4.11. Seen in Figure 4.11A, less than 
3% of the BuChE cargo loaded into microneedle devices was shown to permeate the skin at 24 h. 
For reference, the BuChE release profile is compared to both drug surrogate proteins in Figure 
4.11B. This slow diffusion is likely due to the size of the protein, not its pI; the 45 kDa OVA 
with the same pI was seen to deliver nearly six times more protein over this duration. The 
tetrameric BuChE also released much slower than the 161 kDa aldolase, supporting that protein 
size plays a significant role in tissue penetration.   
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Figure 4.11 Release profiles of BuChE through ex vivo murine tissue over 24 h. (A) BuChE alone, and (B) this 
enzyme in comparison to OVA and aldolase. 
 Upon cell termination, the skin treated with BuChE microneedles was fixed, 
cryosectioned, and imaged on the upright fluorescence/brightfield microscope to map the 
location of the enzyme in the skin after 24 h. A representative image from these studies (Figure 
A B 
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4.12) shows the fluorescent BuChE clearly visible below the surface of the epidermis; however, 
the shallow depth of penetration after 24 h confirms the slow permeation of the protein through 
murine skin. As with other large cargos, longer studies in vivo are required to observe any 
increase in permeation over time and to determine how the enzyme interacts with live tissue.   
 
Figure 4.12 Fluorescent microscopy images, shown as overlays with the brightfield channel, of skin after the 
application microneedles loaded with free tetrameric BuChE for 24 hours on a Franz cell apparatus. The enzyme is 
localized below the skin in select regions of the lower epidermis. Epidermis = top. Scale bar is 40 µm.    
4.2.3 In Vivo Studies with High Activity Free BuChE Microneedles  
To determine the ability of PRINT microneedles loaded with free BuChE to introduce 
enzyme into systemic circulation, patches with very high activity BuChE (>200 U/mg) were 
optimized for in vivo studies with nude mice. In this way, we can optimize the detection of 
BuChE in murine serum at longer time points via the activity assay; to assure the highest chance 
of detection, the high activity BuChE was not tagged with a fluorophore. The experimental 
parameters for the first pilot study performed can be seen in Table 4.3 (n = 3). Four time points 
were selected merely to probe the possible window of detection (up to 48 h). Due to the high 
expense and low availability of 200 U/mg BuChE, the same three mice were used for the 4 and 
24 h time points, and three mice were used for the 8 and 48 h time points; at the shorter time 
point, blood was drawn from the mouse via submandibular bleeds performed with the aid of the 
UNC animal core. Terminal blood was collected via cardiac puncture.  
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Table 4.3 Study parameters for the in vivo detection of BuChE in circulation after treatment with microneedles 
 
 
 
 
 
Microneedle application to the back of these animals had been previously optimized for 
small molecule drug surrogates (Chapter 3). To review, after anesthetizing the mice with 
isoflurane, microneedle patches were “rolled” onto the skin of the mouse, and pressure (gentle 
“force of thumb”) was applied for 1 minute. After application for 8 minutes, water was applied to 
the patch’s water-soluble backing and allowed to dissolve for (approximately 2-3 minutes). The 
skin is then wiped clean with medical wipes.  
The change in cholinesterase levels (U/mL) in the serum of mice after microneedle 
application (at each time point) can be seen in Table 4.4. Baseline cholinesterase levels were 
taken prior to microneedle administration and have been subtracted out; standards prepared by 
dosing BuChE to murine serum showed a linear increase in activity with an increase in enzyme 
concentration. At the conclusion of this in vivo study, the serum from the mice at each time point 
did not show any statically significant increases in BuChE levels due to the administration of the 
microneedles. All time points behaved similarly, indicating the microneedle administration did 
not transport the BuChE to the blood at these sampling intervals.  
 
 
Mice  Male Nu/Nu, 4-5 weeks old  
Microneedles 15 wt% BuChE in PVP 
BuChE Species  Tetrameric, (200+ U/mg) 
Time points for blood draws 48 h, 24 h, 8 h, 4 h  
BuChE Detection Hematology Core Cholinesterase Assay 
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Table 4.4 Change in cholinesterase activity after high activity BuChE microneedle administration in vivo, as 
determined by the UNC Histology Core.  
Mouse Increase in Cholinesterase Activity Detected, U/mL 
4 h 8 h 24 h 48 h 
1 0.0 0.1 0.0 0.0 
2 0.0 1.0 0.0 0.0 
3 0.0 1.1 0.0 0.2 
 
Based upon these results, it is clear that the administration of free tetrameric BuChE with 
our current PRINT microneedle patch would not be an effective antidote to nerve gas 
overexposure. We have concluded that the slow permeation kinetics of the protein from these 
needles does not allow for the rapid uptake of the esterase into the system.24-26 To improve the 
BuChE circulation, we postulate that a concentrated dose of enzyme would need to be delivered 
deeper in the skin, closer to the dermal network of blood vessels. We aim to explore the efficacy 
of longer microneedles with tip-concentrated enzyme to address these concerns. Chapter 6 
outlines future studies with these devices, focusing on the development of new microneedle 
masters to provide longer, sharper microneedle devices.   
4.3 Conclusions 
In this work, we have fabricated rapidly water-soluble PVP PRINT microneedles that 
homogeneously encapsulate 20-25 wt% free BuChE. The activity of the enzyme after processing 
has been confirmed. Additionally, 1 µm PRINT particles composed of 90% tetrameric BuChE 
have been fabricated via a melt-solidification process. Both crosslinked and non-crosslinked 
particles have been incorporated into PVP microneedles at a 5 wt% loading. While the 
crosslinked particles were found to be intact after microneedle fabrication and release in aqueous 
solution, the non-crosslinked particles released active enzyme upon dissolution. Finally, the 
permeation kinetics of the large protein through ex vivo murine tissue were seen to be very slow, 
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and highly active enzyme was not detectable in murine serum after the administration of these 
microneedles in vivo. Therefore, to ensure rapid systemic exposure of this protein, new 
microneedle geometries must be explored. 
4.4 Experimental  
4.4.1 Microneedle Cargo Preparation  
4.4.1.1 Fluorescent BuChE  
For select patches, BuChE was tagged with a fluorophore prior to microneedle 
encapsulation. Low activity (~20 U/mL) tetrameric equine BuChE (Aldrich) was tagged with an 
either NHS-fluorescein (Thermo Scientific) or AlexaFluor 488 NHS Ester (Life Technologies). 
BuChE in phosphate buffered saline (PBS) was mixed with the selected probe (in 
dimethylformamide) at a 3:1 molar excess of dye and allowed to mix for 1 h at RT. The tagged 
protein was separated from the unreacted dye via centrifugal filtration with a 100 kDa filter 
(Millipore) at 14,000 RPM at 4 °C for 25 min. The protein concentration was determined via 
absorption at 280 nm (Nanodrop 2000) through the extinction coefficient (E1%
 = 6.39). The 
tagged protein was dialyzed overnight using a 20 kDa molecular weight cut-off dialysis device 
(Thermo Scientific) at RT before further use.    
4.4.1.2 1 µm BuChE PRINT Particles  
Protein particles were fabricated via small-batch PRINT processing utilizing a melt-
solidification approach. Thin PFPE molds for the fabrication of 1 µm particles were obtained 
from Liquidia Technologies. Particles were fabricated at a controlled relative humidity of 30-
35%. A 10 wt% solids pre-particle solution was prepared in water; a solid composition of 2:1:1 
BuChE:lactos:glycerol (wt%) was optimized. Of the utilized BuChE, 3 wt% was tagged with 
AlexaFluor 488 NHS Ester (Life Technologies) as previously described. Films were cast onto 
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poly(ethylene terephthalate) (PET) sheets with a #7 Mayer rod (R.D. Specialties). To assure 
solvent evaporation, films were exposed to hot air derived from heat guns during casting. After 
setting for 30 seconds, mold was applied to the film then laminated with a nip temperature of 77-
82 °C under 100 PSI pressure. Mold was split from the delivery sheet upon exiting the laminator. 
A Plasdone (Luvitec VA64, BASF) layer was laminated to the mold before harvesting manually 
in IPA. Particle suspensions were passed through a 10 µm filter to remove any large particulates 
before centrifugal washing (MiniMouse II Microcentrifuge, Denville Scientific at 6,000 g for 3 
min) three times in IPA.  
Crosslinked particles were prepared as follows: particles were centrifuged to create a 
pellet and the supernatant IPA was removed. Crosslinker solutions (10 mM) of disuccinimidyl 
suberate (DSS, Pierce Protein Biology) in ACN were prepared. Particles were resuspended in 
this ACN solution at a concentration of 1 mg/mL. The reaction was mixed on a benchtop shaker 
(1400 RMP, 37 °C) for 3 h. Particles were collected via centrifugation (MiniMouse II 
Microcentrifuge, Denville Scientific at 6,000 g for 3 min) and washed in fresh ACN three times 
before incorporation into microneedle devices.  
The particles were characterized via thermal gravimetric analysis (TGA) (TA Q5000) for 
concentration determination and imaged via scanning electron microscopy (SEM) (Hitachi 
model S-4700) for size and shape confirmation. Samples for SEM were prepared by spotting 1 
µL of ~0.5 mg/mL particle solutions in IPA onto a silicon wafer and drying under heat. It has 
also been determined that the protein content in the particles measured at more than 90% BuChE 
post-fabrication via cholinesterase activity compared to the theoretical loading (UNC Histology 
Core, see 4.3.3).     
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4.4.2 BuChE Microneedle Fabrication and Characterization 
Microneedles were fabricated using an adapted PRINT process, described in detail in 
Chapter 2.15 All fabrication conditions (77-82 °C nip, 50 PSI) for protein-loaded microneedles 
were employed for the fabrication of BuChE microneedles. However, the preparation of the pre-
microneedle solutions varied with BuChE form. All aqueous solutions of free BuChE (tagged, 
low activity, and high activity) were composed of 0.0002-30 wt% protein in PVP (15-20 wt% 
solids). Free BuChE incorporated into all organic solvents (ACN, IPA, and EtOH) was done at a 
loading of 5-10 wt% protein in PVP at 40 wt% total solids. Particle loading was consistent at 5 
wt%, employing an ACN casting solvent again at 40 wt% total solids.   
Microneedle patches and films were characterized with ESEM (FEI Quanta 200), 
confocal microscopy (Zeiss LSM 700), and brightfield macroscopy (Leica-Wild M420 
Macroscope). Thermal properties of the microneedle films were determined via DSC (Q200, TA 
Instruments) after storage at 30% relative humidity. Prior to differential scanning calorimetry, 
decomposition experiments were done by heating 5-10 mg of substrate from 0-550 °C at 10 
°C/min via thermogravimetric analysis (PerkinElmer Pyris 1), and the 95% decomposition 
temperature was found. The upper temperature limit for the DSC experiments was to be no more 
than 50 °C lower than the 95% decomposition temperature for each material. DSC was used to 
determine the Tg’s of the substrates. Samples (5-10 mg) were crimped into aluminum pans and 
heated from -20 °C to 100-120 °C at a rate of 5 °C/min, cooled at a rate of 10 °C/min to -20 °C, 
and heated again in a second cycle. Tg’s were determined from the second heating cycle.  
4.4.3 Cholinesterase Assay 
BuChE activity for all samples (materials dissolved in water and whole murine blood) 
were performed at the UNC Hematology Core via the VITROS CHE TE assay (Ortho Clinical 
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Diagnostics). All measurements were taken in accordance to manufacturer specifications.23 
Briefly, slides coated with butyrylthiocholine (290 µg) and potassium ferricyanide (180 µg) were 
acquired and incubated to body temperature (37 °C). A 10 µL aliquot of sample was spotted onto 
the slide and allowed to incubate for 5 min. Active BuChE in the samples reacts with the 
butyrylthiocholine on the slide, producing thiocholine and butyrate. The thiocholine 
subsequently reduces potassium ferricyanide to potassium ferrocyanide. Color loss due to this 
reaction was monitored via reflectance spectrophotometry (VITROS DT60) at 400 nm, and the 
rate of change has been shown to be proportional to the cholinesterase activity of the samples. 
Any samples above the upper limit of the dynamic range of the assay (0.20-12.50 U/mL) were 
diluted and reassessed.  
4.4.4 Assessment of Particle Morphology after Microneedle Encapsulation 
Crosslinked particles were used exclusively for these studies; solid-state films and 
microneedle patches were made and characterized as previously described. The materials were 
then dissolved in 1 mL of water to release the particles from the PVP microneedle matrix. 
Residual PVP was removed via centrifugation (MiniMouse II Microcentrifuge, Denville 
Scientific at 6,000 g for 3 min) and washed in fresh IPA three times before preparation for SEM 
as described above. 
4.4.5 Permeation Studies with a Franz Cell Apparatus 
The permeation kinetics of BuChE through full thickness murine skin were assessed on 
ex vivo murine skin via a Franz diffusion cell apparatus. All experiments were conducted 
identically to the studies on protein drug surrogates, described in detail in Chapter 3. To 
summarize, fluorescently labeled BuChE microneedles were images with an IVIS Kinetic imager 
(Caliper Life Sciences) to determine patch dose. Due to the AlexaFluor 488 tag, an excitation of 
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465 nm and emission of 520 nm was used for all patches. The microneedles had to be applied to 
the skin before affixing the tissue as the membrane. Microneedle patches were applied with the 
gentle force of thumb, followed by the subsequent dissolution of the back of the patch. After the 
substrate dissolved, non-stick medical wipes (Walgreens) were used to wipe the surface of the 
skin clean. Franz diffusion cells (PermeGear) with a 5 mL receptor compartment and a 15 mm 
opening were incubated at 37 °C; PBS (Sigma) was utilized as the receptor solution. Samples of 
the receptor fluid were taken at eight time points over 24 h, immediately replacing the receptor 
fluid with an equivalent volume of 37 °C PBS. The determination of BuChE mass delivered to in 
the receptor fluid was found using a standard plate reader at 550 nm, correlating fluorescence to 
a standard curve prepared in PBS.   
Upon cell termination at 24 h, the skin was removed and immediately placed into fixative 
(2% PFA, USB) for two hours before storage in a PBS solution stabilized with 15% sucrose.  
Fixed skin was embedded with Tissue-Tec® Optimum Cutting Temperature medium, and 
cryosectioned identically to those for the all penetration studies. The 12 μm skin sections were 
exposed briefly to FROZEN-FIX (Cancer Diagnostics), coverslipped, and imaged via both the 
fluorescent and brightfield channels of an upright microscope (Olympus BX61 Upright 
Microscope). Overlays of the fluorescence and brightfield images were obtained and constructed 
in Velocity (Improvision).  
4.4.6 In Vivo Application of High Activity BuChE Microneedles to Nude Mice 
Microneedle patches were tested on nude murine skin in accordance with the animal use 
protocols approved by the UNC Institutional Animal Care and Use Committee (IACUC). Six 
male nude (nu/nu) mice (6 weeks old) were bred by the UNC animal core facility, and 
submandibular bleeds were performed prior to microneedle application to establish baseline 
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cholinesterase levels. Approximately 50-100 µL of serum was collected from each bleed and 
loaded into serum-separator tubes (BD Microtainer™ Capillary Blood Collector and BD 
Microgard™ Closure, Fisher Scientific). After serum collection, the solutions were stored at -20 
°C until core analysis. It has been previously shown in our laboratory that BuChE remains active 
in serum after this freeze/thaw cycle.  
Microneedle patches loaded with high activity tetrameric BuChE were utilized for all 
experiments; the theoretical dose of the BuChE per patch was 77.5 U, assuming an activity of 
200 U/mg. Mice were anesthetized with isoflurane (Baxter) via continuous flow through nose 
cones and placed on a 37 °C stage. Microneedle patches were rolled onto the skin on the back of 
the animals (n = 6), and pressure was applied for 1 min. After 8 min, the substrates were 
dissolved with water, and the surface of the skin was wiped clean. Mice were then taken off 
anesthesia and monitored until serum collection.  
At selected points (4, 8, 24, or 48 h) after microneedle patch administration, the mice 
were bled for serum collection with the assistance of the UNC Animal Studies Core. Of the six 
mice dosed, three were bled at 4 and 24 h, and three were sampled at 8 and 48 h. Blood was 
collected via submandibular techniques at 4 and 8 h. Before terminal collection (24 and 48 h), 
mice were administered a ketamine/dexmedetomidine blend to deeply anesthetize the animal 
prior to cardiac puncture for blood collection. Serum was extracted from whole blood via 
separator tubes and stored at -20 °C prior to cholinesterase testing (UNC Histology Core).   
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CHAPTER 5 PRINT MICRONEEDLES FOR THE TREATMENT OF SKIN-INVADING BREAST 
CANCERS 
 
5.1 Introduction  
Due to the complex biology of cancer, there is a large diversity in how this class of 
diseases manifests in a patient. A select number of cancers show skin involvement; carcinomas 
specifically are derived from epithelial cells such as those found in the skin.1 Skin involvement 
can be as minimal as the invasion of the lowest epidermal layer, as is the case in basal cell 
carcinoma; these cancers are easily treatable by surgical resection, for they show extremely low 
rates of metastasis.2 Other cancers show considerable involvement with epidermal/dermal 
junction and the lymphatic vessels in lower dermis, such as squamous cell carcinoma, lantigo 
maligna melanoma, chest wall recurrent breast cancer, and inflammatory breast cancer (IBC).2-8 
Of these, well-established treatment options for carcinomas and melanomas of the skin – 
including tumor resection, immunotherapy via topical creams, radiation therapy, and laser 
therapy – have been highly successful in preventing recurrance.4-5 However, the treatment of 
locally advanced breast cancers displaying skin involvement is a significant challenge, for 
intravenous (IV) therapies are unlikely to deposit therapeutics near the dermal lymphatics, and 
both surgical and radiation options have often been exhausted for these patients.6-8    
Specifically, microneedles for the treatment of inflammatory carcinoma of the breast 
(IBC), the most aggressive form of invasive breast cancer known, could provide an attractive 
minimally-invasive treatment option. Approximately 1-5% of all breast cancer cases are 
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inflammatory in nature.8 Unlike many breast cancers that present as a lump, IBC dysplastic cells 
commonly reside in the dermal lymphatics, causing obstruction to lymphatic drainage.6 This 
causes the tissue to become red and swollen, thus the “inflamed” skin.6 This morphology, also 
referred to as “peau d’ orange,” causes structural changes to the skin at the site of invasion; one 
such case is shown in Figure 5.1.9  Most IBC cases are in Stage III or IV at the time of diagnosis 
and progress rapidly; the 3-year survival rate for these patients is near 40%, much lower than that 
of patients with non-IBC tumors (85%).7,9,10 Due to the involvement with the lymphatic system, 
metastases are common among IBC patients.8,9 The infrequency of cases has led to few defined 
targets for treatment, due to its generally undefined biology and the lack of an identified 
molecular pathway unique to IBC.11 
 
Figure 5.1 Chest wall presentation of one patient with IBC.9 
Much research on IBC treatment has focused on improving systemic therapies, mainly on 
delivery vehicles that reduce the exposure of toxins to healthy cells. Etrych et al. have developed 
copolymer conjugates for pH sensitive release of paclitaxel to reduce therapeutic cytotoxicity in 
mammary carcinomas.12 Additionally, other block copolymer solubilizers, conjugates, and 
prodrug approaches have been investigated to reduce the side effects of standard therapies.13-15 
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Targeted therapies, namely the use of monoclonal antibodies to inhibit vasculolymphatic 
processes, have been recently postulated.11,16 Emerging therapies for epidermal growth factor 
receptor (EGFR) targets, overexpressed in ~30% of IBC cases, have been developed in recent 
years, including Erlotinib, an EGFR tyrosine kinase inhibitor.11 In spite of these efforts, 
clinicians recognize the complexity of IBC and have stated that prognosis of these patients 
remains poor.6  
As innovative strategies are critical, a novel transdermal-based approach could serve as 
an avenue for a local and possibly systemic, yet minimally invasive, therapy. Of late, 
nanoemuslions of tamoxifene citrate applied topically have been investigated for delivery for 
breast cancer treatment, showing the promise of transdermally applied therapeutics.17 PRINT 
microneedles loaded with pertinent therapeutics could offer an attractive solution to improve the 
efficacy of existing IBC therapies while reducing the deleterious effects commonly associated 
with traditional injections. Herein, we describe the fabrication of PVP microneedles via PRINT 
that successfully encapsulate up to 20 weight percent (wt%) docetaxel, a chemotherapeutic 
routinely used for the treatment of IBC.12 Preliminary animal studies show the ability of the 
devices to pierce healthy and cancerous tissue, as well as the possibility of microneedle delivery 
to reduce systemic toxicity.  
5.2 Results and Discussion  
Docetaxel was chosen as first therapeutic of interest with PRINT microneedles. This 
small molecule (Figure 5.2) is a well-established anti-mitotic chemotherapy effective against 
IBC, and is the standard of care for non-IBC locally advanced cases.18 Initially approved for the 
treatment of metastatic breast cancer, docetaxel (trade name Taxotere®) is traditionally dosed 
weekly as a primary systemic therapy.6,18 However, like all chemotherapeutics, it is also 
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cytotoxic to non-cancerous cells.6 Side effects such as alopecia, peripheral neuropathy, fluid 
retention, and anemia have been observed.18-20 Outside of the standard IV dosing of this taxane, 
oral formulations have been investigated; poor bioavailability was observed due to first pass 
metabolism by the liver and intestines.19  The incorporation of this potent chemotherapeutic into 
PRINT microneedles may localize the toxin to skin, the site of the disease for IBC patients, 
lowering both the required therapeutic dose and the severity of side effects. Additionally, 
combination therapies that include microneedle administration are possible.  
 
Figure 5.2 Structure of docetaxel.  
5.2.1 Fabrication and Characterization of PRINT Microneedles Incorporating Docetaxel  
5.2.1.1 Fabrication of Docetaxel Microneedles with Multiple Loadings 
Due to the hydrophobicity of docetaxel, many approaches to increase the water solubility 
of this small molecule for IV administration have been researched, including pro-drug synthesis 
and polymeric solubilizers.13,21 However, by introducing the drug in a solid state via 
microneedles, solubility is no longer an issue. Utilizing amphiphilic PVP as the microneedle 
matrix, homogenous incorporation of the therapeutic is possible when pre-microneedle solutions 
are prepared in organics. The composition for docetaxel microneedles was optimized in ethanol 
for these purposes, easily solubilizing both the PVP and drug. It was found that docetaxel 
loadings of greater than 20 wt% showed considerable visible phase separation, resulting in 
crystalline films. The presence of crystallinity in the devices would substantially weaken the 
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matrix, causing the PVP microneedles buckle when applied to the skin.22-25 Therefore, films of 0-
20 wt% docetaxel were subjected to thermal analysis (differential scanning calorimetry, DSC) to 
observe any non-visible heterogeneity; if crystalline regions were present in the film, a melting 
endotherm would be present in the scans.  
After analysis, it was seen that all films up to 20 wt% docetaxel exhibited no crystalline 
character; only glass transition temperatures (Tg) were observed.  Figure 5.3 shows the DSC 
trace for the 20 wt% docetaxel film collected from the second heating cycle. The absence of a 
melting endothermic peak indicates that these blends remain amorphous. Additionally, the glass 
transition temperatures of the films were recorded for all loadings (Table 5.1). The Tg’s were 
slightly dampened by the incorporation of docetaxel; generally, an increase in loading linearly 
decreased the glass transition temperature. Up to 20 wt%, however, the temperatures were still 
around 40 °C; the protein microneedles, displaying similar Tg’s, were shown to pierce skin with 
these characteristics. Therefore, docetaxel films with a loading up to 20 wt% were optimized for 
microneedle fabrication.   
 
 
Figure 5.3 DSC trace of the 20 wt% docetaxel (in PVP) film, showing only a glass transition temperature at 38.91 
°C.  
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Table 5.1 Glass transition temperatures (Tg) of the PVP pre-microneedle films loaded with docetaxel. 
Formulation Tg (°C) 
PVP 50.1 
PVP + 1 wt% DOC 48.3 
PVP + 5 wt% DOC 42.1 
PVP + 10 wt% DOC 39.5 
PVP + 20 wt% DOC 38.9 
 
Microneedles were then made via PRINT with these loadings, utilizing the procedure for 
the fabrication of blank PVP microneedles reported in Chapter 2. Briefly, solid-state microneedle 
films were applied to PRINT molds in an isolated area for the processing of chemotherapeutics. 
Patches were sent through a heated nip at 105 °C to fill the mold, and microneedles were 
harvested onto flexible backing layers. Figure 5.1 shows representative environmental scanning 
electron microscopy (ESEM) images of docetaxel loaded microneedles (5 wt%), showing 
dimensions consistent with all PRINT systems.  
 
Figure 5.4 ESEM images of microneedles loaded with 5 wt% docetaxel. Scale bars are 100 µm. 
5.2.1.2 Characterization of Microneedle Dose via High Performance Liquid 
Chromatography  
For all drug surrogates investigated previously, quantitative fluorescence allowed for the 
non-destructive determination of cargo dose in each individual microneedle patch in its solid-
state; however, docetaxel was not amenable to tagging. Therefore, the development of a new 
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method to assess loading was required to accurately determine patch chemotherapeutic dose. In 
this vein, we aimed to discern the percent by weight of docetaxel in the final device at each 
loading. By confirming that the patches of each dose consistently have the same wt% docetaxel, 
individual patches can be non-destructively massed prior to dosing, allowing for accurate dose 
determination for in vivo studies.     
Because the microneedle devices are made exclusively of PVP and docetaxel, accurately 
quantifying the mass each will allow for the determination of the wt% docetaxel in the final 
microneedle devices. This can be simultaneously achieved through by via high performance 
liquid chromatography (HPLC) separations. The quantification of both the agents, separately, has 
been reported on standard HPLC systems utilizing ultraviolet (UV) detection at 200-250 nm and 
a common reverse phase (C18)
 column.26,27 A method that separates the PVP from the docetaxel 
with high resolution is desired to allow for minimal sample preparation; in this way, sample 
microneedle patches could be dissolved, and without further treatment, subjected to quantitative 
HPLC analysis. 
Herein, we report the development of an HPLC method for the separation and 
quantitation of PVP (average Mw
 = 10 kDa) and docetaxel; the parameters can be found in Table 
5.2. Due to the polar amide groups on the PVP backbone, there is a large difference in 
hydrophobicity between the polymer and hydrophobic drug, making efficient separation 
possible. The molecular weight distribution of the polymer, however, results in a very broad 
peak that is likely to overlap with the docetaxel at short times. To overcome this limitation, a 
slow gradient over 45 min was employed, resulting in a peak resolution consistently greater than 
1.0. Detection was optimized at 205 nm for both constituents.    
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Table 5.2 HPLC parameters for the separation and quantification of PVP and docetaxel  
HPLC System Agilent 1200 Series LC 
Aqueous Mobile Phase Water, pure  
Organic Mobile Phase Acetonitrile:2-propanol (55:5) 
Gradient 100% water  100% organic 
Time 45 min 
Flow Rate 1 mL/min  
Column Zorbax C18 Reversed Phase 
Detection 205 nm 
 Standardization of the method was performed in accordance with the conditions found in 
Table 5.2. PVP and docetaxel standards (in ethanol) were prepared in a single vial at a ratio of 
1:20 to best reproduce the conditions of microneedles loaded at 5 wt%. PVP and docetaxel were 
seen at a retention time of 14.3 and 27.0 minutes, respectively (see Experimental, Figure 5.8); as 
expected, peak width for the PVP standards averaged 21.3 min, while tight docetaxel peaks were 
1.0 min in width, on average. PVP calibration curves were highly linear in the concentrations 
relevant to the microneedle patches; the dynamic range used was 10 mg/mL to 0.15 mg/mL. The 
same was observed for docetaxel, quantifiable from 1 mg/mL to 0.007 mg/mL. All curves were 
linear to an R2 value of 0.99 or greater.  
To test this method before analyzing sample microneedle patches, solid-state pre-
microneedle films cast with five docetaxel loadings, 1-20 wt%, were prepared for analysis. Films 
were subsequently dissolved in ethanol, and the solutions were injected to the HPLC without 
further preparation. Peaks at 14.3 and 27.0 min – corresponding to the PVP and docetaxel, 
respectively – were observed in the chromatograms (see Experimental, Figure 5.8). 
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Concentrations of the PVP and docetaxel were calculated through the standard curves and 
normalized to mass.  
The wt% docetaxel in the film determined by dividing the mass of the chemotherapeutic 
recovered by the total mass of both constituents in the device (Table 5.3). As anticipated, the 
wt% docetaxel observed in the films correlated to the amount loaded. Next, the analysis was 
repeated for PRINT microneedle patches fabricated at the same loadings. Table 5.3 shows that 
the final microneedle docetaxel loading is nearly identical to the wt% charged. These results 
prove that the mass of each patch can be taken before use and docetaxel dose can be reliably 
calculated on a per-patch basis. In addition, the consistency of the cargo wt% loading between 
the film and devices indicates that the docetaxel is homogenously distributed in the needles after 
PRINT fabrication. Had the cargo shown a preference for the mold or delivery sheet, it is likely 
the wt% loading would be considerably altered, for the docetaxel would be localized in either the 
devices or the unconsumed film.  
Table 5.3 Chemotherapeutic loading of PVP/docetaxel blends. Pre-microneedle solution wt% represents the actual 
percent charged to the materials. Loading in the solid-state films and microneedles was determined via HPLC (n = 
3).  
Docetaxel Loading in Pre-
Microneedle Solution, 
wt% 
Docetaxel Loading 
in Solid-State Films, 
wt% 
Docetaxel Loading 
in Microneedles, 
wt% 
1 1.0 1.5 
5 5.5 5.2 
10 10.0 9.7 
15 15.8 16.1 
20 19.8 22.9 
   
5.2.2 In Vivo Maximum Tolerated Dose (MTD) Studies with Docetaxel Microneedles 
Next, optimized microneedle devices were applied to nude mice in vivo to down-select a 
device loading for further studies with tumor models. The maximum tolerated dose (MTD) is 
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defined as the maximum dose of a drug that will result in a therapeutic effect without causing 
unacceptable toxicity. The microneedles have the possibility to deliver a large local dose to the 
skin of a mouse, and the ability of the animals to tolerate these doses locally is not understood. It 
is possible that the microneedles with high loadings (such as the 20 wt% needles) would cause 
significant adverse effects to the animals due to the burst release of a high mass of docetaxel to 
the skin; local effects such as burning of the skin may occur. Neutropenia, characterized by 
reduced white blood cell counts (WBC), is likely with docetaxel if an overload of the drug 
reaches the system.7 In addition, animal weight loss is indicative of chemotherapeutic poisoning.  
In this case, we aim to determine the highest loading of docetaxel into a microneedle 
patch with a surface area of 1 cm2 that would be tolerated by the animal over the course of four 
weekly treatments with the patch. Therefore, we executed the study outlined in Table 5.4. Initial 
toxicity was determined with non-tumor-bearing animals. Patch application was optimized over 
the mammary fat pad of the mouse, the site of a breast tumor in murine models. All conditions 
for application (1 min of pressure, 8 min incubation time before substrate dissolution) were 
executed identically to the studies described in Chapters 3 and 4. The skin was wiped clean with 
medical wipes; any removed docetaxel was extracted from the wipes to determine the delivered 
dose. This was done by subtracting the amount of chemotherapeutic removed from the skin from 
the mass of drug in the original patch (as described in 3.4.6). The mass dosed, on average, with 
each loading can be seen in Table 5.5. One week before dosing, baseline bloodwork was 
performed by the UNC Hematology Core to determine native white blood cell, red blood cell, 
lymphocyte, granulocyte, monocyte, and platelet count in whole blood. Blood was drawn every 
two weeks to observe any changes in these counts due to microneedle treatment.  
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Table 5.4 Study parameters for the determination of the MTD of patch-administered docetaxel to the skin 
Mice Female Nu/Nu, 5 weeks old at first dose 
Microneedles 0, 1, 5, 10, and 20 wt% docetaxel in PVP 
Patch Surface Area 1 cm2 
Dosing Once a week for 4 weeks 
Bloodwork RBC and WBC 
Terminal Organ Collection Treated skin, Contralateral Skin 
 
Table 5.5 Average dose delivered with docetaxel per patch loading with a 1 cm2 array 
Patch 
Loading, 
wt% 
Dose 
Docetaxel 
Delivered, mg 
0 0.00 
1 0.02 
5 0.12 
10 0.35 
20 0.85 
 
 Visually, as seen in Figure 5.5, skin burning was not observed for any of the mice after 4 
weeks of treatment. The skin morphology of the region treated with microneedles and the 
contralateral skin appeared identical, which indicated no local burning effects of the treatment. In 
addition, mice continued to gain weight over the treatment and up to one month after the last 
dose (at the time of sacrifice), showing no inhibition in growth due to the systemic toxicity of the 
chemotherapeutic. Finally, it was determined that all red and white blood cell counts were not 
altered significantly from the native levels. Seen in Figure 5.6, levels for all parameters assessed 
did not fluctuate in a dose-dependent manner. Therefore, it can be concluded that even our 
largest dose (20 wt% microneedles) did not cause severe toxicity, and are under the MTD for 
transdermal administration on non-tumor bearing animals.    
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Figure 5.5 Nu/Nu mouse from the microneedle MTD study after four weeks of  dosing with 20 wt% docetaxel 
microneedle patch. Patch application location is outlined with a black circle. Skin conditions appear unchanged 
before and after each dose.  
 
Figure 5.6 Key white blood cell and red blood cell levels as determined from the microneedle MTD study on nude 
non-tumor bearing mice. Total WBC count, as well as lymphocyte, granulocyte, and monocyte individual levels, did 
not vary predictably with dose. Total red blood cell and platelet counts also did not show dose-dependent changes. 
All parameters were within the normal ranges for nu/nu mice.   
It is postulated, then, that the chemotherapeutic administered to the skin was either 
localized to this barrier for the duration of the study or entered systemic circulation at levels that 
did not cause toxicity. To accurately determine where the drug has gone, biodistribution studies 
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on the transdermal application of docetaxel via PRINT microneedles must be done. Currently, 
the largest barrier to performing this analysis is the difficulty in quantifying absolute drug 
concentration in excised skin. While assays have been developed for the detection of docetaxel 
in many tissues – including tumor, liver, kidney, and other internal organs – utilizing sensitive 
mass spectrometry, they have not been adapted to skin.21,18 The dense collagen matrix and rigid 
keratinocytes found in skin have been shown to limit the effectiveness of tissue homogenization 
with this epithelium. Translating these assays to skin would be of highest priority to determine 
the ultimate delivered dose of docetaxel to the skin; in this way, microneedles efficacy as well as 
the biodistribution of the drug over time could be assessed.    
5.2.3 Optimization of Microneedle Administration to Tumor-bearing Mice  
Concurrent to the determination of the PRINT microneedle MTD in non-tumor bearing 
mice, we aimed to optimize the application of a device to a mouse expressing IBC tumors due to 
changes in skin morphology expressed with the disease. However, tumor models for IBC are 
scarce, and the few that have been developed have considerable advantages and disadvantages.29-
33 The “inflammatory” phenotype is accurately expressed in the human derived xenograft model 
MARY-X, growing exclusively in the dermal lymphatics and blood vessels.29 Alpaugh and co-
workers, the developers of the line, observed that MARY-X not only induced erythema in 
murine skin, it also lead to a high rate of pulmonary metastasis, commonly observed in the 
clinic.29 However, this model is not readily available, limiting studies performed with these cells. 
Other lines shown to have some level of lymphatic involvement include SUM102, SUM190, 
SUM149, and FC-IBC02.30-33 SUM149 is considered triple-negative [i.e. the cells lack the 
overexpression of the three most common receptors: hormone epidermal growth factor receptor 2 
(HER-2), estrogen receptor (ER), and progesterone receptor (PR)], making these cancers 
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extremely hard to treat because many targeted therapies cannot be employed.32,33 This patient-
derived IBC cell line is known to demonstrate the “inflammatory” phenotype in some cases, but 
can also present as a solid tumor; even with identical injection protocols, a high variability of 
morphologies has been observed.30-33 This model is readily available and is, consequently, the 
most widely used cell like in IBC research.30 Therefore, the SUM149 line was selected for study. 
PRINT microneedles were then administered to the skin of mice with SUM149 tumors. 
Cells were grown in the DeSimone lab and injected into the mammary fat pad of 5-week-old 
female nude mice. Tumor volumes were monitored over 1 month, and volumes of 90-200 mm3 
were reported at the time of microneedle application. Of note, all mice studied displayed solid 
tumors; the inflammatory phenotype was minimized, for only light red inflammation was 
observed on the skin of the mice. Patches (20 wt% docetaxel) were fabricated with a surface area 
of 1 cm2 and administered to the skin directly above the tumor on the flank of the mouse. As 
seen in Figure 5.7, the flexible arrays were able to conform to the skin around the tumor mass of 
small volumes (~100 mm3). The microneedles were able to penetrate the skin, but delivery into 
the tumor cannot be achieved with the 400 µm tall needles when the cancer presents as a lump. 
Moving forward, longer microneedles may be required to achieve efficacy in the SUM149 model 
due to the lower dermal skin involvement, and even solid tumors, observed during this study.  
 
Figure 5.7 Nu/Nu tumor-bearing mouse (SUM149 model) with a 20 wt% docetaxel microneedle patch affixed to the 
skin directly above the tumor mass. Patch application location is outlined with a black circle.  
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5.3 Conclusions 
In this work, we described preliminary work with PRINT microneedles for the treatment 
of inflammatory and chest wall recurrent breast cancers. This novel, transdermal-based approach 
may fill an unmet need for a local, minimally invasive therapy. PVP microneedles were loaded 
with docetaxel, a well-established anti-mitotic chemotherapy, up to 20 wt% drug. 
Chemotherapeutic loading was confirmed via high performance liquid chromatography. In vivo 
studies on female nude mice with patches of a range of loadings (0-20 wt%) were performed to 
establish the maximum tolerated dose via transdermal delivery. It was seen that the delivery of 
up to 0.85 mg locally (once a week for four weeks) did not cause significant skin morphological 
changes, affect red and white blood cell counts, or contribute to weight loss. Patches were also 
administered to mice with SUM149 xenografts, showing that the devices effectively can be 
applied in the presence of tumors. Moving forward, quantifying docetaxel in vivo is of highest 
priority to determine the absolute delivered dose of the PRINT microneedle patches, and the 
fabrication of longer microneedles is desired to penetrate lower into the dermis where the 
dysplastic cells have been observed. With these modification, the transition of these devices to 
biodistribution, pharmacokinetic, and efficacy studies can be achieved.  
5.4 Experimental  
5.4.1 Fabrication and Characterization of Docetaxel-Loaded PRINT Microneedles  
Microneedles were fabricated using an adapted PRINT process, described in detail in 
Chapter 2.34 All fabrication conditions (105 °C nip, 50 PSI) for blank PVP microneedles were 
employed for the fabrication of chemotherapeutic microneedles. Due to the cargo toxicity, the 
preparation of the pre-microneedle solutions was isolated to a controlled region, and all 
equipment used was exclusively designated for chemotherapeutic work. Pre-microneedle 
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incorporating docetaxel (LC Laboratories) were composed of 0-20 wt% drug in PVP (80-100 
wt% respectively) and employed ethanol as the casting solvent. The solutions were optimized at 
a 30 wt% total solids. Films were dried overnight to allow for ethanol evaporation before PRINT 
processing.  
Thermal properties of the microneedle films were found via DSC (Q200, TA 
Instruments) analysis after storage at 20-30% relative humidity. Decomposition experiments 
were done by heating 5-10 mg of substrate from 0-550 °C at 10 °C/min via thermogravimetric 
analysis (PerkinElmer Pyris 1), and the 95% decomposition temperature was determined. The 
upper temperature limit for the DSC experiments was to be no more than 50 °C lower than the 
95% decomposition temperature for each material. DSC was used to determine the Tg’s of the 
substrates. Samples (5-10 mg) were crimped into aluminum pans and heated from -20 °C to 100-
120 °C at a rate of 5 °C/min, cooled at a rate of 10 °C/min to -20 °C, and heated again in a 
second cycle. Tg’s were determined from the second heating cycle. Microneedle patches were 
characterized with ESEM (FEI Quanta 200) and brightfield macroscopy (Leica-Wild M420 
Macroscope). 
5.4.2 HPLC Methodology 
Docetaxel quantification was performed on an Agilent 1200 LC system coupled with a 
G316510 UV multiple wavelength detector (MWD) (Agilent Technologies) set to 205 nm. A 
Zorbax Eclipse XDB-C18 analytical column (Agilent) was employed for all analyses (4.6 x 150 
mm, 5 µm particles). Aqueous (pure water, HPLC grade, Fisher) and organic [55:5 acetonitrile, 
HPLC grade (Fisher):2-propanol, HPLC grade (Fisher)] mobile phases were mixed. Solvent was 
pumped through the system on a G1311A Quant Pump (Agilent) equipped with a degasser at 1.0 
mL/min.  
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Combination PVP/docetaxel standard solution was prepared in ethanol by dissolving 20 
mg PVP and 1 mg docetaxel in 1 mL of ethanol (n = 3). Serial dilutions were performed down to 
a PVP concentration of 0.15 mg/mL PVP and 0.0078 mg/mL docetaxel. Samples were loaded 
into standard clear glass HPLC vials (10 mm Screw Thread Vials, Fisher). Injections of 20 µL 
were run on a 45 min gradient (100% water to 100% organic). The column temperature was set 
at 20 °C. Post-run, peak area was determined in Agilent ChemStation software. Calibration 
curves were constructed for each constituent of the run and verified to a R2 value of 0.99 or 
greater. The dynamic range of each analyte was found to be 10 mg/mL to 0.15 mg/mL for PVP 
and 1 mg/mL to 0.007 mg/mL for docetaxel. Due to the high doses in the microneedle films, this 
range was ideally suited for analysis. 
 Next, solid-state films of 1, 5, 10, 15, and 20 wt% docetaxel in PVP were prepared for 
analysis by dissolving the entire film (n = 3, ~2-3 mg) in 1 mL of ethanol. Samples were not 
diluted further for analysis. Using the established calibration curves, the concentrations of PVP 
and docetaxel were determined; absolute mass was determined based upon the mass of the 
original film before dissolution. This analysis was repeated for microneedle patches of the same 
compositions (n = 3). Sample chromatograms from the standards, films, and microneedle patches 
can be seen as Figure 5.8.  
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Figure 5.8 Chromatograms of a representative standard, film, and microneedle patch are shown. The PVP peak can 
be seen at 14.3 minutes and the docetaxel peak at 27.0 min all materials analyzed. Chromatograms are displayed as 
observed in ChemStation (Agilent).   
5.4.3 Maximum Tolerated Dose study with Nude Mice 
Microneedle patches were administered to nude mice in accordance with animal use 
protocols approved by the UNC Institutional Animal Care and Use Committee (IACUC). Female 
nude mice (4-6 weeks old) were bred by the UNC animal core facility, a total of 15 animals were 
used, n = 3 for ease dose. With the assistance of the UNC Animal Studies Core, submandibular 
bleeds were performed 1 week prior to the first microneedle patch dose. Bloodwork was run 
immediately by the UNC Hematology Core to determine the white blood cell, red blood cell, 
lymphocyte, granulocyte, monocyte, and platelet count in whole blood collected in 
ethylenediaminetetraacetic acid (EDTA)-coated tubes (Milan, USA). The core determined 
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complete blood counts with differential using Heska’s blood counter. These levels were used as 
the baseline for all subsequent blood draws. Patches of equivalent mass with loading of 1, 5, 10, 
and 20 wt% with a surface area of 1 cm2 were compared to a control (treatment with PVP 
microneedles without cargos). The calculated dose/patch for these studies ranged from 0-1.5 mg 
docetaxel based upon loading and patch mass.  
For patch application, mice were anesthetized with isoflurane (Baxter) via continuous 
flow through nose cones. Microneedle patches were rolled onto the skin on the left flank of the 
animals, the region where an IBC tumor would be located in tumor-bearing studies, and pressure 
was applied for 1 min. After 8 min, the substrates were dissolved with water, and the surface of 
the skin was wiped clean. Mice were then taken off anesthesia and monitored for weight loss and 
skin rash/burning by the UNC Animal Studies Core. Patch application was done once a week for 
four weeks. Every two weeks, submandibular bleeds were performed on all animals, and whole 
blood was delivered immediately on ice to the UNC Hematology core for analysis. Mice were 
sacrificed for skin collection 1 month after the administration of the last microneedle patch dose. 
Skin from both the treated area and the contralateral flank were collected, flash-frozen, and 
stored at -80 °C.  
To determine the maximum therapeutic dose that was delivered to the skin via each 
device, docetaxel was extracted from the medical wipes after patch application. Wipes used to 
clean the skin for each experiment were left to dry overnight, leaving only solids; the wipes were 
then placed in 2.0 mL Eppendorf tubes with 1.5 mL of ethanol. After shaking for 1 h at 750 RPM 
at room temperature, the supernatant solution was removed and loaded into HPLC vials for 
analysis. Wipes dosed with known masses of docetaxel (as a solution in ethanol) were treated 
identically and used to form a standard curve, account for the extraction efficiency of the cargo. 
149 
 
The peak area of the known docetaxel doses were averaged (n = 3) and used to construct a wipe 
extraction standard curve (linear to R2 = 0.998). This curve was used to determine the mass of 
docetaxel removed for the mice and subtracted from the patch loading to determine the delivered 
dose. It was found that the patches delivered 0-0.85 mg of docetaxel from the loadings of 0-20%.  
5.4.4 Administration of Docetaxel-Loaded Microneedles to Tumor-Bearing Mice  
All studies with tumor-bearing animals are executed in accordance with animal use 
protocols approved by the UNC Institutional Animal Care and Use Committee (IACUC). Female 
nude mice (5 weeks old) were bred by the UNC animal core facility. A 200 µL suspension with 
Matrigel® (Corning) of 5 x 106 SUM149 cells (grown in the DeSimone Lab) were injected into 
the mammary fat pad of the mice to develop tumor xenografts. Tumor growth was monitored, 
and tumor volume was calculated using the formula: tumor volume (mm3) = (w2 x l)/2, where w 
= width and l = length in mm as measured by calipers. Tumor volumes of 90-200 mm3 were 
reported at the time of microneedle application after growth for 1 month.  
Patches loaded with 20 wt% docetaxel in PVP with a surface area of 1 cm2 were 
fabricated for these studies. The device was “rolled” into the skin at the site of the tumor and 
held under mild pressure for 1 min. Microneedles were visualized in the skin by eye. After 8 
min, the patch backing was dissolved. Mice were sacrificed with the assistance of the UNC 
Animal Core after the skin was wiped clean. Skin from both the treated area and the contralateral 
flank were collected, flash-frozen, and stored at -80 °C. 
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CHAPTER 6 FUTURE DIRECTIONS AND SUMMARY 
6.1 Future Directions  
6.1.1 Exploring the Fundamental Design Rules of Effective Microneedle Drug Delivery 
In recent years, it has been conclusively shown that biodegradable microneedle devices 
effectively deliver therapeutics to the skin employing safe, compatible materials.1-7 By avoiding 
metal, silicon, or other insoluble arrays, these devices eliminate biohazardous waste associated 
with the patch, remove the possibility of accidental needle sticks, and prevent the deposition of 
materials to the skin that may cause immunogenic consequences.1,2,8,9 The uses of biodegradable 
microneedles are numerous, including the delivery of insulin, human growth hormone, vaccine 
antigens and adjuvants, nanoparticles, and others.1,4,10-13 However, few platforms offer the ability 
to load cargos of nearly any size, charge, and polarity.1,4 The Particle Replication In Non-
Wetting Templates (PRINT) processes allows for highly reproducible microneedle fabrication. 
Devices made with amphiphilic polyvinylpyrrolidone (PVP) have been shown to encapsulate a 
wide range of cargos, and the mild processing conditions employed protect fragile cargos.6 We 
are uniquely able to study the fundamental parameters of effective transdermal delivery with a 
diverse group of therapeutics and drug surrogates, elucidating the fundamental design rules for 
transdermal delivery via rapidly water-soluble microneedles. 
6.1.1.1 Studies with PRINT Microneedles Employing Current Size and Shape  
In this work, we demonstrated the ability of PRINT microneedle devices to efficaciously 
pierce murine skin and deliver all studied surrogates to ex vivo murine tissue; we observed stark 
differences in their ability to transport through full-thickness murine tissue in 24 hours (h) 
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though the use of a Franz diffusion cell apparatus. While small surrogates were shown to 
permeate effectively at these times, larger cargos (high molecular weight proteins and 
nanoparticles) did not deliver relevant doses. Extending these studies beyond 24 h would help 
determine the permeation kinetics of these cargos and, in regards to the nanoparticles, the effect 
of particle surface charge on transport. However, it has been shown that the integrity of most– 
including excised skin (murine, porcine, and human), polymeric scaffolds, and cultured model 
skin – membranes decreases significantly after 24 h, making extended Franz cell experiments 
less likely to mimic in vivo behavior.14,15  
Logically, transitioning in vivo would allow for the systemic study of permeation kinetics 
at these longer time points. In addition, the ability to observe the cargo in live skin permits the 
investigation of drug surrogate interaction with cells; for example, the determination of how 
nanoparticle surface charge influences cell uptake and transport could be examined. Animals 
could be sacrificed at many time points after patch application; these time points can be 
extrapolated using the ex vivo permeation kinetics observed on the Franz cells. Quantitative 
fluorescence imaging techniques can be employed to determine the biodistribution of cargos at 
each point, revealing the true permeation kinetics for murine models. The uptake or association 
of the drug surrogates with different cell types present in the skin – including Langerhans and 
dermal dendritic cells – can be determined via flow cytometry analysis.  
While the drug surrogates studied herein were chosen for their diversity, PVP 
microneedles have the potential to encapsulate other cargos of interest, such as poly(lactic-co-
glycolic acid) (PLGA) nanoparticles.10 It has been shown that PLGA particles of different sizes, 
shapes, and  monomer ratio (lactic acid to glycolic acid) entrap and release therapeutics at 
different rates; encapsulating a range of these particles in microneedles could allow for the study 
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of “depot” patches, in which the highly water-soluble PVP deposits the sustained release 
nanoparticle to the skin.16 This is particularly promising due to concerns that microneedles made 
entirely from a sustained release polymer leave channels in the skin for days that permit 
pathogen invasion.1,17 The investigation of these microneedles, ex vivo and in vivo, would be 
particularly attractive for the delivery of therapeutics requiring routine injections, such as insulin 
or human growth hormone, minimizing the frequency of treatment for these patients.13   
At the conclusion of studies in mice, cargos of further interest could be transitioned to 
studies in Gottingen minipig model to provide relevant pre-clinical data with optimized 
patches.18 This model is considered the gold standard for pre-clinical trials on transdermal 
formulations, chosen for its comparable thickness and transdermal permeability to human skin. 
After initial ex vivo studies, skin histology coupled with the tracking of fluorescently-labeled 
cargo would allow for a qualitative understanding of the in vivo fate of the drug surrogates. Since 
large-animal fluorescence imaging is not feasible, quantitative positron emission tomography 
(PET) imaging using an isotopic tag could be used to determine drug surrogate biodistribution. 
The University of North Carolina has a state-of-the-art MRI/PET system, one of four systems 
available nationwide, making these studies manageable on campus. 
6.1.1.2 Investigating the Role of Microneedle Dimensions on Delivery Efficacy 
Currently, all PRINT microneedles have made from the same master template, resulting 
in needles that are ~400 µm tall with an aspect ratio of two. While this size is very promising in 
murine skin, it was shown that alterations to the microneedle dimensions would be necessary to 
translate to human application. Additionally, a multitude of studies have shown that microneedle 
length, tip diameter, aspect ratio, tip-to-tip spacing, and geometry play a large role in the efficacy 
of biodegradable devices when the microneedle matrix is held constant.1,19-21 In particular, 
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Kochhar et al. have shown that the spacing between microprojections plays a key role in what 
percentage of the needle can penetrate into rat tissue; it was shown that a difference of 800 µm in 
tip-to-tip spacing can increase the penetration depth from 10% to 80% of the needle height.19 Tip 
diameters were shown to be of pivotal importance by Davis et al., outlining that needle insertion 
force increased linearly with increased tip diameter.22 The optimal microneedle design is highly 
debated; some researchers suggest that microneedles 1 mm in height are necessary to ensure 
rapid uptake of drugs into the system, while others argue that needles no longer than 200 µm are 
ideal.1,20 Therefore, varying the physical dimensions and spacing of microneedles composed of 
identical materials is necessary to determine the ideal microneedle device for each intended 
application.  
The key limitation to performing these studies with PRINT is the difficulty, expense, and 
fidelity of microneedle masters attained for molding-based manufacturing. While the fabrication 
of metal microneedles is well established and inexpensive, the out-of-plane design often makes it 
impossible to mold these structures.1 Masters made from silicon via reactive ion etching, 
electrochemical etching, photolithography, and deep x-ray lithography are all fragile and 
expensive, requiring a cleanroom environment and many hours of labor.1,6,23,24 Additionally, the 
standard wafers used to create the silicon structures are 525 µm thick or less, limiting the 
resulting microneedle height significantly.1 While photolithography allows for thicker starting 
films (500-1000 µm) prepared via spin coating, multiple spin and soft-bake steps are required, 
creating layered structures prone to flaws.1 Finally, all processes requiring a wet-etch step to 
remove a material after structure formation limit microneedle tip-to-tip spacing due to the slow 
rates utilized to avoid mask dissolution.   
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Recently, light dynamic mask micro-stereolithography, drawing lithography, and two-
photon polymerization have been discussed as a way to improve the manufacturing of high 
aspect ratio microneedles, enabling easy prototyping of microneedle geometries with decreased 
labor.1,24-28 Stereolithography employs controlled photopolymerization of a liquid resin with high 
spatial resolution to create a 3D structure, achieved by projecting light onto the build area with a 
digital micromirror device.24,25 The pattern of the projected light at any given time is constructed 
by creating an stereolithography (STL) file of the desired microneedle device,  which slices the 
feature into a number of layers and projects them in sequence.25 Structures with heights in the 
range of 500-3000 µm have been reported with this technology; however, the ability to taper the 
structures to a sharp tip is still a challenge.24,25 Still, layer-by-layer fabrication presents an 
inherent trade-off between resolution and speed, wherein decreasing layer thickness results in 
slower manufacturing, due to required separation, recoating, and repositioning steps between 
each projection. Drawing lithography creates 3D ultrahigh aspect ratio structures by extending a 
2D polymeric resin mechanically in the z-direction and solidifying the structures via cooling 
though the glass transition of the polymer.26 Lee and Jung have optimized this process for the 
creation of microneedle arrays (Figure 6.1). Here, an array of pillars is placed on the 2D 
polymeric resin heated above its glass transition temperature and drawn upward; curing occurs 
upon cooling. The pillar array is removed, leaving isolated microneedles of ultrahigh aspect 
ratios. Due to the challenges of molding these masters, this technique has been mainly 
investigated for the direct fabrication of microneedle devices, eliminating the need for molding 
altogether.26 One considerable drawback, however, is the limited control over sidewall profiles 
afforded by the drawing process.  
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Figure 6.1 Drawing lithography for microneedle master fabrication, developed by Lee and Jung.26 (A) The glass 
transition history of the SU-8 polymer in the cooled-down temperature. (B) After the SU-8 contacted the patterned 
pillar, drawing lithography was performed. (C) Drawing caused the appearance of an extended conical-shaped 
bridge between the plate and pillar in the glass transition. (D) The desired liquid bridge was cured to generate a rigid 
structure. (E) The separation of the 3D microstructure bridge at the narrow necking position by isolation drawing 
produced the ultrahigh aspect ratio solid microneedle molds. 
Lastly, two photon polymerization, a technique in which employs a femtosecond laser to 
initiate photopolymerization by localizing two photons in time and space, has been employed for 
microneedle fabrication.27,28 A computer aided design (CAD) file instructs a highly calibrated x,y 
galvanometric mirror scanner’s motion across a glass slide, selectively polymerizing in localized 
volumes. This process provides exceptionally high temporal and spatial (~nm/layer) resolution.28 
Structures up to 1 mm have been created in this way, but the slow processing times limit the 
technology in terms of rapid prototyping or direct biodegradable array fabrication.   
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 By employing one of the emerging master fabrication technologies, PRINT microneedles 
of various dimensions could be manufactured and studied both ex vivo and in vivo. After 
determining the PRINT microneedle array design that demonstrates the greatest efficacy of 
therapeutic delivery, large scale production would be required to transition the technology into 
clinical trials. Therefore, the optimization of the needle dimensions is paramount for each 
intended therapeutic target in order to advance PRINT microneedles to market.  
6.1.2 Optimizing Microneedle Devices for the Effective Delivery of Butyrylcholinesterase 
(BuChE) and Chemotherapeutics  
Based on preliminary findings, the delivery of free or particulate BuChE via microneedle 
devices to rapidly into systemic circulation would be challenging with the current design of 
PRINT microneedles. Investigating new microneedle geometries, therefore, would be of high 
interest for the delivery of this organophosphate scavenger. Additionally, depositing the enzyme 
to the dermal layer exclusively may increase the efficacy of the devices, increasing systemic 
exposure and minimizing local BuChE concentration.  
With these aims, we envision microneedle devices that amass BuChE selectively to three 
skin regions – stratum corneum, lower epidermis, and dermis – though tip-loaded microneedles 
with heights of 25 µm, 450 µm, and 750 µm. The designs, shown in Figure 6.2, employ 
microneedles with ‘projectile’ tips to selectively target distinct regions of the skin. Only the 
‘projectile’ tip would contain cargo, allowing for highly specific release that will not contaminate 
other depths of the skin. The tip would be composed of a rapidly-dissolving, water-soluble 
matrix (e.g. PVP) for quick release of the cargo in vivo. The remainder of the microneedle could 
be filled with a water insoluble, biocompatible material (e.g. PLGA) to serve as a mechanical 
booster to drive the needle to its desired depth; cargo would not be encapsulated in this layer. 
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The shortest microneedles (25 μm) will be entirely composed of water-soluble matrix and cargo, 
i.e., the mechanical booster will be absent, for they are designed to target the outermost layer of 
the skin.  
 
Figure 6.2 Long, medium, and short microneedles to target the dermis, lower epidermis, and stratum corneum 
respectively.  
 These studies would be most efficacious in animal models with thicker skin, making 
minipigs the optimal pre-clinical model for the execution of these experiments (see 6.1.1). 
Down-selection to the optimal microneedle devices will be done via permeation testing on 
excised minipig skin with the Franz cell apparatus. In vivo studies would be performed on these 
formulations to determine the ability of the PRINT microneedles to deliver BuChE systemically. 
Due to the large amount of protein required in systemic circulation for the neutralization of 
organophosphate overexposure, large patches containing 200-300 mg of BuChE will be 
designed.29 Utilizing the taller needles (750 um tall), square microneedle patches measuring 3-4 
x 3-4 inches are postulated to deliver this dose. PRINT technology enables the fabrication of 
patches after scale-up to cGMP manufacturing, and the flexible backing layer would allow for 
such large patches to be administered to the arm. Therefore, by employing PRINT microneedles, 
great strides may be made towards full body protection against nerve gas exposure utilizing the 
transdermal route of administration.  
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 To optimize microneedles for the delivery of chemotherapeutics to skin-invading breast 
cancers, tumor-bearing animal studies must be performed on optimized PRINT microneedle 
devices with docetaxel. Quantitative assays for the detection of this chemotherapeutic in animal 
tissue have been reported; the validation of these methods to skin would be required, for this 
organ is not typically analyzed during studies with solid tumors.31 Next, patient derived SUM149 
tumor xenografts on nude mice would be utilized to determine the efficacy of transdermally-
administered docetaxel in combating the dermal-laden dysplastic cells. Tumor cells grown in the 
DeSimone Lab would be injected into the mammary fat pad of nude mice, and animals would be 
monitored for the “peau d’ orange” morphology or the growth of solid tumors. Microneedle 
therapy will be compared to standard intravenous (IV) treatment as a control. Biodistribution and 
pharmacokinetic studies will be done to determine the fate of the drug in vivo; minimizing the 
systemic circulation of the toxic drug would be prioritized.  
In select cases, a burst release of locally-delivered docetaxel would not be advantageous 
for treatment. Work on the synthesis of lipidized docetaxel using silyl ether chemistry is 
underway in the DeSimone Lab; incorporating these analogs into microneedles could be 
promising.33 Shown in Figure 6.3, these prodrugs have been shown to minimize systemic toxicity 
and display tunable rates of conversion based on the length of the attached alkyl chain.33 These 
analogs could reduce the cytotoxicity of the drug to healthy cells and increase exposure 
throughout the dermal lymphatics. As with the free drug, loading in the needles will be 
optimized to administer a high dose per patch while maintaining the mechanical strength 
necessary to pierce the epidermis. The devices will then be applied to ex vivo and in vivo to 
determine the ultimate efficacy of this approach.  
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Figure 6.3 Structure of (A) docetaxel, (B) lipidized docetaxel with a C4 alkyl chain, (C) lipidized docetaxel with a 
C8 chain. 
6.2 Summary 
6.2.1 Fabrication and Characterization of PRINT Microneedle Patches 
Microneedles are arrays of micron-sized projections for localized and systemic drug 
delivery. Considered minimally-invasive, these devices pierce the skin to administer drugs 
transdermally, creating channels for the passage of a therapeutic without causing pain; 
biodegradable microneedles are of high interest due to their low complexity, ability to deliver a 
wide range of therapeutics, and high levels of safety.1 A main limitation of biodegradable 
microneedles is their arduous manufacturing that requires vacuum and centrifugation steps to fill 
a mold.1 Manufacturing microneedles via the cGMP-compliant PRINT platform has great 
promise to expand this growing field by eliminating these obstacles to clinical translation. 
Herein, the fabrication of 100% water-soluble PRINT microneedles on flexible substrates has 
been demonstrated. Their ability to load therapeutics of nearly any size, shape, and surface 
charge – while maintaining the function of the cargo throughout – has been validated through the 
encapsulation of small molecule dyes, proteins, and hydrogel nanoparticles. These drug 
surrogates have been incorporated into the microneedles at concentrations projected to be 
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therapeutically relevant (0.1-20 wt%), and cargo is seen to distribute homogeneously throughout 
the needle matrix in optimized devices.   
6.2.2 Ex vivo and In vivo Delivery of Drug Surrogate Cargos via PRINT Microneedles 
Next, we demonstrated the ability of the PRINT microneedles to successfully penetrate 
murine skin and release drug surrogate cargo. Utilizing optical coherence tomography, it was 
seen that flexible PVP microneedle patches increase the depth and reproducibility of needle 
penetrations (as compared to rigid patches). Initial penetration studies with murine tissue and 
small molecule drug surrogates highlighted the ability of the microneedles to release cargo at 
short times. The permeation kinetics of the small molecule, protein, and particulate drug 
surrogates were investigated through the use of a Franz diffusion cell apparatus. It was seen that 
microneedles greatly increased the delivered dose (i.e. percent of the cargo detected in the Franz 
cell receptor compartment) of small molecules compared to the same agent applied as a solution. 
Both proteins and 80 x 320 nm hydrogel particles were seen to deposit in the skin after 
application with PRINT microneedles, but cargo size played a large role in the permeation 
kinetics through full thickness murine tissue. PRINT microneedle device application in vivo was 
optimized on nude murine models, and it was shown that these devices efficaciously deliver 
small molecule drug surrogates to living tissue. Finally, the ability of the PRINT microneedles 
pierce excised human skin was shown, highlighting the capability of the technology to transition 
into a clinically-relevant product.  Microneedle dimensions would need to be altered (longer, 
sharper, etc.) to be highly efficacious in human models, and the exploration of additional 
microneedle geometries is planned.   
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6.2.3 PRINT Microneedles for the Delivery of Butyrylcholinesterase to Combat 
Organophosphate Overexposure  
The effective delivery of BuChE is of growing interest due to its ability to scavenge 
various nerve agents and organophosphates from systemic circulation.29 Additionally, strategies 
for delivering this enzyme to the blood stream without the use of a standard needle and syringe 
are desirable. To this aim, we have fabricated PRINT microneedles that homogeneously 
encapsulate 20-25 wt% free BuChE while maintaining the activity of the enzyme. Additionally, 
pure BuChE PRINT particles have been fabricated, and both crosslinked and non-crosslinked 1 
µm particles have been incorporated into PVP microneedles at a 5 wt% loading. While the 
crosslinked particles were found to be intact after microneedle fabrication and release in aqueous 
solution, the non-crosslinked particles released active enzyme upon dissolution. Finally, the 
permeation kinetics of the large protein through ex vivo murine tissue were seen to be very slow, 
and highly active enzyme was not detectable in murine blood after the administration of these 
microneedles in vivo. Therefore, to ensure rapid systemic exposure of this protein, new 
microneedle geometries must be explored.  
6.2.4 PRINT Microneedle for the Treatment of Skin-Invading Breast Cancers 
While many breast cancers present as a lump, a small class of aggressive forms do not. In 
these cancers, dysplastic cells commonly reside in the dermal lymphatics, causing obstruction to 
lymphatic drainage and “inflamed” skin.32,34 For these patients, the prognosis is poor with 
current systemic therapies. PRINT microneedles are being developed for the treatment of 
inflammatory and chest wall recurrent breast cancers. We aimed to introduce a novel 
transdermal-based approach that could serve as an avenue for a local, minimally invasive 
therapy. In this manner, PVP microneedles were loaded with docetaxel, a well-established anti-
mitotic chemotherapy, at loadings up to 20 wt%. Chemotherapeutic loading was confirmed via 
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high performance liquid chromatography. Patches of a range of loadings (0-20 wt%) were 
administered to nude mice in vivo to establish the maximum tolerated dose via transdermal 
delivery. It was seen that the administration of microneedles with all docetaxel loadings (once a 
week for four weeks) did not cause significant changes to red and white blood cell counts or 
animal weight. Patches were also administered to mice with SUM149 xenograft tumors, showing 
that the devices can be applied effectively in the presence of tumors. Moving forward, 
quantifying docetaxel in vivo is of highest priority to determine the absolute delivered dose of the 
PRINT microneedle patches, lending to the transition of these devices to biodistribution, 
pharmacokinetic, and efficacy studies.  
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